
Page: 1 Protocol Number: CA209451 IND Number: 125,872 Ex-US Non-IND EUDRACT Number 2015-002441-61 Date: 02-Jul-2015 Revised Date: 20-Sep-2018

Clinical Protocol CA209451

A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy

(CheckMate 451: CHECKpoint pathway and nivolumab clinical Trial Evaluation 451)



Revised Protocol Number: 06







Revised Protocol No: 06 Date: 20-Sep-2018







Revised Protocol No: 06 Date: 20-Sep-2018



SYNOPSIS

Clinical Protocol CA209451

Protocol Title: A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy

Investigational Product(s), Dose and Mode of Administration, Duration of Treatment with Investigational Product(s):

This is a randomized, double-blind, three-arm, multicenter, Phase 3 study in adult subjects with ED-SCLC, who achieve Stable Disease, Partial Response or Complete Response after completion of platinum based first line chemotherapy.

Approximately 810 subjects will be randomized in a 1:1:1 ratio to treatment with either nivolumab monotherapy (Arm A), nivolumab/ipilimumab combination therapy (Arm B), or placebo (Arm C), and will be stratified according to the following factors:

- ECOG Performance Status: 0 vs 1
- Gender: Male vs Female
- Prophylactic Cranial Irradiation (PCI) following chemotherapy: Yes vs No

The treatment arms are as follows:

Arm A:

Nivolumab 240 mg administered every 2 weeks as a 30 min IV infusion

Arm B:

Nivolumab 1 mg/kg (30 min IV infusion) and ipilimumab 3 mg/kg (90 minute IV infusion) every 3 weeks for four doses, followed by nivolumab 240 mg every 2 weeks.

Arm C:

Placebo

In order to maintain a blinded study, the schedule of investigational and placebo treatments is divided into two 6-week cycles at the start of therapy, followed by ongoing 2-week cycles until discontinuation criteria are met.

On-study tumor assessments will be conducted every 6 weeks (\pm 5 days) for the first 36 weeks. After Week 36, tumor assessments will be performed every 12 weeks (\pm 5 days) until disease progression

Duration of the study from start of randomization to analysis of the primary endpoint will be approximately 35 months (28 months of accrual + 7 months of minimum follow-up, providing an average follow up of 9 months). Additional survival follow-up may continue for up to 5 years from the primary analysis of survival. The study will end once survival follow-up has concluded.

Study Phase: III

Research Hypothesis:

Maintenance treatment with nivolumab monotherapy, or nivolumab in combination with ipilimumab followed by nivolumab monotherapy, will prolong overall survival (OS) as compared with placebo in subjects with ED-SCLC who have completed platinum-based first line chemotherapy.

Objectives:

Primary Objectives:

To compare OS of nivolumab in combination with ipilimumab versus placebo in subjects with ED-SCLC after completion of platinum-based first line chemotherapy.


Secondary Objectives:

- To compare OS of nivolumab versus placebo in subjects with ED-SCLC after completion of platinum-based first line chemotherapy
- To compare Blinded Independent Central Review (BICR) assessed PFS of nivolumab, and nivolumab in combination with ipilimumab versus placebo
- To evaluate (descriptively) OS and BICR-assessed PFS of nivolumab combined with ipilimumab versus nivolumab monotherapy.
- To evaluate tumor mutational burden as a predictive biomarker for OS and PFS of nivolumab, and nivolumab in combination with ipilimumab

Exploratory Objective(s)

- To evaluate the safety and tolerability of nivolumab, and nivolumab in combination with ipilimumab, versus placebo;
- To evaluate Objective Response Rate (ORR) of nivolumab, and nivolumab in combination with ipilimumab, versus placebo;
- To evaluate Duration of Response (DOR) and Time to Response of nivolumab, and nivolumab in combination with ipilimumab, versus placebo;
- To explore PD-L1 expression as an independent predictive biomarker for efficacy of nivolumab, and nivolumab in combination with ipilimumab;
- To correlate potential predictive biomarkers in peripheral blood and tumor specimens, including proteins involved in regulating immune responses (eg, PD-1, PD-L1, PD-L2), mutational as well as immunohistochemistry (IHC) spectrum, with endpoints such as ORR, PFS and OS;
- To characterize immunological pharmacodynamic biomarkers of nivolumab, and nivolumab in combination with ipilimumab
- To characterize pharmacokinetics of nivolumab and ipilimumab and explore exposure response (exposure-safety and exposure-efficacy) relationships with respect to selected safety and efficacy endpoints
- To characterize immunogenicity of nivolumab, and nivolumab in combination with ipilimumab.
- To compare time to symptom deterioration (TTSD) as assessed by the average symptom burden index (ASBI) of the Lung Cancer Symptom Scale (LCSS) among subjects treated with nivolumab, and nivolumab in combination with ipilimumab arm versus placebo;
- To assess the subject's overall health status using the EQ-5D Index and visual analog scale.

Study Design:



Study Population:

Key Inclusion Criteria

- 1) Subjects with SCLC documented by histology or cytology from brushing, washing or needle aspiration of a defined lesion, but not from sputum cytology alone.
- 2) Subjects must have presented at initial diagnosis with extensive stage disease (defined as Stage IV (T any, N any, M1a/b) per NCCN guidelines Version 1.2015, AJCC Cancer Staging Manual, 7th Edition, 2010).
- 3) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. (See Appendix 1)
- 4) Subjects must have received 4 cycles of platinum-based first line chemotherapy and must have an ongoing response of complete response (CR), partial response (PR), or stable disease (SD) after completion of chemotherapy. Acceptable combinations, as recommended per NCCN guidelines, include cisplatin or carboplatin combined with either etoposide or irinotecan.
 - a) As an exception to the above criterion, subjects receiving only 3 cycles of chemotherapy due to toxicity are eligible, if they have an ongoing PR or CR after the 3rd cycle.
 - b) Subjects who have received > 4 cycles of platinum-based first line chemotherapy are not eligible
- 5) Subjects must be randomized ≤ 9 weeks (63 days), from the last dose of platinum-based first line chemotherapy. Subjects receiving PCI or brain RT must be randomized ≤ 11 weeks (77 days) of the last dose of platinum-based first line chemotherapy.
 - a) Study therapy <u>must not</u> be administered < 3 weeks (21 days) from the last dose of platinum-based first line chemotherapy.
 - b) Blinded study therapy must not be administered < 2 weeks (14 days) from the last dose of radiotherapy.
- 6) A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block (preferred) or 10 unstained slides of tumor sample (archival or recent) for biomarker evaluation must be available and submitted to the central lab for correlative studies in order for a subject to be randomized. If fewer than 10 slides are available, the BMS Medical Monitor or Study Director may approve randomization of subject upon review of the case. Specimens must have been submitted to the central laboratory prior to randomization. Excisional, incisional or core needle biopsies are strongly preferred, however samples collected via endobronchial ultrasound (EBUS) guided biopsy

(using a 22g needle or larger) and transbronchial lung biopsy (TBLB) are acceptable. In certain cases, the BMS Medical Monitor or Study Director may approve submission of samples collected via other methods.

Study Drug: includes both Investigational [Medicinal] Products (IP/IMP) and Non-investigational [Medicinal] Products (Non-IP/Non-IMP) as listed:

Study Drug f	or BMS-936558	
Medication	Potency	IP/Non-IP
Nivolumab Solution for Injection	100 mg (10 mg/mL)	IP
Ipilimumab Solution for Injection	200 mg (5 mg/mL)	IP
0.9% Sodium Chloride for Injection	N/A	IP
5% Dextrose for Injection	N/A	IP

Study Assessments:

Safety assessments include AEs, physical examinations, vital signs, ECOG performance status, assessment of signs and symptoms, laboratory tests, pregnancy tests.

Some of the previously referred to assessments may not be captured as data in the eCRF. They are intended to be used as safety monitoring by the treating physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations

Statistical Considerations:

Sample Size: Approximately 810 subjects will be randomized to three treatment arms in a 1:1:1 ratio. The primary objective is to compare OS of nivolumab in combination with ipilimumab versus placebo.

The analysis of primary endpoint of OS will be conducted when at least 386 deaths have been observed pooled across the nivolumab in combination with ipilimumab and the placebo treatment groups. It is expected that 208 events will be observed in placebo and 178 in the experimental arm. With 386 events available for comparison of OS in nivolumab in combination with ipilimumab treatment group vs placebo, power of the log-rank test is approximately 90% to detect a hazard ratio (HR) of 0.72 with a type I error of 0.05 (two-sided). Power calculations were performed using EAST® Software. For nivolumab in combination with ipilimumab, a 3months delay effect versus placebo and an HR of 0.68 post delay was assumed, resulting into an overall HR (experimental vs placebo) of 0.72 at time of the OS analysis. Survival function for placebo arm was modeled using a four hazard pieces to match historical data. Median OS derived from the survival functions were 8.8 and 11.0 months for the placebo and experimental arms, respectively.

Given the observed accrual, it is expected that the duration of the study from start of randomization to analysis of primary endpoint will be approximately 35 months (28 months of accrual + 7 months of follow-up, providing an average follow up of 9 months).

The independent Data Monitoring Committee (DMC) will have access to periodic interim safety and efficacy reports to allow for a risk/benefit assessment.

Analyses: The OS analyses will be conducted using a two-sided log-rank test stratified by the stratification factors in all randomized subjects to compare each of the two experimental treatments to the control group. Hierarchical procedure will be used to control the overall Type I error rate at 0.05. The secondary endpoint, OS comparing nivolumab monotherapy vs placebo, will be tested using 2-sided 5% alpha, if superiority of nivolumab in combination with ipilimumab over placebo is demonstrated at the 5% significance level. HRs and corresponding two-sided CIs will be estimated using a Cox proportional hazards model, with treatment group as a single covariate, stratified by the above factors. OS curves, OS medians with 95% CIs, and OS rates at 6, 12, and 18 months with 95% CIs will be estimated using Kaplan-Meier methodology.

PFS secondary analyses will be conducted using all randomized subjects. HRs and corresponding two-sided CIs will be estimated using a Cox proportional hazards model, with treatment group as a single covariate, stratified by the same stratification factors as above. PFS curves, PFS medians with 95% CIs, and PFS rates at 6, 12, and 18 months with 95% CIs will be estimated for each of the three treatment groups using Kaplan-Meier methodology.

The exploratory endpoint of ORR will be calculated for each treatment group. Exact two-sided 95% CIs for the rates will be computed using the method of Clopper and Pearson for each of the three treatment groups.

Descriptive analyses of OS, PFS, and ORR will be performed to evaluate differences between the two experimental arms, nivolumab combined with ipilimumab and nivolumab monotherapy. These include HRs and medians with corresponding two-sided 95% CIs for OS and PFS, as well as an ORR odds ratio with corresponding 95% CI.

Descriptive analyses will be performed to evaluate the potential of PD-L1 expression and TMB as a predictive biomarker for efficacy.

TABLE OF CONTENTS

TITLE PAGE	1
DOCUMENT HISTORY	3
OVERALL RATIONALE FOR REVISED PROTOCOL 06:	5
SUMMARY OF KEY CHANGES FOR REVISED PROTOCOL 06	5 7
SYNOPSIS	7
TABLE OF CONTENTS	12
1 INTRODUCTION AND STUDY RATIONALE	16
1.1 Study Rationale	16
1.1.1 Rationale for Investigating SCLC 1st Line Maintenance Therapy	16
1.1.2 Rationale for Immuno-oncology Therapeutic Approaches in SCLC	16
1.1.2.1 Nivolumab Mechanism of Action	17
1.1.2.2 Ipilimumab Mechanism of Action	18
1.1.3 Phase 1/2 Data for Nivolumab in SCLC	18
1.1.3.1 Updated Results from CA209032 SCLC Cohorts	22
1.1.4 Safety Profile of Nivolumab Monotherapy	23
1.1.5 Safety Profile of Nivolumab and Ipilimumab Combination Therapy	24
1.1.6 Rationale to Support Nivolumab Monotherapy "Flat" Dose of 240 mg.	25
1.1.7 Rationale for Nivolumab and Ipilimumab Combination	26
1.1.7.1 Rationale for Nivolumab and Ipilimumab Combination Dose and	
Schedule	26
1.1.8 Rationale for Shorter Nivolumab Infusion Times (30 minute infusion)	27
1.1.9 Rationale for Permitting Continued Treatment in Select Cases of	
Progressive Disease	27
1.1.9.1 Rationale for Placebo Control	28
1.1.9.2 Rationale for Duration of Treatment with Nivolumab Alone or in	
Combination with Ipilimumab	28
1.2 Research Hypothesis	29
1.3 Objectives(s)	29
1.3.1 Primary Objectives	29
1.3.2 Secondary Objectives	29
1.3.3 Exploratory Objectives	29
1.4 Product Development Background	30
1.5 Overall Risk/Benefit Assessment	30
2 ETHICAL CONSIDERATIONS	31
2.1 Good Clinical Practice	31
2.2 Institutional Review Board/Independent Ethics Committee	31
2.3 Informed Consent.	31
3 INVESTIGATIONAL PLAN	33
3.1 Study Design and Duration	33
3.1.1 Study Phases	34
3.1.1.1 Screening	34
3.1.1.2 Treatment	35
3.1.1.3 Follow-up	36
3.2 Post Study Access to Therapy	36
• • •	

5.6 Biomarker Assessments	74
5.6.1 Tumor Tissue Specimens	75
5.6.1.1 Tumor Mutational Burden	75
5.6.1.2 Characterization of Tumor Infiltrating Lymphocytes (TILS) and Tumor Antigens	75
5.6.1.3 DNA and RNA Genomic Assessment	75
5.6.1.4 Tumor Sample Collection Details	75
1	76
5.6.2 Peripheral Blood Markers	76
5.6.2.2 Serum Soluble Factors	70
5.6.2.3 Peripheral Blood Mononuclear Cells (PBMCs)	77
5.7 Outcomes Research Assessments	77
5.8 Other Assessments	77
5.8 Other Assessments	77
5. 8. 2 Plin dad Inder an dant Cantual Province (PICP)	78
5.8.2 Blinded Independent Central Review (BICR)	78
6 ADVERSE EVENTS	78
	80
6.1.1 Serious Adverse Event Collection and Reporting	
6.2 Nonserious Adverse Events	81
6.2.1 Nonserious Adverse Event Collection and Reporting	81
6.2.2 Immune-Mediated Adverse Events	81
6.3 Laboratory Test Result Abnormalities	82
6.4 Pregnancy	82
6.5 Overdose	83
6.6 Potential Drug Induced Liver Injury (DILI)	83
6.7 Other Safety Considerations	83
7 DATA MONITORING COMMITTEE AND OTHER EXTERNAL COMMITTEES	
	83 84
8 STATISTICAL CONSIDERATIONS	
8.1 Sample Size Determination	84
8.2 Populations for Analyses - Data set descriptions	85
8.3 Endpoints	85
8.3.1 Primary Endpoint(s)	85
8.3.2 Secondary Endpoint(s)	85
8.3.3 Exploratory Endpoint(s)	86
8.4 Analyses	86
8.4.1 Demographics and Baseline Characteristics	86
8.4.2 Efficacy Analyses	87
8.4.3 Safety Analyses	87
8.4.4 Pharmacokinetic Analyses	88
8.4.5 Biomarker Analyses	88
8.4.5.1 Pharmacodynamic Analyses	88
8.4.5.2 Pharmacogenomic Analyses	88
8.4.6 Outcomes Research Analyses	89
8.4.7 Other Analyses	89
8.5 Interim Analyses	89

9 STUDY MANAGEMENT	89
9.1 Compliance	89
9.1.1 Compliance with the Protocol and Protocol Revisions	89
9.1.2 Monitoring	90
9.1.2.1 Source Documentation	90
9.2 Records	90
9.2.1 Records Retention	90
9.2.2 Study Drug Records	91
9.2.3 Case Report Forms	92
9.3 Clinical Study Report and Publications	92
10 GLOSSARY OF TERMS	94
11 LIST OF ABBREVIATIONS	95
12 REFERENCES	99
APPENDIX 1 ECOG PERFORMANCE STATUS	102
APPENDIX 2 MANAGEMENT ALGORITHMS FOR IMMUNO-ONCOLOGY	
AGENTS	103
APPENDIX 3 RESPONSE EVALUATION CRITERIA IN SOLID TUMORS	
GUIDELINES (VERSION 1.1) WITH BMS MODIFICATIONS	111
APPENDIX 4 LUNG CANCER SYMPTOM SCALE (LCSS)	119
APPENDIX 5 EQ-5D QUESTIONNAIRE	124
APPENDIX 6 EQ-5D QUESTIONNAIRE (PHONE VERSION)	127
APPENDIX 7 REVISED PROTOCOL SUMMARY OF CHANGE HISTORY	131

1 INTRODUCTION AND STUDY RATIONALE

CA209451 is a randomized, double blind, multicenter Phase 3 trial of nivolumab monotherapy versus nivolumab and ipilimumab combination therapy versus placebo in subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) who have completed a first line platinumbased chemotherapy regimen and achieved an ongoing Complete Response (CR), Partial Response (PR) or Stable Disease (SD). This study will determine if nivolumab or nivolumab in combination with ipilimumab improve Overall Survival (OS) versus placebo in this subject population. Additional objectives include further characterization of the efficacy, adverse event profile, pharmacokinetics, patient reported outcomes, and potential predictive biomarkers of nivolumab and nivolumab in combination with ipilimumab in subjects with ED-SCLC.

1.1 Study Rationale

1.1.1 Rationale for Investigating SCLC 1st Line Maintenance Therapy

SCLC accounts for 15 to 20% of new cases of lung cancer, and nearly 33,900 new cases are expected in the US in 2012.¹ SCLC is traditionally classified as Limited Stage Disease (LD-SCLC: TNM stages I to IIIB) and Extensive Stage Disease (ED-SCLC: TNM stage IV with distant metastases (M1) including malignant pleural effusions).² For LD-SCLC, a combined therapeutic approach of radiotherapy, chemotherapy and (rarely) surgery is used with curative intent.³ Most patients at diagnosis have ED-SCLC and are treated with four to six cycles of etoposide plus platinum based therapy (EP), which remains the standard chemotherapy regimen for LD- and ED-SCLC.⁴ The initial response rate is robust with 70 to 90% response seen in LD-SCLC and 50 to 70% response seen in ED-SCLC.³ However, overall survival remains poor with median survival for LD-SCLC at 18 to 30 months⁵ and for ED-SCLC in the range of 10 to 12 months.⁶ Despite high initial response rates, in particular in patients with ED-SCLC, the disease does recur or progress rapidly after completion of chemotherapy, with median PFS of only 2-3 months.⁷

There is no established standard of care for subjects with ED- SCLC who complete first line therapy with EP and have achieved stable disease or response. In a phase 3 trial of topotecan versus observation, topotecan did not show an overall survival prolongation for SCLC patients after completion of EP.⁷ Recently, sunitinib showed an improved PFS in a Phase 2 trial of sunitinib vs placebo in SCLC patients after completion of EP.⁸ However, no therapy has been approved yet for the maintenance treatment of SCLC after completion of first line EP.

Considering the short median overall survival for patients who have completed first line platinum based treatment, as well as the even shorter progression-free survival experienced in this disease, new treatments complementary to SCLC standard first-line platinum-base treatment are required.

1.1.2 Rationale for Immuno-oncology Therapeutic Approaches in SCLC

An analysis of peripheral blood mononuclear cells (PBMCs) from SCLC patients has shown a higher number of T-effector cells in LD-SCLC compared to ED-SCLC subjects and long-term

survivors of SCLC have a higher T-effector to T-regulator ratio.⁹ PD-L1 expression was found in 71.6% of 102 analyzed SCLC tumor samples.¹⁰ Nivolumab has been shown to be effective against non-small cell lung cancer (NSCLC) in two Phase 3 studies, demonstrating improved OS in previously treated squamous¹¹ and non-squamous¹² NSCLC. Preliminary results in a Phase 1/2 trial with nivolumab, and nivolumab in combination with ipilimumab, in pretreated SCLC are promising, with response rates of 17.5% and 30%, respectively, and a tolerable safety profile (details provided in Section 1.1.3). Considering the immune response seen in SCLC patients, and the preliminary results of checkpoint inhibitors nivolumab and ipilimumab in NSCLC patients in later treatment lines, it is reasonable to expect that nivolumab monotherapy and nivolumab and ipilimumab combination therapy are likely to also provide benefit as first line maintenance therapy in SCLC.

1.1.2.1 Nivolumab Mechanism of Action

Nivolumab is a fully human, IgG4 (kappa) isotype mAb that binds the programmed death receptor 1 (PD-1) on activated immune cells and disrupts engagement of the receptor with its ligands PD-L1 (B7-H1/CD274) and PD-L2 (B7-DC/CD273), thereby abrogating inhibitory signals and augmenting the host antitumor response. Programmed death receptor-1 (PD-1, CD279), a 55 kD type I transmembrane protein, is a member of the CD28 family of T cell co stimulatory receptors that also includes CD28, CTLA 4, ICOS, and BTLA.2 PD-1 contains an intracellular membrane proximal immunoreceptor tyrosine inhibitory motif (ITIM) and a membrane distal immunoreceptor tyrosine-based switch motif (ITSM). Two ligands specific for PD-1 have been identified: PD-L1 (B7-H1/CD274) and PD L2 (B7-DC/CD273). PD-L1 and PD L2 have been shown to down-regulate T-cell activation upon binding to PD-1 in both murine and human systems. PD-1 delivers a negative signal by the recruitment of SHP-2 to the phosphorylated tyrosine residue in the ITSM in its cytoplasmic region. PD-1 is primarily expressed on activated T cells, B cells, and myeloid cells. Further evidence for a negative regulatory role of PD-1 comes from studies of PD-1-deficient mice. PD 1-deficient mice develop various autoimmune phenotypes, including dilated cardiomyopathy, a lupus-like syndrome with arthritis and nephritis, and accelerated diabetes mellitus. The emergence of these autoimmune phenotypes is dependent upon the genetic background of the mouse strain and many of these phenotypes emerge at different times and show variable penetrance. In addition to the phenotypes of null mutations, PD-1 inhibition by antibody-mediated blockade in several murine models has been found to play a role in the development of autoimmune diseases such as encephalomyelitis, graft-versus-host disease, and type I diabetes. Taken together, these results suggest that PD-1 blockade has the potential to activate anti-self T cell responses, but these responses are variable and dependent upon various host genetic factors. Thus, PD-1 deficiency or inhibition is not accompanied by a universal loss of tolerance to self antigens.

Preclinical animal models of tumors have shown that blockade by PD-1 by monoclonal antibodies (mAbs) can enhance the anti-tumor immune response and result in tumor rejection. Antitumor activity by PD-1 blockade functions in PD-L1-positive tumors as well as in tumors that are negative for the expression of PD-L1. This suggests that host mechanisms (ie, expression of PD-

L1 in antigen-presenting cells) limit the antitumor response. Consequently, both PD-L1 positive and negative tumors may be targeted using this approach. In humans, constitutive PD-L1 expression is normally limited to macrophage-lineage cells, although expression of PD-L1 can be induced on other hematologic cells as well, including activated T cells. However, aberrant expression of PD-L1 by tumor cells has been reported in a number of human malignancies. PD-L1 expressed by tumor cells has been shown to enhance apoptosis of activated tumor specific T cells in vitro. Moreover, the expression of PD-L1 may protect the tumor cells from the induction of apoptosis by effector T cells. Additional details are available in the Nivolumab Investigator Brochure.

1.1.2.2 Ipilimumab Mechanism of Action

Ipilimumab is a fully human monoclonal IgG1k that binds to the CTLA-4 antigen expressed on a subset of T cells from human and nonhuman primates. CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor response.

1.1.3 Phase 1/2 Data for Nivolumab in SCLC

In a Phase 1/2 study of nivolumab and nivolumab/ipilimumab for treatment of recurrent SCLC (CA209032), subjects who were platinum sensitive or refractory, and had progressive disease were enrolled regardless of tumor PD-L1 status or number of prior chemotherapy regimens. This open-label study randomized subjects to nivolumab 3 mg/kg IV Q2W or nivolumab + ipilimumab (1 + 1 mg/kg, 1 + 3 mg/kg or 3 + 1 mg/kg) IV every 3 weeks (Q3W) for 4 cycles followed by nivolumab 3 mg/kg Q2W. The primary objective was objective response rate (ORR). Other objectives were safety, PFS, OS and biomarker analysis. The CA209032 data shown here are based on an interim database lock date of 16-Feb-2015 and focus on the treatments groups nivolumab monotherapy (3 mg/kg: N = 40) and nivolumab / ipilimumab combination (nivolumab 1 mg kg / ipilimumab 1 mg/kg: N = 3; nivolumab 1 mg kg / ipilimumab 3 mg/kg: N = 47) which represent the groups with the longest follow up. The trial is being conducted at 21 investigational sites in the US, Germany, UK, Italy, Spain, and Finland.

Demographics and Baseline Characteristics

All subjects had prior platinum-based first-line treatment and progression after the most recent treatment regimen. Baseline characteristics were typical for a SCLC population in respect to age, smoking history and gender. A total of 35% of subjects (nivolumab monotherapy) and 56% (nivolumab/ipilimumab combination) had 1 prior chemotherapy treatment regimen. A total of 35% of subjects (nivolumab monotherapy) and 34% (nivolumab/ipilimumab combination) had platinum-resistant or refractory disease.

Exposure and Disposition

As of the 16-Feb-2015 database lock, 20% of subjects (nivolumab monotherapy), 33% (nivolumab 1 mg kg/ipilimumab 1 mg/kg), and 43% (nivolumab 1 mg kg / ipilimumab 3 mg/kg) were continuing study treatment. Subjects in the different cohorts were in part sequentially enrolled with subjects in the combination cohorts in general at later timepoints, resulting in a shorter follow up for subjects in the nivolumab 1 mg/kg/ipilimumab 3 mg/kg group. A total of 7.5% (nivolumab monotherapy) and 11% (nivolumab 1 mg/kg / ipilimumab 3 mg/kg) of subjects permanently discontinued treatment because of treatment related AEs.

<u>Safety</u>

Nivolumab monotherapy in subjects with SCLC was well tolerated. 52.5% of the subjects had drug-related AEs of any grade, 15.0% with Grade 3-4 events (Table 1.1.3-1). There were no drug-related adverse AEs leading to death. The most frequent ($\geq 10\%$, any grade) drug-related AEs were fatigue, diarrhea, nausea, and decreased appetite (Table 1.1.3-1). A total of 7.5% of subjects permanently discontinued treatment because of treatment related AEs (N = 3, limbic encephalitis, hyperglycemia, and stomatitis).

Nivolumab/ipilimumab combination therapy showed a manageable safety profile. While the incidence of drug-related AEs (nivolumab 1 mg kg/ipilimumab 3 mg/kg: 76.6% any grade, 34% Grade 3-4) was higher than in the nivolumab monotherapy group (Table 1.1.3-1), the treatment discontinuation rate for treatment related AEs was 11% (nivolumab 1 mg/kg / ipilimumab 3 mg/kg): N = 5, diarrhea, myasthenia gravis [subsequently developing complications with fatal outcome], pneumonitis, cardiomyopathy, 1 subject with hypothyroidism, hyperglycemia and increased ALT). The most frequent ($\geq 10\%$, any grade) drug-related AEs were diarrhea, fatigue, rash, pruritus, hypothyroidism, rash maculo-papular, nausea, hyperthyroidism, and lipase increased (Table 1.1.3-1).

One treatment-related death in the nivolumab 1 mg/kg / ipilimumab 3 mg/kg cohort occurred. This subject developed myasthenia gravis (reported as Grade 4) after treatment start and suffered from complications causing the subject's death.

Limbic encephalitis was reported in 3 subjects and resolved with immunosuppressive treatment in 2 cases. Another subject had a minor response to immunosuppressive treatment and eventually died due to the underlying tumor disease.

Table 1.1.3-1:Drug-related AEs ≥ 5% (Any Grade) and All Grade 3-5 AEs - SCLC Subjects Treated with Nivolumab
Monotherapy or Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Combination Therapy-CA209032

Charles Course Class (%)	Nivolumab	(N = 40)	Nivolum	nab 1 mg/kg + Ipili	mumab 3 mg/kg	(N = 47)
System Organ Class (%) Preferred Term (%)	Any Grade	Grade 3-4	Grade 5	Any Grade	Grade 3-4	Grade 5
TOTAL SUBJECTS WITH AN EVENT	21 (52.5)	6 (15.0)	0	36 (76.6)	16 (34.0)	0
GASTROINTESTINAL DISORDERS	10 (25.0)	1 (2.5)	0	19 (40.4)	6 (12.8)	0
DIARRHOEA	5 (12.5)	0	0	11 (23.4)	4 (8.5)	0
NAUSEA	4 (10.0)	0	0	6 (12.8)	1 (2.1)	0
VOMITING	1 (2.5)	0	0	4 (8.5)	2 (4.3)	0
GASTRITIS HAEMORRHAGIC	0	0	0	1 (2.1)	1 (2.1)	0
STOMATITIS	1 (2.5)	1 (2.5)	0	1 (2.1)	0	0
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	6 (15.0)	0	0 0	21 (44.7)	4 (8.5)	0
PRURITUS	3 (7.5)	0	0	9 (19.1)	1 (2.1)	0
RASH	1 (2.5)	0	0	10 (21.3)	2(4.3)	0
RASH MACULO-PAPULAR		0	0	6 (12.8)	2 (4.3)	0
GENERAL DISORDERS AND ADMINISTRATION	7 (17.5)	1 (2.5)	0	11 (23.4)	0	0
SITE CONDITIONS FATIGUE	7 (17 E)	1 (O E)	0		0	0
	7 (17.5) 4 (10.0)	1 (2.5) 2 (5.0)	Ŏ	10 (21.3) 9 (19.1)	4 (8.5)	0
INVESTIGATIONS LIPASE INCREASED	4 (10.0)	2 (5.0)	0	9 (19.1) 5 (10.6)	4 (8.5) 3 (6.4)	0
AMYLASE INCREASED	1 (2.5)	1 (2.5)	0	3(10.0) 3(6.4)	1 (2.1)	0
ALANINE AMINOIRANSFERASE INCREASED	1 (2.5) 1 (2.5)	0	0	3 (6.4) 2 (4.3)	1 (2.1) 1 (2.1)	0
NEUTROPHIL COUNT DECREASED	0	0	0	1 (2.1)	1 (2.1) 1 (2.1)	0
GAMMA-GLUTAMYLTRANSFERASE INCREASED	1 (2.5)	1 (2.5)	0	0	0	0
ENDOCRINE DISORDERS	2 (5.0)	0 2.07	ŏ	10 (21.3)	ŏ	ŏ
HYPOTHYROIDISM	1(2.5)	0	Õ	7 (14.9)	0	Õ
HYPERTHYROIDISM	1(2.5)	Ō	Ō	6 (12.8)	Õ	Õ
METABOLISM AND NUTRITION DISORDERS	6 (15.0)	1 (2.5)	Õ	7 (14.9)	1 (2.1)	Ŏ
DECREASED APPETITE	4 (10.0)	0	Ō	2(4.3)	0	Ō
HYPOMAGNESAEMIA	1 (2.5)	0	0	4 (8.5)	0	0
HYPERGLYCAEMIA	1 (2.5)	1 (2.5)	0	1 (2.1)	1 (2.1)	0
NERVOUS SYSTEM DISORDERS	3 (7.5)	0	0	6 (12.8)	1 (2.1)	0
MYASTHENIA GRAVIS	0	0	0 0 0 0 0 0	1 (2.1)	1 (2.1)	0
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS		0	0	4 (8.5)	2 (4.3)	0
DYSPNOEA	1 (2.5)	0	0	1 (2.1)	1 (2.1)	0
PNEUMONITIS	2 (5.0)	0	0	1 (2.1)	1 (2.1)	0
CARDIAC DISORDERS	0	0	0	3 (6.4)	1 (2.1)	0
CARDIOMYOPATHY	0	0	0	1 (2.1)	1 (2.1)	0
INFECTIONS AND INFESTATIONS	3 (7.5)	1 (2.5)	0 0 0 0 0 0 0	2 (4.3)	0	Ŭ
ENCEPHALITIS	1 (2.5)	1 (2.5)	0	1 (2.1)	0	U
HEPATOBILIARY DISORDERS	U	U	U	1 (2.1)	1 (2.1)	U
HYPERTRANSAMINASAEMIA	U	0	U	1 (2.1)	1 (2.1)	U

MedDRA Version: 17.1, CTC Version 4.0. Includes events reported between first dose and 100 days after last dose of study therapy.

<u>Efficacy</u>

Nivolumab had single-agent activity in subjects with SCLC (N = 40), who were heavily pretreated ($65.5\% \ge 2$ prior treatment regimens) including 35% having platinum resistant or refractory disease. The investigator assessed ORR was 18%, the disease control rate (CR+ PR + SD) was 38% (Table 1.1.3-2).

Nivolumab/ipilimumab combination therapy in subjects with SCLC (N = 46) showed additional activity (Table 1.1.3-2). At the time of the database lock the overall response rate was 17%, and the disease control rate (CR + PR + SD) was 54%. After the 16-Feb-2015 database lock, 7 additional subjects with previously reported SD had a confirmed PR, resulting in an updated ORR of 30%. This updated ORR was confirmed in a subsequent database lock on 26-Jun-2015. Subjects in the nivolumab/ipilimumab combination group were heavily pretreated (44% \geq 2 prior treatment regimens) including 34% having platinum resistant or refractory disease.

Objective responses were long lasting (Figure 1.1.3-1). The median duration of response was not reached in the nivolumab monotherapy group (range: 4.1 to 11+ months) and 6.9 months (range: 1.5 to 11.1+ months) in the nivolumab/ipilimumab combination group (Table 1.1.3-2).

The median OS was 4.4 months (95% CI: 2.9, 9.4) in the nivolumab monotherapy group and 8.2 months (95% CI: 3.7, NR) in the nivolumab/ipilimumab combination group.

	Nivolumab	Nivolumab + Ipilimumab*
	(n = 40)	(n = 46)
ORR, %	18	17
Complete response, %	0	2.2
Partial response, %	18	15
Stable disease, %	20	37
Disease control rate, %	38	54
Progressive disease, %	53**	37
Death prior to first response assessment, %	10	6.5***
Not evaluable (no tumor assessment follow-up), %	0	2.2****
Median time to objective response, mos	1.6	2.2
Median DOR, mos (95% CI)	NR	6.9 (1.5, NR)
Range	4.1–11+	1.5-11.1+
Subsequent Lock (26-Jun-2015)	(n = 40)	(n = 50)
ORR, %	18	30****

Table 1.1.3-2:Summary of Clinical Activity


Combined data for nivolumab 1 + Ipilimumab 1 and nivolumab 1 + ipilimumab 3 cohorts. In the nivolumab 1 + ipilimumab 3 cohort, 4 pts had not reached first tumor assessment at DBL.

** 1 pt had PD in spine requiring surgery.

*** 1 pt died due to unrelated AE, 1 pt died due to treatment-related myasthenia gravis, 1 pt died due to PD.

- ****1 pt had unrelated AE leading to permanent discontinuation and had no post baseline tumor assessment.
- *****After the 26-Feb-2015 database lock, 7 additional subjects with previously reported SD had a confirmed PR, resulting in an updated ORR of 30%. This updated ORR was confirmed in a subsequent database lock on 26-Jun-2015.





^aCombined data for nivolumab 1 + ipilimumab 1 and nivolumab 1 + ipilimumab 3 cohorts. Only pts with target lesion at baseline and \geq 1 on-treatment tumor assessment are included (nivolumab, n = 34, nivolumab + ipilimumab, n = 40).

1.1.3.1 Updated Results from CA209032 SCLC Cohorts

Recently, updated results from CA209032 have been published,¹³ confirming the activity of both nivolumab 3 mg/kg and nivolumab 1 mg/kg + ipilimumab 3 mg/kg in 2L+ SCLC,¹⁴ and demonstrating initial evidence of tumor mutational burden (TMB) as a potential predictive biomarker of efficacy.¹⁵

Hellman et al have shown that patients with high TMB treated with either nivolumab monotherapy or nivolumab plus ipilimumab had improved efficacy compared with those with medium or low TMB.¹³ The combination of nivolumab and ipilimumab showed a greater clinical benefit compared with nivolumab monotherapy in the high TMB subgroup, with near doubling of estimated 1-year survival rates for the combination versus monotherapy. In this study, SCLC patients with high TMB treated with nivolumab plus ipilimumab had outcomes that surpass historical survival expectations for patients with previously treated SCLC. Patients with low or medium tumor mutational burden had increased objective response rates with nivolumab plus ipilimumab compared with nivolumab monotherapy.

Tumors with a high mutational burden may have a higher number of neo-antigens which, in principle, would be expected to be more immunogenic than tumors with comparatively low mutational burden.1 Therefore, high TMB has been hypothesized to correlate with improved

efficacy in patients treated with immune-oncology (IO) therapies. This hypothesis has been supported by multiple publications across IO therapies, tumor types, and lines of treatment. These observations suggested that tumor mutational burden has a potential role as a biomarker for immunotherapy in SCLC.

1.1.4 Safety Profile of Nivolumab Monotherapy

In clinical trials, nivolumab has demonstrated an acceptable benefit-risk across multiple tumor types, including advanced melanoma, renal cell carcinoma (RCC), NSCLC, and lymphomas. The three clinical trials that have contributed the most to the clinical experiences of nivolumab monotherapy are studies CA209003, CA209017 and CA209057.

CA209003 is a completed Phase 1 open label, multiple dose escalation study in 306 subjects with select previously treated advanced solid tumors, including melanoma, RCC, NSCLC, colorectal cancer, and hormone-refractory prostate cancer. Subjects received nivolumab at doses of 0.1, 0.3, 1, 3, or 10 mg/kg IV Q2W, up to a maximum of 2 years of total therapy. A total of 306 subjects were treated with nivolumab in the dose range of 0.1 to 10 mg/kg.

No maximal tolerated dose was identified in CA209003. The incidence, severity and relationship of AEs were generally similar across dose levels and tumor types. Nivolumab-related AEs of any grade occurred in 75.2% of subjects. Of the 306 treated subjects, 303 (99.0%) subjects had at least 1 reported AE regardless of causality. The most frequently reported AEs were fatigue (54.9%), decreased appetite (35.0%), diarrhea (34.3%), nausea (30.1%), and cough (29.4%). Treatment-related AEs were reported in 230 (75.2%) of the 306 subjects. The most frequently reported treatment-related AEs were fatigue (28.1%), rash (14.7%), diarrhea (13.4%), and pruritus (10.5%). Most treatment-related AEs were low grade. Treatment-related high grade (Grade 3 - 4) AEs were reported in 52 (17.0%) of subjects. The most common treatment-related high grade AEs were fatigue (2.3%) and diarrhea (1%). Drug related SAEs occurred in 11.5% of subjects. Grade 3 - 4 drug-related SAEs reported in at least 2 subjects included: diarrhea (3 subjects, 1.0%), pneumonitis (3 subjects, 1.0%), pneumonia (2 subjects, 0.7%) and lipase increased (2 subjects, 0.7%).

Select AE categories (events with a potential inflammatory mechanism requiring more frequent monitoring and/or unique intervention such as immunosuppressants and/or endocrine replacement therapy) include: GI AEs, pulmonary AEs, renal AEs, hepatic AEs, skin AEs, and endocrinopathies. In addition, select AEs include a category for infusion reactions. Each category is composed of a discrete set of preferred terms, including those of greatest clinical relevance. These select AEs are considered events of interest based on the mechanism of action and were previously referred to as immune-related AEs or immune-mediated AEs. Most high grade events resolved following the treatment guidelines for the treatment of pulmonary events, GI events, hepatic events, renal events, and endocrine events, respectively. Overall, the safety profile at 3 mg/kg (n = 54) was similar to safety profile across the dose ranges from 0.1 mg/kg to 10 mg/kg (n = 306).

Treatment-related AEs leading to discontinuation were reported in 32 (10.5%) of the 306 treated subjects on CA209003. The most frequent of these were pneumonitis (8 subjects; 2.6%) and colitis

(3 subjects; 1.0%). There were 3 (1%) drug related deaths; each occurred after development of pneumonitis.

Nivolumab monotherapy was also studied in two phase 3 trials in comparison to docetaxel in patients with squamous (CA209017)¹¹ and non-squamous (CA209057)¹² NSCLC progressing during or after a first-line platinum doublet.

In CA209017, grade 3–4 drug-related AEs occurred in 7% (9/131) of nivolumab-treated and 55% (71/129) of docetaxel-treated patients. No deaths were related to nivolumab vs 3 docetaxel-related deaths.

In CA209057, Grade 3–5 drug-related AEs occurred in 10.5% (30/287) of nivolumab-treated and 53.7% (144/268) of docetaxel-treated patients. There was one death in each treatment group attributed to study drug toxicity. (The death in the nivolumab group, although reported prior to database lock, had its causality changed after database lock).

Additional details on the safety profile of nivolumab, including results from other clinical studies, are also available in the nivolumab investigator brochure (IB).

1.1.5 Safety Profile of Nivolumab and Ipilimumab Combination Therapy

The CA209067 study was conducted to evaluate the safety and efficacy of nivolumab alone or nivolumab combined with ipilimumab in comparison with ipilimumab alone in patients with previously untreated metastatic melanoma.¹⁶ Eligible patients had histologically confirmed stage III (unresectable) or stage IV melanoma and had received no prior systemic treatment for advanced disease. In this double-blind, phase 3 study, enrolled patients were randomly assigned in a 1:1:1 ratio to receive one of the following regimens: 3 mg/kg of nivolumab per kilogram of body weight every 2 weeks (plus ipilimumab-matched placebo); 1 mg/kg of nivolumab per kilogram every 3 weeks plus 3 mg/kg of ipilimumab per kilogram every 3 weeks for 4 doses, followed by 3 mg/kg of nivolumab per kilogram every 3 weeks for 4 doses (plus nivolumab-matched placebo). Overall, 945 patients were enrolled (nivolumab: n = 316; ipilimumab: n = 315; nivolumab plus ipilimumab n = 314).

Treatment-related adverse events of any grade occurred in 82.1% of the patients in the nivolumab group, 95.5% of those in the nivolumab-plus-ipilimumab group, and 86.2% of those in the ipilimumab group. The most common adverse events in the nivolumab-plus-ipilimumab group were diarrhea (in 44.1% of patients), fatigue (in 35.1%), and pruritus (in 33.2%). The incidence of treatment-related adverse events of grade 3 or 4 was also higher in the nivolumab-plus-ipilimumab group (55.0%) than in the nivolumab group (16.3%) or the ipilimumab group (27.3%).

Treatment-related adverse events of any grade that led to discontinuation of the study drug occurred in 7.7% of the patients in the nivolumab group, 36.4% of those in the nivolumab-plus-ipilimumab group, and 14.8% of those in the ipilimumab group, with the most common events being diarrhea (in 1.9%, 8.3%, and 4.5%, respectively) and colitis (in 0.6%, 8.3%, and 7.7%, respectively). One death due to toxic effects of the study drug was reported in the

nivolumab group (neutropenia) and one in the ipilimumab group (cardiac arrest); none were reported in the nivolumab-plus-ipilimumab group.

Immune-modulatory agents, including topical agents, to manage adverse events were used in 47.0% of the patients in the nivolumab group, 83.4% of those in the nivolumab-plus-ipilimumab group, and 55.9% of those in the ipilimumab group, with secondary immunosuppressive agents (eg, infliximab) used in 0.6%, 6.1%, and 5.1% of the patients, respectively. Resolution rates for select adverse events of grade 3 or 4 were between 85 and 100% in the nivolumab-plus-ipilimumab group for most organ categories. As in prior studies, most endocrine events did not resolve and patients continued on physiological hormone substitution.

In general, the safety profile of the combination therapy was consistent with previous experience with nivolumab or ipilimumab alone. No new safety signals were identified, and there were no drug-related deaths in the combination group. Adverse events were manageable with established treatment guidelines, and most select adverse events resolved with the use of immune-modulatory agents.

1.1.6 Rationale to Support Nivolumab Monotherapy "Flat" Dose of 240 mg

Nivolumab monotherapy has been extensively studied in NSCLC patient population and other solid tumor indications with body weight normalized dosing (mg/kg). Nivolumab pharmacokinetics (PK) and exposures of subjects in these studies have been characterized by population pharmacokinetic (PPK) analysis of data collected in these studies, together with PK data from several Phase 1, 2, and 3 clinical studies of nivolumab monotherapy in solid tumors. Nivolumab PK was determined to be linear, with dose proportional exposures over a dose range of 0.1 to 10 mg/kg. Nivolumab clearance and volume of distribution was found to increase with increasing body weight, but the increase was less than proportional, indicating that a mg/kg dose represents an over-adjustment for the effect of body weight on nivolumab PK. Conversely, given the relationship between nivolumab PK and body weight, a flat dose is expected to lead to lower exposures in heavier patients, relative to the exposures in lighter patients. Table 1.1.6-1 presents summary statistics of the estimated nivolumab steady-state trough, peak and time-averaged concentration (Cminss, Cmaxss, and Cavgss, respectively) in NSCLC subjects receiving 3 mg/kg, together with corresponding statistics of exposures predicted for a flat nivolumab dose of 240 mg. It should be noted that a dose of 240 mg nivolumab is identical to a dose of 3 mg/kg for subjects weighing 80 kg, which is the approximate median body weight of NSCLC subjects in the 3 Phase 2 and 3 clinical studies of nivolumab monotherapy in NSCLC patients (CA209017, CA209057, and CA209063). As evident from the data presented in Table 1.1.6-1, the geometric mean values of Cminss, Cmaxss, and Cavgss with flat dosing are slightly (< 15%) higher than that produced by a 3 mg/kg dose, and the coefficient of variation (cv%) in these measures of exposure are only slightly (< 10%) greater than that of 3 mg/kg dosing.

Nivolumab Dose	Cminss Geo. Mean [ug/mL] (cv%)	Cmaxss Geo. Mean [ug/mL] (cv%)	Cavgss Geo Mean [ug/mL] (cv%)
3 mg/kg	54.7 (41.9)	118.9 (31.8)	73.3 (35.6)
240 mg	61.5 (44.6)	133.7 (35.0)	84.2 (38.2)

Table 1.1.6-1: Summary Statistics of Nivolumab Steady-state Exposure
--

Nivolumab has been shown to be safe and well tolerated up to a dose level of 10 mg/kg, and the relationship between nivolumab exposure produced by 3 mg/kg and efficacy has been found to be relatively flat. Taken together, the PK, safety, and efficacy data indicate that the safety and efficacy profile of 240 mg nivolumab will be similar to that of 3 mg/kg nivolumab.

Based on these clinical results, a flat dose of 240 mg will be utilized for the monotherapy Arm A, as well as the maintenance dosing for the combination Arm B.

1.1.7 Rationale for Nivolumab and Ipilimumab Combination

The combination of nivolumab and ipilimumab was chosen as an experimental arm because of preclinical and preliminary clinical evidence suggesting synergy between nivolumab and ipilimumab. While PD-1 and CTLA-4 are both co-inhibitory molecules, evidence suggests that they use distinct mechanisms to limit T cell activation. Preliminary indirect data from peripheral T cell assessments suggest that a given T cell checkpoint inhibitor may modulate host immune cell phenotype rendering them more susceptible to alternate checkpoint inhibitors and thereby enhancing anti-tumor activity. Specifically, nivolumab increased peripheral CTLA-4+ and regulatory T cells in subjects without clinical response in CA209006.¹⁷ In a preclinical melanoma model, anti-CTLA-4 therapy increased PD 1+, PD L1+ and CTLA-4+ tumor infiltrating T cells.¹⁸ In addition, in the Phase 2 ipilimumab monotherapy study CA184004, increases in tumor infiltrating lymphocytes (TILs) and interferon-y-inducible genes were observed following treatment with ipilimumab, and PD-L1 positive tumor cells co-localize with both TILs and interferon-y expression in metastatic melanoma.^{19,20} Preliminary results from Study CA209032 in platinum-based pretreated SCLC subjects showed an ORR of 30% in the nivolumab / ipilimumab combination arm and an ORR of 18% in the nivolumab arm, suggesting a synergistic effect by combining nivolumab with ipilimumab.

1.1.7.1 Rationale for Nivolumab and Ipilimumab Combination Dose and Schedule

In CA209004, a Phase 1B dose-escalation study of nivolumab in combination with ipilimumab in subjects with unresectable stage III or IV malignant melanoma, the 3 mg/kg nivolumab and 3 mg/kg ipilimumab cohort exceeded the maximum tolerated dose per protocol. While both Cohort 2 (1 mg/kg nivolumab + 3 mg/kg ipilimumab) and Cohort 2a (3 mg/kg nivolumab + 1 mg/kg ipilimumab) had similar clinical activity, a dose of 3 mg/kg of ipilimumab every 3 weeks for a total of four doses and 1 mg/kg nivolumab every 3 weeks for four doses followed by nivolumab 3mg/kg every 2 weeks until progression was chosen. Exposure-response analysis of nivolumab

monotherapy across dose ranges of 1 mg/kg to 10 mg/kg reveals similar clinical activity while exposure-response analysis of 0.3 mg/kg, 3 mg/kg, and 10 mg/kg of ipilimumab monotherapy have demonstrated increasing activity with increase in dose in the phase 2 study CA184022.²¹ Therefore, theoretically the selection of 3 mg/kg of ipilimumab (Cohort 2) may be more clinically impactful than selection of 3 mg/kg of nivolumab (Cohort 2a).

Recently, data from the phase III Study CA209067 in subjects with advanced melanoma showed that the administration schedule of 1 mg/kg of nivolumab every 3 weeks plus 3 mg/kg of ipilimumab every 3 weeks for 4 doses, followed by 3 mg/kg of nivolumab every 2 weeks for cycle 3 and beyond is safe and well tolerated.¹⁶ Preliminary data from Study CA209032 showed safety and tolerability of this treatment schedule in heavily pretreated SCLC subjects (Section 1.1.3).

1.1.8 Rationale for Shorter Nivolumab Infusion Times (30 minute infusion)

Long infusion times, especially when multiple agents are administered sequentially, place a burden on patients and treatment centers. Establishing that nivolumab can be safely administered using shorter infusion times of 30 minutes duration will reduce this burden, provided there is no change in safety profile.

Previous clinical studies of nivolumab monotherapy have used a 60 minute infusion duration for nivolumab (1-3 mg/kg). Nivolumab has been administered safely over 60 minutes at doses ranging up to 10 mg/kg over long treatment duration. In Study CA209010, (a Phase 2, randomized, double-blinded, dose-ranging study of nivolumab in subjects with advanced/metastatic clear cell RCC) a dose association was observed for infusion site reactions and hypersensitivity reactions (1.7% at 0.3 mg/kg, 3.7% at 2 mg/kg and 18.5% at 10 mg/kg). All the events were grade 1-2 and were manageable. An infusion duration of 30 minutes for 3 mg/kg nivolumab (30% of the dose provided at 10 mg/kg) is not expected to present any safety concerns compared to the prior experience at 10 mg/kg nivolumab dose infused over a 60 minute duration.

Overall, infusion reactions, including high-grade hypersensitivity reactions, have been uncommon across the nivolumab clinical development program, and a change in safety profile is not anticipated with 30-minute infusion of nivolumab.

1.1.9 Rationale for Permitting Continued Treatment in Select Cases of Progressive Disease

Accumulating clinical evidence indicates some subjects treated with immune system stimulating agents may develop progression of disease (by conventional response criteria) before demonstrating clinical objective responses and/or stable disease. This phenomenon was observed in a Phase 1 study of nivolumab²² and also in combination with ipilimumab.²³ Two hypotheses have been put forth to explain this phenomenon. First, enhanced inflammation within tumors could lead to an increase in tumor size which would appear as enlarged index lesions and as newly visible small non-index lesions. Over time, both the malignant and inflammatory portions of the mass may then decrease leading to overt signs of clinical improvement. Alternatively, in some individuals, the kinetics of tumor growth may initially outpace anti-tumor immune activity. With

sufficient time, the anti-tumor activity will dominate and become clinically apparent. Therefore subjects will be allowed to continue blinded study therapy after initial investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST 1.1, Appendix 3) defined progression if they are assessed to be deriving clinical benefit and tolerating study drug (Section 4.5.5). Such subjects must discontinue blinded study therapy upon evidence of further progression.

1.1.9.1 Rationale for Placebo Control

There is no established standard of care for subjects with ED-SCLC who complete first line platinum based therapy, and have achieved stable disease or an objective response; active surveillance is consistent with current National Comprehensive Cancer Network (NCCN) guidelines.³ Tumor assessments in Study CA209451 are performed every 6 weeks during for the first 36 weeks and every 12 weeks thereafter, ensuring that a disease progression is detected early and subjects on the placebo arm are not exposed to an undue risk. The use of placebo in the control arm is therefore justified.

1.1.9.2 Rationale for Duration of Treatment with Nivolumab Alone or in Combination with Ipilimumab

The optimal duration of immunotherapy is currently unknown. However, because immunotherapy engages the immune system to control the tumor, continuous treatment as is required with targeted agents or cytotoxic therapy may not be necessary.

Growing evidence from clinical trials of nivolumab and ipilimumab across different tumor types indicate that the majority radiographic responses occur shortly after the start of treatment, with a median time to response of 2-4 months in melanoma, NSCLC, and other tumor types.^{24,25,26,27,28} A recent pooled analysis of multiple melanoma studies suggests that the majority of patients who discontinue nivolumab and/or ipilimumab for toxicity maintain disease control in the absence of further treatment..²⁹ Furthermore, a limited duration of ipilimumab including only 4 induction doses resulted in long term survival in patients with metastatic melanoma, with a sustained plateau in survival starting at around year 3.³⁰

While there is no randomized data evaluating stopping at 2 years, accumulating data suggests 2 years of I-O treatment may be sufficient for long term benefit. In CheckMate 003, a dose-escalation cohort expansion trial evaluating the safety and clinical activity of nivolumab in patients with advanced solid tumors, nivolumab monotherapy was discontinued at 96 weeks (~ 2 years). With a median follow-up of 60 months, among the 16 subjects enrolled in the NSCLC cohort, 12 subjects were progression free at >5 years without further therapy after stopping nivolumab. Of the 4 subjects that progressed prior to completion of 2 years of therapy, 3 received subsequent therapy and were alive at 5 years.³¹

Similar results have been seen in published studies of pembrolizumab, a PD-L1 inhibitor with similar mechanism of action to nivolumab. In Keynote -010, a phase 3 randomized trial of pembrolizumab versus docetaxel in previously treated, PD-L1-positive, advanced NSCLC, patients who completed the maximum 24 months of pembrolizumab were observed to have durable

clinical benefit. While the median follow up at the time of publication was 2.1 years (range = 1.5-3 years), only 4% of patients were found to have progressed after completion of 24 months of therapy. The OS benefit was maintained and a survival plateau above 30% was observed after 2 years of treatment.³²

Long term follow up data from Keynote 006, a phase 3 melanoma study, demonstrated that pembrolizumab provides durable efficacy in patients who complete the protocol-specified duration of treatment at 2 years. Among the 104 patients who completed 24 months of pembrolizumab treatment, 102 (98%) were alive at the time of analysis, with a median follow-up of 33.9 months.³³

For these reasons, in study CA209451 treatment will be given for up to 24 months in the absence of disease progression or unacceptable toxicity.

1.2 Research Hypothesis

Maintenance treatment with nivolumab monotherapy, or nivolumab in combination with ipilimumab followed by nivolumab monotherapy, will prolong overall survival (OS) as compared with placebo in subjects with ED-SCLC who have completed platinum-based first line chemotherapy.

1.3 Objectives(s)

1.3.1 Primary Objectives

To compare OS of nivolumab in combination with ipilimumab versus placebo in subjects with ED-SCLC after completion of platinum-based first line chemotherapy.

1.3.2 Secondary Objectives

- To compare OS of nivolumab versus placebo in subjects with ED-SCLC after completion of platinum-based first line chemotherapy.
- To compare Blinded Independent Central Review (BICR) assessed PFS of nivolumab, and nivolumab in combination with ipilimumab versus placebo
- To evaluate (descriptively) OS and BICR-assessed PFS of nivolumab combined with ipilimumab versus nivolumab monotherapy.
- To evaluate tumor mutational burden as a predictive biomarker for OS and PFS of nivolumab, and nivolumab in combination with ipilimumab

1.3.3 Exploratory Objectives

- To evaluate the safety and tolerability of nivolumab, nivolumab in combination with ipilimumab, and placebo;
- To evaluate Objective Response Rate (ORR) of nivolumab, and nivolumab in combination with ipilimumab, versus placebo;
- To evaluate Duration of Response (DOR) and Time to Response of nivolumab, and nivolumab in combination with ipilimumab, versus placebo;

- To explore PD-L1 expression as an independent predictive biomarker for efficacy of nivolumab, and nivolumab in combination with ipilimumab;
- To correlate potential predictive biomarkers in peripheral blood and tumor specimens, including proteins involved in regulating immune responses (eg, PD-1, PD-L1, PD-L2), mutational as well as immunohistochemistry (IHC) spectrum, with efficacy endpoints such as ORR, PFS and OS;
- To characterize immunological pharmacodynamic biomarkers of nivolumab, and nivolumab in combination with ipilimumab
- To characterize pharmacokinetics of nivolumab and ipilimumab and explore exposure response (exposure-safety and exposure-efficacy) relationships with respect to selected safety and efficacy endpoints
- To characterize immunogenicity of nivolumab, and nivolumab in combination with ipilimumab.
- To compare time to symptom deterioration (TTSD) as assessed by the average symptom burden index (ASBI) of the Lung Cancer Symptom Scale (LCSS) among subjects treated with nivolumab, and nivolumab in combination with ipilimumab arm versus placebo;
- To assess the subject's overall health status using the EQ-5D Index and visual analog scale.

1.4 Product Development Background

Nivolumab is in clinical development for the treatment of subjects with NSCLC, RCC, glioblastoma and other cancer types. Recently, nivolumab was approved by the FDA for the treatment of patients with advanced squamous NSCLC and melanoma. Nivolumab is also approved for the treatment of advanced melanoma in Europe, Japan, and other countries.

In the Phase 1/2 trial, CA209032, in subjects with heavily pretreated SCLC, nivolumab monotherapy showed an ORR of 18%, while the combination of nivolumab and ipilimumab demonstrated an ORR of 30% in an updated analysis.³⁴ Study CA209451 will be the second Phase 3 study in the clinical development program for nivolumab in SCLC and will evaluate the efficacy and safety of nivolumab monotherapy and nivolumab and ipilimumab combination therapy, as maintenance treatment following first line platinum-based chemotherapy in subjects with ED-SCLC.

1.5 Overall Risk/Benefit Assessment

ED-SCLC is a disease with high unmet medical need. Despite a robust initial response rate to first line platinum-containing chemotherapy regimens, subsequent progression is typically rapid and overall survival rates are poor. Further, there are currently no agents approved in the maintenance setting for patients who respond to first line therapy. The clinical activity of nivolumab monotherapy, as well as nivolumab and ipilimumab combination therapy, observed in the CA209032 study suggests the potential for improved clinical outcomes relative to the current standard practice of observation and best supportive care.

Nivolumab, both as monotherapy and in combination with ipilimumab, can cause clinically relevant AEs, including liver toxicities, thyroiditis, pneumonitis, and diarrhea. However, these

toxicities are typically manageable or reversible with the Management Algorithms provided in Appendix 2 and the nivolumab IB.

To assure an ongoing favorable benefit-risk assessment for subjects enrolled onto CA209451, an independent Data Monitoring Committee (DMC) will be utilized to monitor the safety and efficacy of nivolumab versus nivolumab and ipilimumab versus placebo throughout the conduct of the trial.

2 ETHICAL CONSIDERATIONS

2.1 Good Clinical Practice

This study will be conducted in accordance with Good Clinical Practice (GCP), as defined by the International Conference on Harmonisation (ICH) and in accordance with the ethical principles underlying European Union Directive 2001/20/EC and the United States Code of Federal Regulations, Title 21, Part 50 (21CFR50) and applicable local requirements.

The study will be conducted in compliance with the protocol. The protocol and any amendments and the subject informed consent will receive Institutional Review Board/Independent Ethics Committee (IRB/IEC) approval/favorable opinion prior to initiation of the study.

All potential serious breaches must be reported to BMS immediately. A serious breach is a breach of the conditions and principles of GCP in connection with the study or the protocol, which is likely to affect, to a significant degree, the safety or physical or mental integrity of the subjects of the study or the scientific value of the study.

Personnel involved in conducting this study will be qualified by education, training, and experience to perform their respective tasks.

This study will not use the services of study personnel where sanctions have been invoked or where there has been scientific misconduct or fraud (eg, loss of medical licensure, debarment).

2.2 Institutional Review Board/Independent Ethics Committee

Before study initiation, the investigator must have written and dated approval/favorable opinion from the IRB/IEC for the protocol, consent form, subject recruitment materials (eg, advertisements), and any other written information to be provided to subjects. The investigator or BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product labeling information to be provided to subjects and any updates.

The investigator or BMS should provide the IRB/IEC with reports, updates and other information (eg, expedited safety reports, amendments, and administrative letters) according to regulatory requirements or institution procedures.

2.3 Informed Consent

Investigators must ensure that subjects are clearly and fully informed about the purpose, potential risks, and other critical issues regarding clinical studies in which they volunteer to participate.

In situations where consent cannot be given to subjects, their legally acceptable representatives (as per country guidelines) are clearly and fully informed about the purpose, potential risks, and other critical issues regarding clinical studies in which the subject volunteers to participate.

BMS will provide the investigator with an appropriate (ie, Global or Local) sample informed consent form which will include all elements required by ICH, GCP and applicable regulatory requirements. The sample informed consent form will adhere to the ethical principles that have their origin in the Declaration of Helsinki.

Investigators must:

- 1) Provide a copy of the consent form and written information about the study in the language in which the subject is most proficient prior to clinical study participation. The language must be non-technical and easily understood.
- 2) Allow time necessary for subject or subject's legally acceptable representative to inquire about the details of the study.
- 3) Obtain an informed consent signed and personally dated by the subject or the subject's legally acceptable representative and by the person who conducted the informed consent discussion.
- 4) Obtain the IRB/IEC's written approval/favorable opinion of the written informed consent form and any other information to be provided to the subjects, prior to the beginning of the study, and after any revisions are completed for new information.
- 5) If informed consent is initially given by a subject's legally acceptable representative or legal guardian, and the subject subsequently becomes capable of making and communicating his or her informed consent during the study, consent must additionally be obtained from the subject.
- 6) Revise the informed consent whenever important new information becomes available that is relevant to the subject's consent. The investigator, or a person designated by the investigator, should fully inform the subject or the subject's legally acceptable representative or legal guardian, of all pertinent aspects of the study and of any new information relevant to the subject's willingness to continue participation in the study. This communication should be documented.

The confidentiality of records that could identify subjects must be protected, respecting the privacy and confidentiality rules applicable to regulatory requirements, the subjects' signed ICF and, in the US, the subjects' signed HIPAA Authorization.

The consent form must also include a statement that BMS and regulatory authorities have direct access to subject records.

Subjects unable to give their written consent (eg, stroke or subjects with or severe dementia) may only be enrolled in the study with the consent of a legally acceptable representative. The subject must also be informed about the nature of the study to the extent compatible with his or her understanding, and should this subject become capable, he or she should personally sign and date the consent form as soon as possible. The explicit wish of a subject who is unable to give his or her written consent, but who is capable of forming an opinion and assessing information to refuse participation in, or to be withdrawn from, the clinical study at any time should be considered by the investigator.

The rights, safety, and well-being of the study subjects are the most important considerations and should prevail over interests of science and society.

3 INVESTIGATIONAL PLAN

3.1 Study Design and Duration

This is a randomized, double-blind, three-arm, multicenter, Phase 3 study in adult subjects with ED-SCLC, who achieve Stable Disease, Partial Response or Complete Response after completion of platinum based first line chemotherapy.

Approximately 810 subjects will be randomized in a 1:1:1 ratio to treatment with either nivolumab monotherapy (Arm A), nivolumab/ipilimumab combination therapy (Arm B), or placebo (Arm C), and will be stratified according to the following factors:

- ECOG Performance Status: 0 vs 1
- Gender: Male vs Female
- Prophylactic Cranial Irradiation (PCI) following chemotherapy: Yes vs No

The treatment arms are as follows:

• Arm A:

Nivolumab 240 mg administered every 2 weeks as a 30 min IV infusion, as described in Table 4.5-1 and Table 4.5-2

- Arm B:
 - Nivolumab 1 mg/kg (30 min IV infusion) and ipilimumab 3 mg/kg (90 minute IV infusion) every 3 weeks for four doses, followed by nivolumab 240 mg every 2 weeks, as described in Table 4.5-1 and Table 4.5-2
- Arm C:
 - Placebo administered as described in Table 4.5-1 and Table 4.5-2

In order to maintain a blinded study, the schedule of investigational and placebo treatments is divided into two 6-week cycles at the start of therapy, followed by ongoing 2-week cycles until discontinuation criteria are met (Section 4.5.3.4). This schedule is described in Table 4.5-1 and Table 4.5-2.

On-study tumor assessments will be conducted every 6 weeks (\pm 5 days) for the first 36 weeks. After Week 36, tumor assessments will be performed every 12 weeks (\pm 5 days) until disease progression (Section 5.4).

Duration of the study from start of randomization to analysis of the primary endpoint will be approximately 37 months (28 months of accrual + 9 months of follow-up).

Additional survival follow-up may continue for up to 5 years from the primary analysis of survival. The study will end once survival follow-up has concluded.

The subjects safety will be monitored on an ongoing basis as described fully in Section 5.3. In addition, a BMS Medical Safety Team (MST) routinely reviews safety signals across the nivolumab program.

A Data Monitoring Committee (DMC) will be implemented to provide safety and overall risk/benefit monitoring of the study (Section 7).

The study design schematic is presented in Figure 3.1-1.




Figure 3.1-1:Study Design Schematic

The start of the trial is defined as first visit for the first subject screened. The end of trial is defined as the last visit for the last subject. Study completion is defined as the final date on which data for the primary endpoint was collected.

3.1.1 Study Phases

The study is divided into the following phases: Screening, Treatment, and Follow-up.

3.1.1.1 Screening

- Screening begins after the subject signs the informed consent form (ICF)
- The subject is enrolled using the Interactive Voice Response System (IVRS)
- Tumor tissue must be available and submitted to the central lab for correlative studies in order for a subject to be randomized (except as described in Inclusion Criteria 2f). Subjects must

consent to allow the acquisition of tumor tissue by study personnel for performance of the correlative studies

- Baseline assessments must be performed within the timeframes described in Table 5.1-1:
- Prophylactic Cranial Irradiation (PCI) may be offered to subjects following the completion of first-line chemotherapy, per local standard of care
- For patients with known brain metastases, brain radiotherapy (Whole Brain Radiation Therapy (WBRT) or stereotactic radiation) may be offered , per local standard of care
- Brain radiotherapy (including PCI) must be completed ≥ 2 weeks prior to the start of blinded study therapy
- Subjects with incidental asymptomatic brain metastasis findings at screening are eligible only if, according to the clinical judgment of the investigator, these findings are unlikely to represent progression of disease after chemotherapy.
- Randomization must be performed ≤ 9 weeks from the last dose of chemotherapy for subjects not receiving brain radiotherapy (including PCI) and ≤ 11 weeks from the last dose of chemotherapy for subjects receiving brain radiotherapy (including PCI)
 - Blinded study therapy <u>must not</u> be administered < 3 weeks (21 days) from the last dose of platinum-based first line chemotherapy.
- The screening phase either ends with confirmation of full eligibility and randomization of the subject or with the confirmation that the subject is a screen failure
- This study permits the re-enrollment of a subject that has discontinued the study as a pre-treatment failure prior to randomization. If re-enrolled, the subject must be re-consented. A new subject identification number will be assigned by IVRS at the time of re-enrollment.

3.1.1.2 Treatment

- The treatment phase begins with the randomization call to the IVRS. The subject is randomly assigned to one of the 3 treatment arms. Treatment is to begin within 3 business days of randomization
- Blinded study therapy is administered as described in Table 4.5-1 until disease progression, discontinuation due to toxicity, withdrawal of consent, the study ends, or other criteria for discontinuation are met as described in Section 3.5 and 4.5.3.4. Subjects may be treated beyond initial progression as specified in Section 5.4
- Subjects will be evaluated for response according to RECIST 1.1 criteria. Radiographic assessments will be obtained in all treatment arms every 6 weeks for the first 36 weeks, and subsequently every 12 weeks, or more frequently as clinically indicated, until disease progression (or until discontinuation of blinded study drug in patients treated beyond progression) or withdrawal of study consent
- The Treatment phase ends when the subject is discontinued from blinded study drug(s)

Study assessments are to be collected as outlined in Table 5.1-2 and Table 5.1-3.

3.1.1.3 Follow-up

- Begins when the decision to discontinue a subject from blinded study therapy is made (no further treatment with blinded study drug(s))
- Subjects who discontinue blinded study therapy for reasons other than disease progression will continue to have radiographic assessments every 6 weeks (± 5 days) for the first 36 weeks after randomization, and subsequently every 12 weeks, until disease progression or withdrawal of study consent
- Follow up visits occur as follows:
 - X01 Follow up Visit 1 = 35 days ± 7 days from last dose,
 - X02 Follow up Visit 2 = 80 days ± 7 days from X01 Follow Up Visit 1
 - Survival Follow Up visits begin after the X02 Follow Up Visit 2:
 - For Survival Follow Up Visits, for all subjects, contact will be made (in person or by telephone) every 12 weeks upon entry into this phase to evaluate Overall Survival and collect data on the initiation of subsequent therapy for the treatment of SCLC

Study assessments are to be collected as outlined in Table 5.1-4.

3.2 Post Study Access to Therapy

At the conclusion of the study, subjects assigned to active study drug who continue to demonstrate clinical benefit will be eligible to receive BMS supplied study drug for the maximum of 24 months including time on-study treatment. Study drug will be provided via an extension of the study, a rollover study requiring approval by responsible health authority and ethics committee or through another mechanism at the discretion of BMS. BMS reserves the right to terminate access to BMS supplied study drug if any of the following occur: a) the marketing application is rejected by responsible health authority; b) the study is terminated due to safety concerns; c) the subject can obtain medication from a government sponsored or private health program; or d) therapeutic alternatives become available in the local market.

3.3 Study Population

For entry into the study, the following criteria MUST be met.

3.3.1 Inclusion Criteria

1. Signed Written Informed Consent

- a) Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care
- b) Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study

2. Target Population

- a) Subjects with SCLC documented by histology or cytology from brushing, washing or needle aspiration of a defined lesion, but not from sputum cytology alone
- b) Subjects must have presented at initial diagnosis with extensive stage disease (defined as Stage IV (T any, N any, M1a/b) per NCCN guidelines Version 1.2015, AJCC Cancer Staging Manual, 7th Edition, 2010)
- c) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 (See Appendix 1)
- d) Subjects must have received 4 cycles of platinum-based first line chemotherapy and must have an ongoing response of complete response (CR), partial response (PR), or stable disease (SD) after completion of chemotherapy. Acceptable combinations, as recommended per NCCN guidelines, include cisplatin or carboplatin combined with either etoposide or irinotecan
 - i) As an exception to the above criterion, subjects receiving only 3 cycles of chemotherapy due to toxicity are eligible, if they have an ongoing PR or CR after the 3rd cycle
 - ii) Subjects who have received > 4 cycles of platinum-based first line chemotherapy are not eligible
- e) Subjects must be randomized ≤ 9 weeks (63 days), from the last dose of platinum-based first line chemotherapy. Subjects receiving PCI or Brain RT must be randomized ≤ 11 weeks (77 days) from the last dose of platinum-based first line chemotherapy
 - i) Blinded study therapy <u>must not</u> be administered < 3 weeks (21 days) from the last dose of platinum-based first line chemotherapy
 - ii) Blinded study therapy must not be administered < 2 weeks (14 days) from the last dose of radiotherapy
- f) A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block (preferred) or 10 unstained slides of tumor sample (archival or recent) for biomarker evaluation must be available and submitted to the central lab for correlative studies in order for a subject to be randomized. If fewer than 10 slides are available, the BMS Medical Monitor or Study Director may still approve randomization of subjects upon review of the case. Specimens must have been submitted to the central laboratory prior to randomization. Excisional, incisional or core needle biopsies are strongly preferred, however samples collected via endobronchial ultrasound (EBUS) guided biopsy (using a 22g needle or larger) and transbronchial lung biopsy (TBLB) are acceptable. In certain cases, the BMS Medical Monitor or Study Director may approve submission of samples collected via other methods.
- g) Subject Re-enrollment: This study permits the re-enrollment of a subject that has discontinued the study as a pre-treatment failure (ie, subject has not been randomized / has not been treated). If re-enrolled, the subject must be re-consented

3. Age and Reproductive Status

a) Men and women \geq 18 years of age or age of majority inclusive.

- b) Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of blinded study drug
- c) Women must not be breastfeeding
- d) WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with blinded study drug (s) plus the time required for the investigational drug to undergo approximately five half-lives plus 30 days (duration of ovulatory cycle) for a total of 5 months post-treatment completion
- e) Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with blinded study drug (s) plus the time required for the investigational drug to undergo approximately five half-lives plus 90 days (duration of sperm turnover) for a total of 7 months post-treatment completion
- f) Azoospermic males and WOCBP who are continuously not heterosexually active are exempt from contraceptive requirements. However they must still undergo pregnancy testing as described in this section

Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise on the use of highly effective methods of contraception which have a failure rate of < 1% when used consistently and correctly.

- a) Males, ages 18 or age of majority, inclusive
- b) Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) blinded study therapy plus the time required for the investigational drug to undergo approximately five half-lives plus 90 days (duration of sperm turnover) for a total of 7 months post-treatment completion.
- c) Azoospermic males are exempt from contraceptive requirements.
- d) Male subjects must be willing to refrain from sperm donation during the entire study and for the time required for the investigational drug to undergo approximately7 months after the end of study treatment.

Investigators shall counsel male subjects who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy. Investigators shall advise male subjects who are sexually active with WOCBP on the use of highly effective methods of contraception. Highly effective methods of contraception have a failure rate of < 1% when used consistently and correctly.

At a minimum, subjects must agree to the use of one highly effective method of contraception as listed below:

HIGHLY EFFECTIVE METHODS OF CONTRACEPTION

Highly effective methods of contraception have a failure rate of < 1% when used consistently and correctly. WOCBP and female partners of male subjects, who are WOCBP, are expected to use one of the highly effective methods of contraception listed below. Male subjects must inform their

female partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner. Contraception methods are as follows:

Highly Effective Contraceptive Methods That Are User Dependent

- Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation^a
 - oral
 - intravaginal
 - transdermal
- Progestogen-only hormonal contraception associated with inhibition of ovulation^a
 - oral
 - injectable

Highly Effective Methods That Are User Independent

- Implantable progestogen-only hormonal contraception associated with inhibition of ovulation a
- Hormonal methods of contraception including oral contraceptive pills containing a combination of estrogen and progesterone, vaginal ring, injectables, implants and intrauterine hormone-releasing system (IUS)b
- Intrauterine device (IUD)b
- Bilateral tubal occlusion
- Vasectomized partner

A vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used.

• Sexual abstinence

Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.

- It is not necessary to use any other method of contraception when complete abstinence is elected.
- WOCBP participants who choose complete abstinence must continue to have pregnancy tests, as specified in Section 2.
- Acceptable alternate methods of highly effective contraception must be discussed in the event that the WOCBP participants chooses to forego complete abstinence

NOTES:

- ^a Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of the contraceptive method. Hormonal contraception is permissible only when there is sufficient evidence that the IMP and other study medications will not alter hormonal exposures such that contraception would be ineffective or result in increased exposures that could be potentially hazardous. In this case, alternative methods of contraception should be utilized.
- ^b Intrauterine devices and intrauterine hormone releasing systems are acceptable methods of contraception in the absence of definitive drug interaction studies when hormone exposures from intrauterine devices do not alter contraception effectiveness

Unacceptable Methods of Contraception*

- Male or female condom with or without spermicide. Male and female condoms cannot be used simultaneously
- Diaphragm with spermicide
- Cervical cap with spermicide
- Vaginal Sponge with spermicide
- Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mechanism of action
- Periodic abstinence (calendar, symptothermal, post-ovulation methods)
- Withdrawal (coitus interruptus).
- Spermicide only
- Lactation amenorrhea method (LAM)

* Local laws and regulations may require use of alternative and/or additional contraception methods.

3.3.2 Exclusion Criteria

1. Target Disease Exceptions

- a) Symptomatic CNS metastases are excluded. Subjects with previous brain metastases are eligible provided that they are asymptomatic, do not require treatment with radiation therapy, steroids or anticonvulsants, and have stable disease at the screening tumor assessment. In addition, subjects must have been either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent). Blinded study therapy must not be administered < 2 weeks (14 days) from the last dose of radiotherapy
- b) Subjects receiving consolidative chest radiation are excluded.
- c) Carcinomatous meningitis
- d) Pleural effusion which cannot be controlled with appropriate interventions

- e) All toxicities attributed to prior anti-cancer therapy must have been resolved to Grade 1 (NCI CTCAE Version 4) or baseline before administration of blinded study drug(s) other than:
 - i) Subjects with toxicities attributed to prior anti-cancer therapy that either are not expected to resolve and/or result in long lasting sequelae, such as neuropathy after platinum based therapy, or are not expected to interfere with treatment on study, such as fatigue or alopecia, are eligible
 - ii) Subjects with grade 2 anemia, however hemoglobin level must be $\ge 8.0 \text{ g/dL}$

2. Medical History and Concurrent Diseases

- a) Women who are pregnant or breastfeeding
- b) Active, known or suspected autoimmune disease. Subjects with an autoimmune paraneoplastic syndrome requiring concurrent immunosuppressive treatment are excluded. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
- c) A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Corticosteroids with minimal systemic absorption (inhaled or topical steroids), and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
- d) Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways)
- e) Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
- f) Previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma, or breast) unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period
- g) Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or blinded study drug(s) administration or interfere with the interpretation of safety results
- h) Major surgery or significant traumatic injury that is not recovered at least 14 days before the first dose of blinded study drug(s)

3. Physical and Laboratory Test Findings

- a) Positive test for hepatitis B virus (HBV) using HBV surface antigen (HBVsAg) test or positive test for hepatitis C virus (HCV) using HCV ribonucleic acid (RNA) or HCV antibody test indicating acute or chronic infection
 - i) Subjects with a positive test for HCV antibody but no detection of HCV RNA indicating no current infection are eligible
- b) Known medical history of testing positive for human immunodeficiency virus (HIV) or known medical history of acquired immunodeficiency syndrome (AIDS).
- c) Inadequate hematologic function defined by:
 - i) Absolute neutrophil count (ANC) < 1,000/mm3[.]
 - ii) Platelet count $< 100,000/\text{mm}^3$, or
 - iii) Hemoglobin level < 8.0 g/dL
- d) Inadequate hepatic function as defined by either:
 - i) Total bilirubin level ≥ 1.5 times the ULN (except subjects with Gilbert's Syndrome, who are excluded if total bilirubin ≥ 3 times ULN), or
 - ii) AST and ALT levels \geq 2.5 times the ULN or \geq 5 times the ULN if liver metastases are present
- e) Inadequate pancreatic function as defined by either:
 - i) Lipase > 1.5 ULN. Subjects with lipase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis, OR
 - ii) Amylase > 1.5 ULN. Subjects with amylase > 1.5 ULN may enroll if there are neither clinical nor radiographic signs of a pancreatitis

4. Allergies and Adverse Drug Reaction

a) History of allergy or hypersensitivity to any of the study drugs or study drug components

5. Other Exclusion Criteria

- a) Prisoners or subjects who are involuntarily incarcerated
- b) Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
- c) Treatment with botanical preparations (eg, herbal supplements or traditional Chinese medicines derived from plants, minerals, or animals) intended for general health support or to treat the disease under study within 2 weeks prior to randomization/treatment

Eligibility criteria for this study have been carefully considered to ensure the safety of the study subjects and that the results of the study can be used. It is imperative that subjects fully meet all eligibility criteria.

3.3.3 Women of Childbearing Potential

A Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral

oophorectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes. In addition, females under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level > 40mIU/mL to confirm menopause.

*Females treated with hormone replacement therapy, (HRT) are likely to have artificially suppressed FSH levels and may require a washout period in order to obtain a physiologic FSH level. The duration of the washout period is a function of the type of HRT used. The duration of the washout period below are suggested guidelines and the investigators should use their judgment in checking serum FSH levels. If the serum FSH level is > 40 mIU/ml at any time during the washout period, the woman can be considered postmenopausal:

- 1 week minimum for vaginal hormonal products (rings, creams, gels)
- 4 week minimum for transdermal products
- 8 week minimum for oral products

Postmenopausal women may continue HRT after FSH testing is completed and postmenopausal status is confirmed.

Other parenteral products may require washout periods as long as 6 months.

3.4 Concomitant Treatments

3.4.1 **Prohibited and/or Restricted Treatments**

The following medications are prohibited during the study:

- Immunosuppressive agents (except to treat a drug-related AE or an autoimmune paraneoplastic syndrome). Subjects with an autoimmune paraneoplastic syndrome at enrollment requiring concurrent immunosuppressive treatment are not eligible.
- Thymosin, thymalfasin, and thymopentin are prohibited
- Systemic corticosteroids > 10 mg daily prednisone equivalent, except as stated in Section 3.4.3 or to treat a drug-related AE
- Any concurrent systemic antineoplastic therapy (ie, chemotherapy, hormonal therapy, immunotherapy, standard or investigational agents for the treatment of cancer).
- Surgical resection of tumor
- Any botanical preparations (eg herbal supplements or traditional Chinese medicines derived from plants, minerals, or animals) intended to treat the disease under study or provide supportive care
- Note: the following radiotherapy is permitted
 - Palliative bone radiotherapy as described in section 3.4.2
 - Palliative radiotherapy to a single metastatic site, other than bone, in subjects who do not require immediate initiation of second line systemic anti-cancer therapy. See Section 3.4.2 for additional restrictions.
- Any live / attenuated vaccine (eg varicella, zoster, yellow fever, rotavirus, oral polio and measles, mumps, rubella (MMR)) during treatment and until 100 days post last dose.

3.4.2 Other Restrictions and Precautions

Blinded study therapy must be resumed ≤ 6 weeks from the last dose or the subject must be permanently discontinued from blinded study therapy. (See exceptions in Sections 3.5 and 4.5.3.4 Discontinuation Criteria)

Non-target bone lesions that do not include lung tissue in the planned radiation field may receive palliative radiotherapy at any time while on study treatment. Radiotherapy to non-bone lesions is permitted only as described in Section 3.4.1. Study treatment must be withheld during radiotherapy and for two weeks after completion of radiotherapy. Details of palliative radiotherapy should be documented in the source records and case report form (CRF). Details in the source records should include: dates of treatment, anatomical site, dose administered and fractionation schedule, and AEs.

Subjects requiring palliative radiotherapy should be carefully assessed for disease progression. Subjects considered as having progressive disease are required to discontinue blinded study therapy, unless eligible to continue treatment beyond progression per the guidance in Section 5.4 (Treatment Beyond Disease Progression).

3.4.2.1 Imaging Restrictions and Precautions

It is the local imaging facility's responsibility to determine, based on subject attributes (eg, allergy history, diabetic history and renal status), the appropriate imaging modality and contrast regimen for each subject. Imaging contraindications and contrast risks should be considered in this assessment. Subjects with renal insufficiency should be assessed as to whether or not they should receive contrast and if so, what type and dose of contrast is appropriate. Specific to MRI, subjects with severe renal insufficiency (ie, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m²) are at increased risk of nephrogenic systemic fibrosis. MRI contrast should not be given to this subject population. In addition, subjects are excluded from MRI if they have tattoos, metallic implants, pacemakers, etc.

The ultimate decision to perform MRI in an individual subject in this study rests with the site radiologist, the investigator and the standard set by the local Ethics Committee.

3.4.3 *Permitted Therapy*

Subjects are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses including doses > 10 mg daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by a contact allergen) is permitted.

Postmenopausal women may continue HRT after FSH testing is completed and postmenopausal status is confirmed.

Concomitant palliative and supportive care for disease-related symptoms (including bisphosphonates and RANK-L inhibitors) are allowed. See Section 3.4.2 for guidance on concomitant palliative radiotherapy

3.5 Discontinuation of Subjects following any Treatment with Study Drug(s)

Subjects MUST discontinue investigational product (and non-investigational product at the discretion of the investigator) for any of the following reasons:

- Disease progression as assessed by RECIST 1.1 criteria (Appendix 3), unless the subject meets criteria for treatment beyond progression (Section 5.4)
- Subject's request to stop study treatment
- Any clinical adverse event (AE), laboratory abnormality or intercurrent illness which, in the opinion of the investigator, indicates that continued participation in the study is not in the best interest of the subject
- Termination of the study by Bristol-Myers Squibb (BMS)
- Loss of ability to freely provide consent through imprisonment or involuntarily incarceration for treatment of either a psychiatric or physical (eg, infectious disease) illness
- Unblinding a subject for any reason (emergency or non-emergency)
- Additional protocol-specified reasons for discontinuation, as described in Section 4.5.3.4

In the case of pregnancy, the investigator must immediately notify the Sponsor or designee of this event. In most cases, the blinded study drug(s) will be permanently discontinued in an appropriate manner. If the investigator determines a possible favorable benefit/risk ratio that warrants continuation of blinded study drug(s), a discussion between the investigator and the Sponsor or designee must occur.

All subjects who discontinue blinded study drug(s) should comply with protocol specified followup procedures as outlined in Section 5. The only exception to this requirement is when a subject withdraws consent for all study procedures including post-treatment study follow-up or loses the ability to consent freely (ie, is imprisoned or involuntarily incarcerated for the treatment of either a psychiatric or physical illness).

Subjects must be followed for at least 100 days after the last dose of blinded study therapy. Followup (FU1) occurs approximately 35 days (+/- 7 days) after last dose of coinciding with the date of discontinuation (+/- 7 days) if the date of discontinuation is greater than 35 days after the last dose. Follow up visit 2 (FU2) occurs approximately 80 days (+/- 7 days) after FU1. Survival visits are every 3 months from FU2 up to 5 years and may be conducted during a clinic visit or via the phone. The endpoint of this study is OS, and so tracking reporting the subject's status in the follow up setting according to the protocol guidelines for disease progression and survival are critical to the final study analysis. The importance of follow up should be clearly communicated to study subjects.

If blinded study drug(s) is discontinued prior to the subject's completion of the study, the reason for the discontinuation must be documented in the subject's medical records and entered on the appropriate case report form (CRF) page.

3.6 Post Study Drug Study Follow up

In this study, overall survival is a key endpoint of the study. Post study follow-up is of critical importance and is essential to preserving subject safety and the integrity of the study. Subjects who discontinue study drug must continue to be followed for collection of outcome and/or survival follow-up data as required and in line with Section 5 until death or the conclusion of the study.

BMS may request that survival data be collected on all randomized subjects outside of the protocol defined window (See Table 5.1-4). At the time of this request, each subject will be contacted to determine their survival status unless the subject has withdrawn consent for all contact.

3.6.1 Withdrawal of Consent

Subjects who request to discontinue blinded study therapy will remain in the study and must continue to be followed for protocol specified follow-up procedures. The only exception to this is when a subject specifically withdraws consent for any further contact with him/her or persons previously authorized by subject to provide this information. Subjects should notify the investigator of the decision to withdraw consent from future follow-up **in writing**, if possible. The withdrawal of consent should be explained in detail in the medical records by the investigator, as to whether the withdrawal is from further treatment with blinded study therapy only or also from study procedures and/or post treatment study follow-up, and entered on the appropriate CRF page. In the event that vital status (whether the subject is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law.

3.6.2 Lost to Follow-Up

All reasonable efforts must be made to locate subjects to determine and report their ongoing status. This includes follow-up with persons authorized by the subject as noted above. Lost to follow-up is defined by the inability to reach the subject after a minimum of three documented phone calls, faxes, or emails as well as lack of response by subject to one registered mail letter. All attempts should be documented in the subject's medical records. If it is determined that the subject has died, the site will use permissible local methods to obtain the date and cause of death.

If investigator's use of third-party representative to assist in the follow-up portion of the study has been included in the subject's informed consent, then the investigator may use a Sponsor-retained third-party representative to assist site staff with obtaining subject's contact information or other public vital status data necessary to complete the follow-up portion of the study. The site staff and representative will consult publicly available sources, such as public health registries and databases, in order to obtain updated contact information. If after all attempts, the subject remains lost to follow-up, then the last known alive date as determined by the investigator should be reported and documented in the subject's medical records.

4 STUDY DRUG

Study drug includes both Investigational [Medicinal] Product (IP/IMP) and Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and can consist of the following:

Product Description / Class and Dosage Form	Potency	IP/Non-IMP	Blinded or Open Label	Packaging/ Appearance	Storage Conditions (per label)
Nivolumab Solution for Injection	100 mg (10 mg/mL)	IP	Open Label ^a	10 mL/vial (5 or 10 vials/carton)	Store at 2° - 8°C. Protect from light and freezing.
Ipilimumab Solution for Injection	200 mg (5 mg/mL)	IP	Open Label ^a	40 mL/vial (4 vials/carton)	Store at 2° - 8°C. Protect from light and freezing.
0.9% Sodium Chloride for Injection	N/A	IP	Open Label ^a	Various (local commercial product)	As per as per package insert
5% Dextrose for Injection	N/A	IP	Open Label ^a	Various (local commercial product)	As per as per package insert

Table 4-1:Study Drugs for CA209451

^a The term "open label" refers to the medication as it is upon receipt at the pharmacy. The trial will be conducted in a double-blinded fashion.

Pre-medications or medications used to treat infusion-related reactions should be sourced by the investigative sites if available and permitted by local regulations. Solutions used as diluent or placebo (ie, 0.9% Sodium Chloride Injection or 5% Dextrose Injection) should also be sourced by investigative sites if available and permitted by local regulations.

4.1 Investigational Product

An investigational product, also known as investigational medicinal product in some regions, is defined a pharmaceutical form of an active substance or placebo being tested or used as a reference in a clinical study, including products already with a marketing authorization but used or assembled (formulated or packaged) differently than the authorized form, or used for an unauthorized indication, or when used to gain further information about the authorized form.

The investigational product should be stored in a secure area according to local regulations. It is the responsibility of the investigator to ensure that investigational product is only dispensed to study subjects. The investigational product must be dispensed only from official study sites by authorized personnel according to local regulations.

In this protocol, the investigational medicinal products are:

- Nivolumab
- Ipilimumab
- Placebo for nivolumab (0.9% sodium chloride injection or 5% dextrose injection)
- Placebo for ipilimumab (0.9% sodium chloride injection or 5% dextrose injection)

4.2 Non-investigational Product

Other medications used as support or escape medication for preventative, diagnostic, or therapeutic reasons, as components of the standard of care for a given diagnosis, may be considered as non-investigational products. Non-investigational products should be sourced by the investigator sites if available and permitted by local regulations.

4.3 Storage of Study Drug

The product storage manager should ensure that the study drug is stored in accordance with the environmental conditions (temperature, light, and humidity) as determined by BMS. If concerns regarding the quality or appearance of the study drug arise, the study drug should not be dispensed and contact BMS immediately.

Study drug not supplied by BMS will be stored in accordance with the package insert.

Please refer to Section 9.2.2 for guidance on IP records and documentation.

Infusion-related supplies (eg, IV bags, in-line filters, 0.9% sodium chloride injection, 5% dextrose injection) will not be supplied by the sponsor and should be purchased locally if permitted by local regulations.

Please refer to the current version of the Investigator Brochure (IB) for complete storage, handling, dispensing, and infusion information for nivolumab, ipilimumab, and matching placebo.

The unblinded pharmacist will obtain treatment assignment by IVRS and prepare blinded drug.

The infusion duration of nivolumab/matching placebo is 30 minutes and for ipilimumab/matching placebo is 90 minutes.

4.4 Method of Assigning Subject Identification

The subject number will be assigned through an interactive voice response system (IVRS) once the subject has signed the informed consent form and is registered. Every subject that signs the informed consent form must be assigned a subject number in IVRS. Specific instructions for using IVRS will be provided to the investigational site in a separate document.

The investigator or designee will register the subject for enrollment by following the enrollment procedures established by BMS. The following information is required for enrollment:

- Date that informed consent was obtained
- Date of birth
- Gender at birth

Once enrolled in IVRS, subjects that have met all eligibility criteria for whom tumor tissue has been shipped to the central lab will be ready for treatment assignment and drug vial (nivolumab versus placebo) assignment through the IVRS. The following information is required for drug vial assignment:

- Subject number
- Date of birth
- Tumor tissue must be available and submitted to the central lab
- ECOG Performance Status: 0 vs 1
- Gender: Male vs Female
- Prophylactic Cranial Irradiation (PCI) following chemotherapy: Yes vs No

Subjects meeting all eligibility criteria will be randomized in a 1:1:1 ratio Arm A (nivolumab), Arm B (nivolumab/ ipilimumab), or Arm C (placebo). Randomization will be achieved using the permuted blocks within each stratum. The randomization schedule will allocate subjects among the 3 treatment arms in a 1:1:1 ratio.

The exact procedures for using the IVRS will be detailed in the IVRS manual.

4.5 Selection and Timing of Dose for Each Subject

The dosing schedule is detailed in Table 4.5-1 and Table 4.5-2.

	1 Cycle = 42 Days = 6 weeks								
	C1D1	C1D8	C1D15	C1D22	C1D29	C1D36			
Arm A (Nivo)	Nivo: 240 mg (24 mL diluted to 100 mL) Ipi pbo: 100 mL	N/A	Nivo: 240 mg (24 mL diluted to 100 mL)	Nivo pbo: 100 mL Ipi pbo: 100 mL	Nivo: 240 mg (24 mL diluted to 100 mL)	N/A			
Arm B (Nivo + Ipi)	Nivo: 1 mg/kg (diluted to 100 mL) Ipi: 3 mg/kg (diluted to 100 mL)	N/A	Nivo pbo: 100 mL	Nivo: 1 mg/kg (diluted to 100 mL) Ipi: 3 mg/kg (diluted to 100 mL)	Nivo pbo: 100 mL	N/A			
Arm C (Placebo)	Nivo pbo: 100 mL Ipi pbo: 100 mL	N/A	Nivo pbo: 100 mL	Nivo pbo: 100 mL Ipi pbo: 100 mL	Nivo pbo: 100 mL	N/A			

Table 4.5-1:Blinded Dosing Schedule (Cycles 1 and 2)

Please note instructions below for reduced total volumes for subjects weighing < 35 kg.

Table 4.5-2:	Blinded Dosing Schedule (Cycle 3+)
--------------	------------------------------------

1 Cycle = 14 Days = 2 weeks					
	C3D1	C3D8			
Arm A (Nivo)	Nivo: 240 mg (24 mL diluted to 100 mL)	N/A			
Arm B (Nivo + Ipi)	Nivo: 240 mg (24 mL diluted to 100 mL)	N/A			
Arm C (Placebo)	Nivo pbo: 100 mL	N/A			

All subjects will be monitored continuously for AEs while on study treatment. Treatment modifications (eg, dose delay, or discontinuation) will be based on specific laboratory and AE criteria, as described in Sections 4.5.3 and 4.5.4.

When study drugs (ipilimumab or nivolumab) or matched placebos are to be administered on the same day, separate infusion bags and filters must be used for each infusion. Nivolumab or nivolumab placebo is to be administered first. The second infusion will always be the ipilimumab or ipilimumab-placebo study drug, and will start no sooner than 30 minutes after completion of the nivolumab or nivolumab-placebo infusion.

Ipilimumab or ipilimumab-placebo must be diluted to 100 mL 0.9% Sodium Chloride Solution or 5% Dextrose solution. Nivolumab or nivolumab-placebo must be diluted to 100 mL 0.9% Sodium

Chloride Solution or 5% Dextrose solution. The dilution volumes required to maintain the blind are described in Table 4.5-1 and Table 4.5-2.

For weight-based dosing, if the subject's weight on the day of dosing differs by > 10% from the weight used to calculate the dose, the dose must be recalculated. All doses should be rounded up or to the nearest milligram per institutional standard. There will be no dose modifications allowed.

Subjects weighing < 35 kg: For subjects weighing < 35 kg, nivolumab and ipilimumab must be diluted to 50 mL in 0.9% sodium chloride or 5% dextrose solution. Matching placebo volumes must also be 50 mL to maintain the blind.

4.5.1 Dosing Windows

During Cycles 1 and 2:

- Subjects may be dosed no less than <u>12 days</u> between
 - C1D1 and C1D15
 - C1D15 and C1D29
 - C1D29 and C2D1
 - C2D1 and C2D15
 - C2D15 and C2D29
 - C2D29 and C3D1
- Subjects may be dosed no less than <u>5 days</u> between
 - C1D15 and C1D22
 - C1D22 and C1D29
 - C2D15 and C2D22
 - C2D22 and C2D29

During Cycle 3 and beyond:

• Subjects may be dosed no less than 12 days from the previous dose of drug

Subjects may be dosed up to 3 business days after the scheduled date if necessary, or longer in the event of a toxicity requiring dose delay. Subsequent dosing should be based on the actual date of administration of the previous dose of drug.

Treatment compliance will be monitored by drug accountability as well as the subject's medical record and eCRF.

4.5.2 Study Medications

4.5.2.1 Nivolumab Monotherapy (Arm A)

For subjects randomized to Arm A, nivolumab 240 mg will be administered every 2 weeks as a 30 min IV infusion until progression, unacceptable toxicity, withdrawal of consent, completion of 24 months of treatment, or the study ends, whichever occurs first. Subjects should begin study treatment within 3 business days of randomization. The rationale for this dosage schedule is

provided in Section 1.1.6. In order to maintain a blinded study, the schedule of investigational and placebo treatments is divided into two 42-day cycles at the start of therapy, followed by ongoing 2-week cycles. This dosing schedule is described in detail in Table 4.5-1 and Table 4.5-2.

Refer to the Investigator Brochure for more detail. There are no pre-medications recommended on the first cycle. If an acute infusion reaction is noted, subjects should be managed according to Section 4.5.6.

See Section 4.5.4 for information on Management Algorithms for Immuno-Oncology Agents.

4.5.2.2 Nivolumab and Ipilimumab Combination Therapy (Arm B)

For subjects randomized to Arm B, nivolumab/placebo 1 mg/kg (30 min IV infusion) and ipilimumab 3 mg/kg (90 minute IV infusion) will be administered every 3 weeks for 4 doses, followed by nivolumab 240 mg every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, completion of 24 months of treatment, or the study ends, whichever occurs first. Subjects should begin study treatment within 3 business days of randomization. The rationale for this dosage schedule is provided in Section 1.1.7. In order to maintain a blinded study, the schedule of investigational and placebo treatments is divided into two 42-day cycles at the start of therapy, followed by ongoing 2-week cycles. This dosing schedule is described in detail in Table 4.5-1 and Table 4.5-2.

Refer to the Investigator Brochure for more detail. There are no pre-medications recommended on the first cycle. If an acute infusion reaction is noted, subjects should be managed according to Section 4.5.6.

See Section 4.5.4 for information on Management Algorithms for Immuno-Oncology Agents.

4.5.2.3 Placebo Therapy (Arm C)

For subjects randomized to Arm C, placebo (0.9% Sodium Chloride Solution or 5% Dextrose) will be administered as described in Table 4.5-1 and Table 4.5-2.

4.5.3 Dose Modifications and Delays

4.5.3.1 Dose Modifications

Dose reductions for the management of toxicities of individual subjects or dose escalations are not permitted. All dose modification rules apply to all treatment arms given the blinded nature of this study.

4.5.3.2 Dose Delays

Dose delay criteria apply for all drug-related adverse events (regardless of whether or not the event is attributed to nivolumab, ipilimumab, or both). All blinded study drugs must be delayed until treatment can resume.

Dose delay criteria also apply for the placebo version of each agent, given the blinded nature of this study.

Blinded study therapy administration should be delayed for the following:

- Grade 2 non-skin, drug-related adverse event, with the exception of fatigue
- Grade 2 drug related creatinine, AST, ALT and/or Total Bilirubin abnormalities
- Any Grade 3 skin, drug-related adverse event
- Any Grade 3, drug-related laboratory abnormality, with the following exceptions:
 - Grade 3 lymphopenia does not require dose delay
 - Grade \geq 3 drug related amylase or lipase abnormality that are not associated with symptoms or clinical manifestations of pancreatitis do not require a dose delay
 - Grade ≥ 3 drug related AST, ALT, or total bilirubin will require dose discontinuation (see section 4.5.3.3 and section 4.5.3.4)
- Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of the investigator, warrants delaying the dose of blinded study medication

Subjects who require delay of nivolumab should be re-evaluated weekly or more frequently as clinically indicated and resume nivolumab dosing when re-treatment criteria are met.

4.5.3.3 Criteria to Resume Treatment

Subjects may resume treatment with blinded study therapy when the drug-related AE(s) resolve to Grade ≤ 1 or baseline value, with the following exceptions:

- Subjects may resume treatment in the presence of Grade 2 fatigue
- Participants who have not experienced a Grade 3 drug-related skin AE may resume treatment in the presence of Grade 2 skin toxicity
- Subjects with Grade 2 AST/ALT and/or total bilirubin abnormalities may resume treatment when laboratory values return to baseline and management with corticosteroids, if needed is complete.
- Subjects with a combined Grade 2 AST/ALT AND Total Bilirubin values meeting discontinuation criteria (section 4.5.3.4) should have treatment permanently discontinued
- Drug-related pulmonary toxicity, diarrhea, or colitis, must have resolved to baseline before treatment is resumed. Subjects with persistent Grade 1 pneumonitis after completion of steroid taper over at least 1 month may be eligible for retreatment if discussed with and approved by the BMS Medical Monitor
- Drug-related endocrinopathies adequately controlled with only physiologic hormone replacement may resume treatment after consultation with the BMS Medical Monitor. Adrenal insufficiency requires discontinuation regardless of control with hormone replacement.

If the criteria to resume treatment are met, the subject should restart treatment at the next scheduled timepoint per protocol. Doses should not be skipped. In particular, this is to ensure that subjects in Arm B will receive 4 administrations of combined nivolumab and ipilimumab treatment if toxicity allows.

If treatment is delayed > 6 weeks (42 days) from the last dose due to blinded study drug-related toxicity, the subject must be permanently discontinued from blinded study therapy, except as specified in Section 4.5.3.4. In the event treatment is delayed > 6 weeks due to reasons other than blinded study drug-related toxicity, the case should be discussed with the Medical Monitor before proceeding.

4.5.3.4 Discontinuation Criteria

Treatment with blinded study therapy should be permanently discontinued for the following:

- Any Grade 2 drug-related uveitis or eye pain or blurred vision that does not respond to topical therapy and does not improve to Grade 1 severity within the re-treatment period OR requires systemic treatment
- Any Grade 3 non-skin, drug-related AE lasting > 7 days, with the following exceptions:
 - Grade 3 drug-related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, neurologic toxicity, myocarditis, hypersensitivity reaction, or infusion reaction of any duration requires discontinuation
 - Grade 3 drug-related endocrinopathies adequately controlled with only physiologic hormone replacement do not require discontinuation. Adrenal insufficiency requires discontinuation regardless of control with hormone replacement
 - Grade 3 drug-related laboratory abnormalities do not require treatment discontinuation except:
 - Grade 3 drug-related thrombocytopenia > 7 days or associated with bleeding requires discontinuation
 - Grade \geq 3 drug-related AST.ALT or Total Bilirubin requires discontinuation
 - Concurrent AST or ALT > 3 x ULN and total bilirubin > 2 x ULN

*In most cases of Grade 3 AST or ALT elevation, study drug(s) will be permanently discontinued. If the investigator determines a possible favorable benefit/risk ration that warrants continuation of study drug(s), a discussion between the investigator and the BMS Medical Monitor/designee must occur.

- Any Grade 4 drug-related AE or laboratory abnormality, except for the following events which do not require discontinuation:
 - Grade 4 neutropenia \leq 7 days
 - Grade 4 lymphopenia or leukopenia
 - Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with clinical sequelae and are corrected with supplementation/appropriate management within 72 hours of their onset
 - Isolated Grade 4 amylase or lipase abnormalities that are not associated with symptoms or clinical manifestations, or radiographic signs of pancreatitis.
 - For Grade 4 endocrinopathy AEs such as hyper or hypothyroidosis, or glucose intolerance, which resolve or are adequately controlled with physiologic hormone replacement (steroids, thyroid hormones) or glucose controlling agents, respectively, retreatment can be considered after discussion with the BMS Medical Monitor.

- Any dosing delays lasting > 6 weeks from the last dose with the following exceptions:
 - Dosing delays to allow for prolonged steroid tapers to manage drug-related AEs are allowed. Prior to re-initiating treatment in a subject with a dosing delay lasting > 6 weeks from the last dose, the BMS Medical Monitor must be consulted
 - Dosing delays > 6 weeks from the last dose that occur for non-drug-related reasons may be allowed if approved by the BMS Medical Monitor
- Any AE, laboratory abnormality, or intercurrent illness which, in the judgment of the Investigator, presents a substantial clinical risk to the subject with continued blinded study therapy dosing

Tumor assessments for all subjects should continue as per protocol even if blinded study therapy dosing is delayed. Periodic study visits to assess safety and laboratory studies should continue at least every 6 weeks or more frequently if clinically indicated during such dosing delays.

4.5.4 Management Algorithms for Immuno-Oncology Agents

Immuno-oncology agents are associated with AEs that can differ in severity and duration than AEs caused by other therapeutic classes. Nivolumab and ipilimumab are considered an immuno-oncology agents in this protocol. Early recognition and management of AEs associated with immuno-oncology agents may mitigate severe toxicity. Management algorithms have been developed to assist investigators in assessing and managing the following groups of AEs:

- Gastrointestinal
- Renal
- Pulmonary
- Hepatic
- Endocrinopathies
- Skin
- Neurological

While the ipilimumab investigator brochure contains very similar safety management algorithms for these adverse events, <u>the recommendation is to follow the nivolumab algorithms for immune-oncology agents (I-O) in order to standardize the safety management across the three blinded treatment arms.</u>

The algorithms are found in the Nivolumab Investigator Brochure and Appendix 2 of this protocol.

4.5.5 Treatment Beyond Disease Progression

Accumulating evidence indicates a minority of subjects treated with immunotherapy may derive clinical benefit despite initial evidence of progressive disease (PD).³⁵ The assessment of clinical benefit should be balanced by clinical judgment as to whether the subject is clinically deteriorating and unlikely to receive any benefit from continued blinded study therapy.

Subjects will be permitted to continue treatment beyond initial RECIST 1.1 defined PD as long as all of the following criteria are met and clearly documented:

- Investigator-assessed clinical benefit and no rapid disease progression;
- Tolerating blinded study drug(s);
- Stable performance status;
- Treatment beyond progression will not delay an imminent intervention to prevent serious complications of disease progression
- Subject provides written informed consent prior to receiving additional blinded study therapy, using an ICF describing any reasonably foreseeable risks or discomforts, or other alternative treatment options

All decisions to continue treatment beyond initial progression must be discussed with the Medical Monitor and documented in the study records. The subject will continue to receive monitoring according to the Time and Events Schedules in Table 5.1-2 and Table 5.1-3.

A radiographic assessment should be performed within 6 weeks of original PD to determine whether there has been a decrease in the tumor size, or continued PD.

For the subjects who continue blinded study therapy beyond PD, further progression is defined as an additional 10% increase in tumor burden from time of initial PD. This includes an increase in the sum of all target lesions and/ or the development of new measurable lesions. For subjects with evaluable disease only, further progression is defined as unequivocal disease progression of nontarget lesions or the development of new lesions from time of initial PD. Treatment should be discontinued permanently upon documentation of further disease progression.

New lesions are considered measurable at the time of initial progression if the longest diameter is at least 10 mm (except for pathological lymph nodes, which must have a short axis of at least 15 mm). Any new lesion considered non-measurable at the time of initial progression may become measurable and therefore included in the tumor burden measurement if the longest diameter increases to at least 10 mm (except for pathological lymph nodes, which must have an increase in short axis to at least 15 mm).

For statistical analyses that include the investigator-assessed progression date, subjects who continue treatment beyond initial investigator-assessed, RECIST 1.1-defined progression will be considered to have investigator-assessed progressive disease at the time of the initial progression event.

For subjects in all treatment arms, global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as 'symptomatic deterioration'. Every effort should be made to document objective progression (ie, radiographic confirmation) even after discontinuation of treatment.

4.5.6 Treatment of Nivolumab- or Ipilimumab-Related Infusion Reactions

Since nivolumab and ipilimumab contain only human immunoglobulin protein sequences, they are unlikely to be immunogenic and induce infusion or hypersensitivity reactions. However, if such a

reaction were to occur, it might manifest with fever, chills, rigors, headache, rash, pruritus, arthralgias, hypo or hypertension, bronchospasm, or other symptoms. All Grade 3 or 4 infusion reactions should be reported within 24 hours to the BMS Medical Monitor and reported as a serious adverse event (SAE) if criteria are met. Infusion reactions should be graded according to NCI CTCAE (version 4.0) guidelines.

Treatment recommendations are provided below and may be modified based on local treatment standards and guidelines as appropriate:

For Grade 1 symptoms: (Mild reaction; infusion interruption not indicated; intervention not indicated)

• Remain at bedside and monitor subject until recovery from symptoms. The following prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) at least 30 minutes before additional blinded study therapy administrations

For Grade 2 symptoms: (Moderate reaction requires therapy or infusion interruption but responds promptly to symptomatic treatment [eg, antihistamines, non-steroidal anti inflammatory drugs, narcotics, corticosteroids, bronchodilators, IV fluids]; prophylactic medications indicated for ≤ 24 hours).

- Stop the blinded study therapy infusion, begin an IV infusion of normal saline, and treat the subject with diphenhydramine 50 mg IV (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen); remain at bedside and monitor subject until resolution of symptoms. Corticosteroid or bronchodilator therapy may also be administered as appropriate. If the infusion is interrupted, then restart the infusion at 50% of the original infusion rate when symptoms resolve; if no further complications ensue after 30 minutes, the rate may be increased to 100% of the original infusion rate. Monitor subject closely. If symptoms recur then no further blinded study therapy will be administered at that visit. Administer diphenhydramine 50 mg IV, and remain at bedside and monitor the subject until resolution of symptoms. The amount of blinded study drug infused must be recorded on the case report form (CRF).
- The following prophylactic premedications are recommended for future infusions: diphenhydramine 50 mg (or equivalent) and/or paracetamol 325 to 1000 mg (acetaminophen) should be administered at least 30 minutes before additional blinded study therapy administrations. If necessary, corticosteroids (recommended dose: up to 25 mg of IV hydrocortisone or equivalent) may be used.

For Grade 3 or Grade 4 symptoms: (Severe reaction, Grade 3: prolonged [ie, not rapidly responsive to symptomatic medication and/or brief interruption of infusion]; recurrence of symptoms following initial improvement; hospitalization indicated for other clinical sequelae [eg, renal impairment, pulmonary infiltrates]). Grade 4: (life threatening; pressor or ventilatory support indicated).

• Immediately discontinue infusion of blinded study therapy. Begin an IV infusion of normal saline, and treat the subject as follows. Recommend bronchodilators, epinephrine 0.2 to 1 mg of a 1:1,000 solution for subcutaneous administration or 0.1 to 0.25 mg of a 1:10,000 solution injected slowly for IV administration, and/or diphenhydramine 50 mg IV with

methylprednisolone 100 mg IV (or equivalent), as needed. Subject should be monitored until the investigator is comfortable that the symptoms will not recur. Blinded study therapy will be permanently discontinued. Investigators should follow their institutional guidelines for the treatment of anaphylaxis. Remain at bedside and monitor subject until recovery from symptoms.

In the case of late-occurring hypersensitivity symptoms (eg, appearance of a localized or generalized pruritus within 1 week after treatment), symptomatic treatment may be given (eg, oral antihistamine, or corticosteroids)

4.6 Blinding/Unblinding

The Sponsor, subjects, investigator and site staff will be blinded to the study therapy administered. Each investigative site must assign an unblinded pharmacist/designee, and an unblinded site monitor will be assigned to provide oversight of drug supply and other unblinded study documentation.

Designated staff and associates of the Sponsor may be unblinded prior to database lock to facilitate the bioanalytical analysis of pharmacokinetic samples and immunogenicity. A bioanalytical scientist in the Bioanalytical Sciences department of Bristol-Myers Squibb Research & Development (or a designee in the external central bioanalytical laboratory) may be unblinded to the randomized treatment assignments in order to minimize unnecessary bioanalytical analysis of samples.

Blinding of treatment assignment is critical to the integrity of this clinical study. However, in the event of a medical emergency or pregnancy in an individual subject in which knowledge of the investigational product is critical to the subject's management, the blind for that subject may be broken by the investigator. The subject's safety takes priority over any other considerations in determining if a treatment assignment should be unblinded.

Before breaking the blind of an individual subject's treatment, the investigator should determine that the unblinded information is necessary, ie, that it will alter the subject's immediate management. In many cases, particularly when the emergency is clearly not related to the investigational product, the problem may be properly managed by assuming that the subject is receiving active product. It is highly desirable that the decision to unblind treatment assignment be discussed with the Medical Monitor, but the investigator always has ultimate authority for the decision to unblind. The Principal Investigator should only call in for emergency unblinding AFTER the decision to discontinue the subject has been made.

Emergency unblinding is available as an option in the IVRS. Consult IVRS Manual for instructions on Emergency unblinding).

In cases of accidental unblinding, contact the Medical Monitor and ensure every attempt is made to preserve the blind. Any request to unblind a subject for non-emergency purposes should be discussed with the Medical Monitor.

4.7 Treatment Compliance

Treatment compliance will be monitored by drug accountability as well as the subject's medical record and CRF.

4.8 Destruction or Return of Investigational Product

For this study, IP (those supplied by BMS, a vendor or sourced by the investigator) such as partially used study drug containers, vials and syringes may be destroyed on site.

lf	Then
IP supplied by BMS (including its vendors)	Any unused IP supplied by BMS can only be destroyed after being inspected and reconciled by the responsible Study Monitor unless IP containers must be immediately destroyed as required for safety, or to meet local regulations (e.g., cytotoxics or biologics). If IP will be returned, the return will be arranged by the responsible Study Monitor.
IP sourced by site, not supplied by BMS (or its vendors) (examples include IP sourced from the sites stock or commercial supply, or a specialty pharmacy)	It is the investigator's or designee's responsibility to dispose of all containers according to the institutional guidelines and procedures.

It is the investigator's or designee's responsibility to arrange for disposal, provided that procedures for proper disposal have been established according to applicable federal, state, local and institutional guidelines and procedures, and provided that appropriate records of disposal are kept. The following minimal standards must be met:

- On-site disposal practices must not expose humans to risks from the drug
- On-site disposal practices and procedures are in agreement with applicable laws and regulations, including any special requirements for controlled or hazardous substances
- Written procedures for on-site disposal are available and followed. The procedures must be filed with the site's SOPs and a copy provided to BMS upon request
- Records are maintained that allow for traceability of each container, including the date disposed of, quantity disposed, and identification of the person disposing the containers. The method of disposal, ie, incinerator, licensed sanitary landfill, or licensed waste disposal vendor must be documented
- Accountability and disposal records are complete, up-to-date, and available for the Monitor to review throughout the clinical trial period

It is the investigator's or designee's responsibility to arrange for disposal of all empty containers.

If conditions for destruction cannot be met the responsible Study Monitor will make arrangements for return of IP provided by BMS (or its vendors). Destruction of non-IP sourced by the site, not supplied by BMS, is solely the responsibility of the investigator or designee.

Please refer to Section 9.2.2 for guidance on IP records and documentation.

4.9 Retained Samples for Bioavailability / Bioequivalence

Not Applicable

5 STUDY ASSESSMENTS AND PROCEDURES

5.1 Flow Chart/Time and Events Schedule

Table 5.1-1:Screening Procedural Outline (CA209451)

Procedure	Screening	Notes
Eligibility Assessments		
Informed Consent	X	Informed Consent may be obtained at any time, provided it is prior to conduct of any study- related procedures. Note that SAEs are collected from the date of consent.
Inclusion/Exclusion Criteria	Х	All inclusion/exclusion criteria should be assessed at screening and confirmed prior to randomization
Medical History	X	
Prior Systemic Therapy	X	
Safety Assessments		
Physical Examination	X	
Physical Measurements	Х	Include Height, Weight, and ECOG performance Status. Within 14 days prior to randomization
Vital Signs and Oxygen saturation	X	Temperature, BP, HR, and O2 saturation at rest by pulse oximetry. Obtain vital signs at the screening visit and within 72 hours prior to randomization.
Assessment of Signs and Symptoms	X	Within 14 days prior to randomization
Concomitant Medication Collection	X	Within 14 days prior to randomization
Laboratory Tests	X	CBC with differential, Chemistry panel including LDH, AST, ALT, ALP, T.Bili, BUN or serum urea level, uric acid, creatinine, Ca, Mg, Na, K, Cl, P, glucose, bicarbonates (optional), albumin, amylase <u>or</u> lipase, TSH (reflex to free T3, free T4 for abnormal TSH result), hepatitis B surface antigen (HBV sAg), and hepatitis C antibody (HCV Ab) within 14 days prior to randomization. Screening labs done within 72 hours prior to first dose can also be used for on treatment lab purposes at Day 1 dosing.
ECG	X	Within 28 days prior to randomization
Pregnancy Test	X	Performed within 24 hours prior to first dose for WOCBP only (serum or urine - local/site)

Table 5.1-1:Screening Procedural Outline (CA209451)

Procedure	Screening	Notes
Efficacy/Biomarker Assessments		
Radiographic Tumor Assessment	Х	CT/ Chest, CT/MRI Abdomen, Pelvis, and any other known sites of disease; MRI/CT Brain (refer to section 5.4 for detail on cases where CT of the Brain is acceptable)
		Within 21 days prior to randomization.
		Additional sites of known or suspected disease (including CNS) should be imaged at the screening visit and at subsequent on-study assessments.
Collection of tumor tissue for biomarker evaluation	Х	See Section 3.3.1, Inclusion 2f
IVRS/Clinical Drug Supplies		
Phone calls to IVRS		Phone calls must be made to IVRS as follows:
		Screening phone call to IVRS: For subject number assignment at the time informed consent is obtained.

Procedure	Cycle 1-2 Day 1	Cycle 1 Day 8	Cycle 1-2 Day 15	Cycle 1-2 Day 22	Cycle 1-2 Day 29	Notes
Safety Assessmen	ts					
Targeted Physical Examination	X		Х	Х	Х	Within 72 hours prior to dosing
Vital Signs and Oxygen Saturation	Х		Х	Х	Х	Temperature, BP, HR, O2 saturation at rest by pulse oximetry at rest (also monitor amount of supplemental oxygen if applicable) within 72 hours prior to dosing and at any time a subject has any new or worsening respiratory symptoms
Physical Measurements	X		Х	Х	Х	Includes Weight and ECOG performance status within 72 hours prior to dosing
Adverse Events Assessment						Assessed using NCI CTCAE v. 4.0. SAEs should be approved in TAO within 5 days from entry
Review of Concomitant Medications	X		Х	Х	Х	
Extended Laboratory Tests	X		Х		х	Extended on-study local laboratory assessments should be done within 72 hours prior to dosing on Days 1, 15, 29 and include: CBC with differential, uric acid, BUN or serum urea level, creatinine, Na, K, Ca, Mg, phosphorus, chloride, bicarbonate (optional), amylase <u>or</u> lipase, glucose, AST, ALT, total bilirubin, alkaline phosphatase, LDH.
Limited Laboratory Tests				Х		Limited on-study local laboratory assessment should be done within 72 hours prior to dosing on Days 22 and include: CBC with differential, AST, ALT, total bilirubin, alkaline phosphatase and creatinine.
Thyroid Function Testing	X					TSH (reflex to free T3 and free T4 if abnormal result) to be performed). (Day 1 of Cycle 1 & 2 or within 72 hours prior to dosing)
Pregnancy Test	X		See	e Note		Serum or urine within 24 hours prior to first dose and then at least once every 4 weeks regardless of dosing schedule.

Table 5.1-2:On-Treatment Assessments for All Subjects, Cycle 1-2 [Cycle length 42 days]

Table 5.1-2:On-Treatment Assessments for All Subjects, Cycle 1-2 [Cycle length 42 days]

Procedure	Cycle 1-2 Day 1	Cycle 1 Day 8	Cycle 1-2 Day 15	Cycle 1-2 Day 22	Cycle 1-2 Day 29	Notes				
Efficacy Assessme	Efficacy Assessments									
Radiographic Tumor See Note Assessment						CT chest, CT/MRI abdomen, and any other known or suspected sites of disease. Repeat CT/MRI of pelvis is required for subjects with pelvic metastases at baseline, or if clinically indicated Subjects with a history of brain metastasis should have surveillance MRI/CT of the brain (refer to section 5.4 for detail on cases where CT of the Brain is acceptable) every 6 weeks, or sooner if clinically indicated.				
						See Table 5.4-1 for CT and MRI scan schedule.				
Additional Explor	ratory Bioma	rker Testi	ng							
Serum Whole Blood Tumor Biopsy			See Note			See Table 5.6-1 of Biomarker Sampling Schedule				
PK and Immunog	genicity Asses	sments								
PK samples			See Note			See Table 5.5-1 of PK and Immunogenicity Sampling				
Immunogenicity samples			See Note			See Table 5.5-1 of PK and Immunogenicity Sampling				
Outcomes Resear	Outcomes Research Assessments									
Patient Reported Outcomes (PRO)	X		Х	x	Х	For on-treatment visits: Assessments (Lung Cancer Symptom Scale and EQ-5D) will be performed on treatment day prior to study treatment.				
Health Resource Utilization	X		Х	X	Х	Except cycle 1. Note that concomitant medication collection will be included.				

Table 5.1-2:	On-Treatment Assessments for All Subjects, Cycle 1-2 [Cycle length 42 days]	
---------------------	---	--

Procedure	Cycle 1-2 Day 1	Cycle 1 Day 8	Cycle 1-2 Day 15	Cycle 1-2 Day 22	Cycle 1-2 Day 29	Notes		
Clinical Drug Sup	Clinical Drug Supplies							
Randomization	X					Call IVRS for randomization		
Administer Blinded Study Drug	X		Х	Х	Х	IVRS should be called within 1 day prior to blinded study therapy administration to receive vial assignment. Note: The subject must receive the blinded study medication within 3 business days after vial assignment. See section 4.5.1 for minimum dosing intervals between Cycles. A call to IVRS is made for every dosing visit.		

Table 5.1-3:On-Treatment Assessments for All Subjects, Cycle 3 and subsequent cycles [Cycle 3+ length 14 days]
(CA209451)

Procedure	Cycle 3 and subsequent cycles, Day 1	Notes
Safety Assessments		
Targeted Physical Examination	Х	Within 72 hours prior to dosing
Vital Signs and Oxygen Saturation	Х	Temperature, BP, HR, O2 saturation at rest by pulse oximetry at rest (also monitor amount of supplemental oxygen if applicable) within 72 hours prior to dosing and at any time a subject has any new or worsening respiratory symptoms
Physical Measurements	Х	Includes Weight and ECOG performance status within 72 hours prior to dosing
Adverse Events Assessment	Continuously	Assessed using NCI CTCAE v. 4.0. SAEs should be approved in TAO within 5 days from entry
Review of Concomitant Medications	Х	
Extended Laboratory Tests	X (See note: Alternate Cycles 3, 5, 7, 9, etc)	Extended on-study local laboratory assessments should be done within 72 hours prior to dosing for Cycle 3 and every alternate dose thereafter (Cycles 5, 7, 9, 11 etc.) and include: CBC with differential, uric acid, BUN or serum urea level, creatinine, Na, K, Ca, Mg, phosphorus, chloride, bicarbonate (optional), amylase <u>or</u> lipase, glucose, AST, ALT, total bilirubin, alkaline phosphatase, LDH.
Limited Laboratory Tests	X (see note: Alternate Cycles 4, 6, 8, 10, 12, etc)	Limited on-study local laboratory assessment should be done within 72 hours prior to dosing (beginning at Cycle 4 and every alternate dose thereafter (Cycles 6, 8, 10, 12, etc.) and include: CBC with differential, AST, ALT, total bilirubin, alkaline phosphatase and creatinine.
Thyroid Function Testing	X See Note (every 3 Cycles)	TSH (reflex to free T3 and free T4 if abnormal result) to be performed every 3rd cycle within 72 hours prior to dosing. (C3D1, C6D1, C9D1, etc)
Pregnancy Test	X See Note	Serum or urine at least once every 4 weeks regardless of dosing schedule.

Table 5.1-3:On-Treatment Assessments for All Subjects, Cycle 3 and subsequent cycles [Cycle 3+ length 14 days]
(CA209451)

Procedure	Cycle 3 and subsequent cycles, Day 1	Notes		
Efficacy Assessments				
Radiographic Tumor Assessment	See Note	CT chest, MRI/CT brain, abdomen, and any other known or suspected sites of disease,. Repeat CT/MRI of pelvis is required for subjects with pelvic metastases at baseline, or if clinically indicated (refer to section 5.4 for detail on cases where CT of the Brain is acceptable). Tumor assessments will be conducted every 6 weeks (\pm 5 days) for the first 36 weeks then every 12 weeks (\pm 5 days) or sooner if clinically indicated until disease progression. See Table 5.4-1 for CT and MRI scan schedule		
Additional Explorato	ry Biomarker Testing			
Serum				
Whole Blood	See Note	See Table 5.6-1 of Biomarker Sampling Schedule		
Tumor Biopsy				
PK and Immunogenic	city Assessments			
PK samples	See Note	See Table 5.5-1 of PK and Immunogenicity Sampling		
Immunogenicity samples	See Note	See Table 5.5-1 of PK and Immunogenicity Sampling		
Outcomes Research A	Assessments			
Patient Reported Outcomes (PRO)	Х	For on-treatment visits: Assessments (Lung Cancer Symptom Scale and EQ-5D) will be performed on treatment day prior to study treatment. Assessments will be performed at each cycle on Day 1 for the remainder of the first 6 months on study, then every 6 weeks thereafter for the remainder of the treatment period.		
Health Resource Utilization	Х	Except cycle 1. Note that concomitant medication collection will be included.		
Clinical Drug Supplie	es			
Administer Blinded Study Drug	Х	IVRS should be called within 1 day prior to blinded study drug administration to receive vial assignment. Note: The subject must receive the blinded study therapy within 3 business days of vial assignment. See Section 4.5.1 for minimum dosing intervals between Cycles. A call to IVRS is made for every dosing visit.		

Procedure	Follow-Up ^a Visits 1 and 2	Survival Follow-Up ^b Visits	Notes	
Safety Assessments				
Targeted Physical Examination	X	To assess for potential late emergent study drug related issues		
Adverse Events Assessment	X	X	NSAEs and SAEs must be collected up to 100 days after blinded study drug discontinuation. SAEs that relate to any later protocol specified procedure must be collected. SAEs should be approved in TAO within 5 days from entry.	
Review of Concomitant Medication	X	Х	Collection of concomitant medications only for treatment-related AEs or SAEs until the medication is discontinued.	
Extended Laboratory Tests	X		CBC with differential, uric acid, BUN or serum urea level, serum creatinine, sodium, potassium, calcium, magnesium, chloride, phosphorus, bicarbonate (optional), amylase <u>or</u> lipase, glucose, AST, ALT, total bilirubin, alkaline phosphatase, LDH	
Thyroid Function Testing	X		TSH (reflex to free T3 and free T4 if abnormal result)	
Pregnancy Test	Х		Serum or urine	
Efficacy Assessments		•		
Radiographic Tumor Assessment CT/MRI	See Note	See note	See Table 5.4-1 for CT/MRI	
Outcomes Research Assessments				
Patient Reported Outcomes (PRO)	X	EQ-5D only	Both the Lung Cancer Symptom Scale and EQ-5D will be given in FU Visits 1 & 2. In Survival Visits, EQ-5D is collected every 3 months for the first year of the Follow-up Phase, then every 6 months thereafter. For Survival Visits these can be collected in person or via telephone contact.	
Healthcare resource utilization	Х			

Table 5.1-4:	Follow-Up Assessments for All Subjects (CA209451)
---------------------	---

Procedure	Follow-Up ^a Visits 1 and 2	Survival Follow-Up ^b Visits	Notes				
Exploratory Biomarker Testing							
Serum			Collection of Biomarker samples at time of progression is				
Whole Blood	See Note.		optional.				
Tumor Biopsy			See Table 5.6-1 of Biomarker Sampling Schedule.				
Subject Status							
Survival Status	Х	Х	Every 3 months after X02; may be accomplished by visit or phone contact, to update survival information and assess subsequent anti-cancer therapy.				

^a Follow-up visits occur as follows: X01 = 35 days ± 7 days from last dose, X02 = 80 days ± 7 days from X01

^b Survival visits continue every 3 months \pm 14 days after Follow-up Visit 2 until death, lost to follow-up, or withdrawal of study consent

5.1.1 Retesting During Screening

Retesting of laboratory parameters and/or other assessments within the Screening period will be permitted (in addition to any parameters that require a confirmatory value).

Any new result will override the previous result (ie, the most current result prior to Randomization) and is the value by which study inclusion will be assessed, as it represents the subject's most current, clinical state.

Laboratory parameters and/or assessments that are included in Table 5.1-1, Screening Procedural Outline may be repeated in an effort to find all possible well-qualified subjects. Consultation with the Medical Monitor may be needed to identify whether repeat testing of any particular parameter is clinically relevant.

5.2 Study Materials

The following materials will be provided to the site by BMS.

- NCI CTCAE version 4.0
- Nivolumab Investigator Brochure
- Ipilimumab Investigator Brochure
- Pharmacy Binder
- Laboratory manuals for collection and handling of blood (including biomarker and immunogenicity) and tissue specimens
- Site manual for operation of interactive voice response system, including enrollment worksheets
- Imaging Manual for image acquisition and submission to central vendor
- Manual for entry of local laboratory data
- Pregnancy Surveillance Forms
- Serious Adverse Events (or eSAE) case report forms
- Lung Cancer Symptom Score and EuroPRO Group's EQ-5D questionnaires

5.3 Safety Assessments

Safety assessments include AEs, physical examinations, vital signs, ECOG performance status, assessment of signs and symptoms, laboratory tests, pregnancy tests as outlined in Section 5.1.

Some of the previously referred to assessments may not be captured as data in the eCRF. They are intended to be used as safety monitoring by the treating physician. Additional testing or assessments may be performed as clinically necessary or where required by institutional or local regulations.

5.3.1 Imaging Assessment for the Study

Any incidental findings of potential clinical relevance that are not directly associated with the objectives of the protocol should be evaluated and handled by the Study Investigator as per standard medical/clinical judgment.

5.4 Efficacy Assessments

Study evaluations will take place in accordance with the flow charts in Section 5.1.

Contrast-enhanced computed tomography (CT) of the chest and CT or magnetic resonance imaging (MRI) of abdomen, and any other known or suspected sites of disease are the preferred methods of radiographic assessment of tumors. Repeat CT/MRI of pelvis is required for subjects with pelvic metastases at baseline, or if clinically indicated. Brain MRI scan is the preferred imaging method for evaluating CNS metastasis, and assessment is required at screening, however CT of the brain is acceptable if MRI is contraindicated. If a subject has a known allergy to contrast material, please use local prophylaxis standards to obtain the assessment with contrast if at all possible, or use the alternate modality. In cases where contrast is strictly contraindicated, a non-contrast scan will suffice.

All known or suspected sites of disease (including CNS) should be assessed at screening and at subsequent assessments using the same imaging method and technique. If more than one method is used at screening, then the most accurate method according to RECIST 1.1 should be used when recording data, and should again be used for all subsequent assessments.

Bone scan, PET scan, or ultrasound are not adequate for assessment of RECIST 1.1 response. In selected circumstances where such modalities are the sole modality used to assess certain non target organs, those non target organs may be evaluated less frequently. For example, bone scans may need to be repeated only when complete response is identified in target disease or when progression in bone is suspected.

Previously treated CNS metastases are not considered measurable lesions for purposes of RECIST 1.1 response. Subjects with a history of brain metastasis should have surveillance MRI/CT approximately every 6 weeks up to 36 weeks and then every 12 weeks, or sooner if clinically indicated.

Baseline assessments should be performed within 21 days of randomization.

Subjects will be evaluated for tumor response beginning 6 weeks from the date of randomization $(\pm 5 \text{ days})$, then every 6 weeks $(\pm 5 \text{ days})$ thereafter up to 36 weeks. Beyond Week 36, tumor assessments will be performed every 12 weeks $(\pm 5 \text{ days})$, or more frequently as clinically indicated or per local Standard of Care, until disease progression (or until discontinuation of study drug in subjects receiving blinded study therapy beyond progression), lost to follow-up, withdrawal of study consent, or the study ends. See Table 5.4-1 for a schedule of tumor assessments. Tumor assessments for all subjects should continue as per protocol even if dosing is delayed. Tumor measurements should be made by the same investigator or radiologist for each assessment whenever possible.

Tumor imaging assessments for ongoing study treatment decisions will be completed by the investigator using RECIST 1.1 criteria; see Appendix 3.

Time On Study	Assessment Frequency	Assessment Week (Day 1 of Week Shown)	Assessment Window
Baseline		Week 0	– 21 days
Between Week 6 and Week 36	Every 6 weeks	6, 12, 18, 24, 30, 36	\pm 5 days
Beyond Week 36	Every 12 weeks	48, 60, 72+	\pm 5 days

 Table 5.4-1:
 Schedule of CT/MRI Tumor Assessments

5.4.1 Use of CT Component of a PET/CT Scan

Combined modality scanning such as with FDG-PET/CT is increasingly used in clinical care, and is a modality/technology that is in rapid evolution; therefore, the recommendations outlined here may change rather quickly with time. At present, low dose or attenuation correction CT portions of a combined FDG-PET/CT are of limited use in anatomically based efficacy assessments and it is therefore suggested that they should not be substituted for dedicated diagnostic contrast enhanced CT scans for anatomically based RECIST diagnostic quality to a diagnostic CT (with IV and oral contrast) then the CT portion of the FDG-PET/CT can be used for RECIST v1.1 measurements. Note, however, that the FDG-PET/CT portion of the CT introduces additional data which may bias an investigator if it is not routinely or serially performed.

5.4.2 Primary and Secondary Efficacy Assessments

The primary endpoint is to compare OS in subjects randomized to nivolumab in combination with ipilimumab, versus subjects randomized to placebo. The secondary endpoints are to compare OS of nivolumab versus placebo, to compare BICR-assessed PFS of nivolumab and nivolumab combined with ipilimumab versus placebo, and to evaluate (descriptively) OS and BICR-assessed PFS of nivolumab combined with ipilimumab versus nivolumab monotherapy. See Section 8.3 for the definition of OS and PFS.

Every effort will be made to collect survival and imaging data on all subjects, including subjects withdrawn from treatment for any reason, who are eligible to participate in the study and who have not withdrawn consent for additional data collection. If the death of a subject is not reported, all dates in this study representing a date of subject contact will be used in determination of the subject's last known date alive.

5.5 Pharmacokinetic Assessments

Table 5.5-1:Pha	armacokinetic (PK) and	d Immunogenicity San	ple Collections
-----------------	------------------------	----------------------	-----------------

Part ^a	Study Day 1 Cycle = 6 Weeks (Part A) 1Cycle=2 Weeks (Part B)	Time (Relative to Dosing) Hour	Time (Relative to Dosing) Hour: Min	Pharmacokinetic Blood Samples for Nivolumab	Immunogenicity Blood Samples for Nivolumab	Pharmacokinetic Blood Samples for Ipilimumab	Immunogenicity Blood Samples for Ipilimumab
А	C1D1	0 (predose) ^b	00:00	Х	Х	Х	Х
А	C1D22	0 (predose) ^b	00:00	Х	Х	Х	Х
А	C2D22	0 (predose) ^b	00:00	Х	Х	Х	Х
В	C9D1	0 (predose) ^b	00:00	Х	Х	Х	Х
В	C17D1	0 (predose) ^b	00:00	Х	Х	Х	Х
В	C25D1	0 (predose) ^b	00:00	Х	Х	Х	Х
В	D1 of every 12 th cycle after C25D1until end of study treatment or up to 2 years of treatment	0 (predose) ^b	00:00	Х	Х	Х	Х

^a Part A indicates first 12 weeks of treatment (nivolumab + ipilimumab dosing). Part B indicates nivolumab monotherapy period starting from Week 13.

^b Predose (0 Hour) samples may be collected up to 4 days prior to dosing. However, if a predose sample is collected, and the dose is subsequently delayed, an additional predose sample should not be collected.

Clinical Protocol	CA209451
BMS-936558	nivolumab

Samples for PK and immunogenicity assessments will be collected from study subjects assigned to all 3 treatment arms at the time points indicated in Table 5.5-1. All on-treatment PK timepoints are intended to align with days on which nivolumab/ nivolumab placebo is administered. If it is known that a dose is going to be delayed, then the predose sample should be collected just prior to the delayed dose. However, if a predose sample is collected, but the dose is subsequently delayed, an additional predose sample should not be collected. Separate, detailed instructions for the collection, processing, handling, labeling, storage, and shipment of PK and immunogenicity samples will be provided in the central lab manual.

5.6 Biomarker Assessments

A variety of factors that could potentially predict clinical response to nivolumab and ipilimumab will be investigated in tumor specimens obtained at screening, and in peripheral blood taken both at screening (prior to first dose of blinded study drug) and during the study, from all randomized subjects as outlined in Table 5.6-1.

Collection	Serum	PBMC ^b	Tumor	Whole Blood
Timing^a Study Day	Soluble Biomarkers	Immuno- phenotyping	Tumor Biopsy ^c	SNP
Screening			X ^d	
Day 1 (C1D1)	Х	Х		Х
Day 8 (C1D8)	X ^b	X ^b		
Day 15 (C1D15)	Х	Х		
Day 22 (C1D22)	Х	Х		
Day 43 (C2D1)	Х	Х		
Upon Progression ^e	Х	Х	Х	

Table 5.6-1:	Biomarker Sampling Schedule for All Subjects (CA209451)
--------------	---

^a Biomarker sampling occurs prior to dosing and can occur up to 4 days prior to dosing. However, if a sample is collected and the dose is subsequently delayed an additional sample should not be collected.

^b PBMC and serum samples on non-study drug dosing days optional. PBMC's collected only for US and Canada due to shipping restrictions

^c Optional biopsies on-treatment and upon progression and may be taken at the discretion of the investigator

^d Submission of a tumor sample prior to randomization is mandatory.

^e Samples from subjects that have confirmed progression are optional but must collected before starting subsequent therapy.

5.6.1 Tumor Tissue Specimens

Archival or recently collected FFPE tumor tissue (in the form of paraffin embedded block or unstained slides, as described in Section 3.3.1, Inclusion 2f) collected prior to enrollment, must be sent at screening to a central laboratory (received by the central laboratory prior to randomization) for retrospective determination of PD-L1 status, tumor mutational burden (TMB), and/or other potential predictive biomarkers.

A biopsy sample of subjects who experience progression at any time while on treatment is optional, but strongly encouraged for the purposes of understanding mechanisms of resistance to therapy. Samples must be collected prior to the initiation of subsequent treatment.

Biopsy samples may be used for the following assessments. Tumor tissue collection details are provided in Section 5.6.1.4.

5.6.1.1 Tumor Mutational Burden

To explore the potential association of tumor mutational burden with clinical outcomes, tumor tissue will be evaluated by using FoundationOne CDxTM (F1CDx) assay, a comprehensive genomic profile (CGP) assay based on baseline tumor tissue.

5.6.1.2 Characterization of Tumor Infiltrating Lymphocytes (TILS) and Tumor Antigens

Immunohistochemistry (IHC) will be used to assess the number and composition of immune infiltrates in order to define the immune cell subsets present within FFPE tumor tissue before and after exposure to therapy. These IHC analyses will include, but not necessarily be limited to, the following markers: CD4, CD8, CD45RO, FOXp3, PD-1, and PD-L2.

5.6.1.3 DNA and RNA Genomic Assessment

DNA or RNA extracted from tumor provided may be subject to whole genome or exome sequencing using next-generation sequencing to identify mutational load and transcriptional expression.

5.6.1.4 Tumor Sample Collection Details

A formalin-fixed, paraffin-embedded (FFPE) tumor tissue block (preferred) or 10 unstained slides of tumor sample (archival or recent) for biomarker evaluation must be available and submitted to the central lab for correlative studies in order for a subject to be randomized. If fewer than 10 slides are available, the BMS Medical Monitor or Study Director may still approve randomization of subjects upon review of the case. Specimens must have been submitted to the central laboratory prior to randomization. Excisional, incisional or core needle biopsies are strongly preferred, however samples collected via endobronchial ultrasound (EBUS) guided biopsy (using a 22g needle or larger) and transbronchial lung biopsy (TBLB) are acceptable. In certain cases, the BMS Medical Monitor or Study Director may approve submission of samples collected via other methods.

Tumor samples obtained from bone metastases are not acceptable for PD-L1 testing because the PD-L1 assay does not include a decalcification step.

Formalin-fixed paraffin embedded tissue may be evaluated also by fluorescence in situ hybridization (FISH), genetic mutation detection methods, and/or by quantitative polymerase chain reaction (QPCR) for exploratory analyses of prognostic or predictive molecular markers associated with SCLC (eg, gene mutation, amplification or overexpression), to determine if these factors influence response to nivolumab. Such analyses will be completed retrospectively and within the scope of informed consent.

If feasible, tumor biopsies may be obtained for subjects who have progressed on nivolumab treatment. Changes in expression of immunoregulatory proteins will be assessed in these specimens.

If a new biopsy is taken, up to 4 core biopsies are recommended. An assessment of biopsy quality by a pathologist is encouraged at the time of the procedure. The tumor tissue that is obtained from these biopsies will be divided equally into FFPE samples and RNA later. The investigator, in consultation with the radiology staff, must determine the degree of risk associated with the procedure and find it acceptable. Biopsies may be done with local anesthesia or conscious sedation. Institutional guidelines for the safe performance of biopsies should be followed. Excisional biopsies may be performed to obtain tumor biopsy samples. Invasive procedures that require general anesthesia should not be performed to obtain a biopsy specimen. However, if a surgical procedure is performed for a clinical indication, excess tumor tissue may be used for research purposes with the consent of the subject.

Pathology report should be provided with tumor samples.

5.6.2 Peripheral Blood Markers

A variety of factors that may impact the immunomodulatory properties and efficacy of nivolumab will be investigated in peripheral blood specimens taken from all subjects prior to or during treatment. Data from these investigations will be evaluated for associations with response, survival, and/or safety (adverse event) data. Several analyses will be completed and are described briefly below.



5.6.2.2 Serum Soluble Factors

To understand the prevalence of circulating proteins and the impact they may have on the clinical activity of nivolumab, the protein concentrations of a panel of cytokines, chemokines, and other relevant immunomodulatory, serum-soluble factors (eg, soluble PD-L1) will be investigated at baseline and during treatment.

5.6.2.3 Peripheral Blood Mononuclear Cells (PBMCs)

At participating sites (US and Canada), peripheral blood mononuclear cells in whole blood taken from subjects at baseline and on treatment and will be analyzed by flow cytometry or other methods (eg, ELIspot) to assess immune cell activity.

5.7 Outcomes Research Assessments

The evaluation of health related quality of life is an increasingly important aspect of a clinical efficacy. Such data provides an understanding of the impact of treatment from the subjects' perspective and offers insights into the patient experience that may not be captured through physician reporting. Generic health related quality of life scales additionally provide data necessary in calculating utility values for health economic models. The EQ-5D will be collected in order to assess the impact of study treatment on generic health related quality of life, which will also be used in populating health economic models most notably, cost effectiveness analysis.

The Lung Cancer Symptom Scale (LCSS) will be collected to assess the impact of study treatment on patient reported disease related symptoms (See Appendix 4). The Lung Cancer Symptom Scale is a validated instrument designed to assess the impact of treatment on disease-related symptoms. It consists of 6 symptom specific questions related to dyspnea, cough, fatigue, pain, hemoptysis and anorexia plus 3 summary items: symptom distress, interference with activity, and global health related quality of life (HRQoL). The degree of impairment is recorded on a 100 mm visual analogue scale with scores from 0 to 100 with zero representing the best score.

General health status will be measured using the EQ-5D (EQ-5D-3L See Appendix 5). The EQ-5D is a standardized instrument for use as a measure of self-reported health status. The EQ-5D comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety) and a visual analog rating scale (VAS). The utility data generated from the EQ-5D is recommended for and commonly used in cost effectiveness analysis.

Healthcare resource utilization data (eg, hospitalizations, non-protocol specified medical visits, diagnostics, etc) will be collected for all randomized subjects. The resource utilization capture is specific to hospital admission utilization data and non-protocol specified visits related to study therapy.

5.8 Other Assessments



Revised Protocol No: 06 Date: 20-Sep-2018



5.8.2 Blinded Independent Central Review (BICR)

A Blinded Independent Central Review will be performed for randomized subjects to determine RECIST 1.1 response for the analysis of PFS and ORR. Details of the Imaging responsibilities and procedures will be specified in the Imaging charter. Tumor assessments should be submitted to the third-party BICR vendor as they are performed on an ongoing basis.

Sites will be informed of quality issues or the need for repeat scanning via queries from the central imaging vendor. Results of Central Imaging analysis will not be returned to the site.

6 ADVERSE EVENTS

An *Adverse Event (AE)* is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation subject administered blinded study drug and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of blinded study drug, whether or not considered related to the blinded study drug.

The causal relationship to blinded study drug is determined by a physician and should be used to assess all adverse events (AE). The causal relationship can be one of the following:

Related: There is a reasonable causal relationship between blinded study drug administration and the AE.

Not related: There is not a reasonable causal relationship between blinded study drug administration and the AE.

The term "reasonable causal relationship" means there is evidence to suggest a causal relationship.

Adverse events can be spontaneously reported or elicited during open-ended questioning, examination, or evaluation of a subject. (In order to prevent reporting bias, subjects should not be questioned regarding the specific occurrence of one or more AEs.)

BMS will be reporting adverse events to regulatory authorities and ethics committees according to local applicable laws including European Directive 2001/20/EC and FDA Code of Federal Regulations 21 CFR Parts 312 and 320.

6.1 Serious Adverse Events

A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose:

- results in death
- is life-threatening (defined as an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe)
- requires inpatient hospitalization or causes prolongation of existing hospitalization (see **NOTE** below)
- results in persistent or significant disability/incapacity
- is a congenital anomaly/birth defect
- is an important medical event (defined as a medical event(s) that may not be immediately lifethreatening or result in death or hospitalization but, based upon appropriate medical and scientific judgment, may jeopardize the subject or may require intervention [eg, medical, surgical] to prevent one of the other serious outcomes listed in the definition above.) Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization.) Potential drug induced liver injury (DILI) is also considered an important medical event. (See Section 6.6 for the definition of potential DILI.)

Suspected transmission of an infectious agent (eg, pathogenic or nonpathogenic) via the blinded study drug is an SAE.

Although pregnancy, overdose, cancer, and potential drug induced liver injury (DILI) are not always serious by regulatory definition, these events must be handled as SAEs. (See Section 6.1.1 for reporting pregnancies).

Any component of a study endpoint that is considered related to blinded study therapy (eg, death is an endpoint, if death occurred due to anaphylaxis, anaphylaxis must be reported) should be reported as SAE (see Section 6.1.1 for reporting details).

NOTE:

The following hospitalizations are not considered SAEs in BMS clinical studies:

- a visit to the emergency room or other hospital department < 24 hours, that does not result in admission (unless considered an important medical or life-threatening event)
- elective surgery, planned prior to signing consent
- admissions as per protocol for a planned medical/surgical procedure
- routine health assessment requiring admission for baseline/trending of health status (eg, routine colonoscopy)
- medical/surgical admission other than to remedy ill health and planned prior to entry into the study. Appropriate documentation is required in these cases

- admission encountered for another life circumstance that carries no bearing on health status and requires no medical/surgical intervention (eg, lack of housing, economic inadequacy, caregiver respite, family circumstances, administrative reason).
- Admission for administration of anticancer therapy in the absence of any other SAEs (applies to oncology protocols)

6.1.1 Serious Adverse Event Collection and Reporting

Sections 5.6.1 and 5.6.2 in the Investigator Brochure (IB) represent the Reference Safety Information to determine expectedness of serious adverse events for expedited reporting. Following the subject's written consent to participate in the study, all SAEs, whether related or not related to blinded study drug, must be collected, including those thought to be associated with protocol-specified procedures. All SAEs must be collected that occur during the screening period and within 100 days of discontinuation of dosing. For subjects who are randomized but never treated with study drug, SAEs should be collected for 30 days from the date of randomization. If applicable, SAEs must be collected that relate to any later protocol-specified procedure (eg, a follow-up skin biopsy).

The investigator must report any SAE that occurs after these time periods and that is believed to be related to blinded study drug or protocol-specified procedure.

An SAE report must be completed for any event where doubt exists regarding its seriousness.

If the investigator believes that an SAE is not related to blinded study drug, but is potentially related to the conditions of the study (such as withdrawal of previous therapy or a complication of a study procedure), the relationship must be specified in the narrative section of the SAE Report Form.

SAEs, whether related or not related to blinded study drug, and pregnancies must be reported to BMS (or designee) within 24 hours of awareness of the event. SAEs must be recorded on the SAE Report Form; pregnancies on a Pregnancy Surveillance Form (electronic or paper forms). The preferred method for SAE data reporting collection is through the eCRF. The paper SAE/pregnancy surveillance forms are only intended as a back-up option when the eCRF system is not functioning. In this case, the paper forms are to be transmitted via email or confirmed facsimile (fax) transmission to:

SAE Email Address: Refer to Contact Information list.

SAE Facsimile Number: Refer to Contact Information list.

For studies capturing SAEs through electronic data capture (EDC), electronic submission is the required method for reporting. In the event the electronic system is unavailable for transmission, paper forms must be used and submitted immediately. When paper forms are used, the original paper forms are to remain on site.

SAE Telephone Contact (required for SAE and pregnancy reporting): Refer to Contact Information list.

If only limited information is initially available, follow-up reports are required. (Note: Follow-up SAE reports must include the same investigator term(s) initially reported.)

If an ongoing SAE changes in its intensity or relationship to blinded study drug or if new information becomes available, the SAE report must be updated and submitted within 24 hours to Sponsor or designee using the same procedure used for transmitting the initial SAE report.

All SAEs must be followed to resolution or stabilization.

BMS will be reporting adverse events to regulatory authorities and ethics committees according to local applicable laws including European Directive 2001/20/EC and FDA Code of Federal regulations 21 CFR Parts 312 and 320. A Suspected Unexpected Serious Adverse Reaction (SUSAR) is a subset of SAEs and will be reported to the appropriate regulatory authorities and investigators following local and global guidelines and requirements.

6.2 Nonserious Adverse Events

A *nonserious adverse event* is an AE not classified as serious.

6.2.1 Nonserious Adverse Event Collection and Reporting

The collection of nonserious AE information should begin at initiation of blinded study drug. Nonserious AE information should also be collected from the start of a placebo lead-in period or other observational period intended to establish a baseline status for the subjects.

Nonserious AEs should be followed to resolution or stabilization, or reported as SAEs if they become serious (see Section 6.1.1). Follow-up is also required for nonserious AEs that cause interruption or discontinuation of blinded study drug and for those present at the end of study treatment as appropriate. All identified nonserious AEs must be recorded and described on the nonserious AE page of the CRF (paper or electronic).

All nonserious AEs (not only those deemed to be treatment-related) should be collected continuously during the treatment period and for a minimum of 100 days following the last dose of study treatment.

Completion of supplemental CRFs may be requested for AEs and/or laboratory abnormalities that are reported/identified during the course of the study.

6.2.2 Immune-Mediated Adverse Events

Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. Information supporting the assessment will be collected on the participant's case report form.

Every adverse event must be assessed by the investigator with regard to whether it is considered immune-mediated. For events which are potentially immune-mediated, additional information will be collected on the participant's case report form.

6.3 Laboratory Test Result Abnormalities

The following laboratory test result abnormalities should be captured on the nonserious AE CRF page or SAE Report Form (paper or electronic) as appropriate:

- Any laboratory test result that is clinically significant or meets the definition of an SAE
- Any laboratory test result abnormality that required the subject to have blinded study drug discontinued or interrupted
- Any laboratory test result abnormality that required the subject to receive specific corrective therapy

It is expected that wherever possible, the clinical rather than laboratory term would be used by the reporting investigator (eg, anemia versus low hemoglobin value).

6.4 Pregnancy

If, following initiation of the blinded study drug, it is subsequently discovered that a study subject is pregnant or may have been pregnant at the time of study exposure, including during at least 5 half lives after product administration, the investigator must immediately notify the BMS Medical Monitor/designee of this event and complete and forward a Pregnancy Surveillance Form to BMS Designee within 24 hours of awareness of the event and in accordance with SAE reporting procedures described in Section 6.1.1.

In most cases, the blinded study drug will be permanently discontinued in an appropriate manner (eg, dose tapering if necessary for subject safety). Please call the BMS Medical Monitor within 24 hours of awareness of the pregnancy.

In the rare event that the benefit of continuing blinded study drug is thought to outweigh the risk, after consultation with BMS, the pregnant subject may continue blinded study drug after a thorough discussion of benefits and risk with the subject

Protocol-required procedures for study discontinuation and follow-up must be performed on the subject unless contraindicated by pregnancy (eg, x-ray studies). Other appropriate pregnancy follow-up procedures must be performed on the subject.

The investigator must immediately notify the BMS (or designee) Medical monitor of this event and complete and forward a Pregnancy Surveillance Form to BMS (or designee) within 24 hours of awareness of the event and in accordance with SAE reporting procedures described in Section 6.1.1.

Follow-up information regarding the course of the pregnancy, including perinatal and neonatal outcome and, where applicable, offspring information must be reported on the Pregnancy Surveillance Form.

Any pregnancy that occurs in a female partner of a male study participant should be reported to Sponsor or designee. In order for BMS to collect any pregnancy surveillance information from the female partner, the female partner must sign an informed consent form for disclosure of this information. Information on this pregnancy will be collected on the Pregnancy Surveillance Form.

6.5 Overdose

An overdose is defined as the accidental or intentional administration of any dose of a product that is considered both excessive and medically important. All occurrences of overdose must be reported as an SAE (see Section 6.1.1 for reporting details.).

6.6 Potential Drug Induced Liver Injury (DILI)

Wherever possible, timely confirmation of initial liver-related laboratory abnormalities should occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting the defined criteria, must be reported as SAEs (see Section 6.1.1 for reporting details).

Potential drug induced liver injury is defined as:

- AT (ALT or AST) elevation > 3 times upper limit of normal (ULN) AND
- Total bilirubin > 2 times ULN, without initial findings of cholestasis (elevated serum alkaline phosphatase),

AND

3. No other immediately apparent possible causes of AT elevation and hyperbilirubinemia, including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the administration of other drug(s) known to be hepatotoxic

6.7 Other Safety Considerations

Any significant worsening noted during interim or final physical examinations, electrocardiogram, x-ray filming, any other potential safety assessment required or not required by protocol should also be recorded as a nonserious or serious AE, as appropriate, and reported accordingly.

7 DATA MONITORING COMMITTEE AND OTHER EXTERNAL COMMITTEES

A Data Monitoring Committee (DMC) will be utilized to provide general oversight and safety considerations for this study. The DMC will provide advice to the Sponsor regarding actions the committee deems necessary for the continuing protection of subjects enrolled in this study. The DMC will be charged with assessing such actions in light of an acceptable risk/benefit profile for nivolumab monotherapy and nivolumab in combination with ipilimumab. The DMC will act in an advisory capacity to BMS and will monitor subject safety data for the study approximately every 6 months for the duration of the trial.

The DMC will be advisory to the clinical study leadership team. The clinical study leadership will have responsibility for overall conduct of the study including managing the communication of study data. The group will be responsible for promptly reviewing the DMC recommendations, for providing guidance regarding the continuation or termination of the study, and for determining whether amendments to the protocol or changes to the study conduct are required.

Details of the DMC responsibilities and procedures will be specified in the DMC charter.

When required, adjudicated events will be submitted to the DMC and Health Authorities for review on a specified timeframe in accordance with the adjudication documentation.

8 STATISTICAL CONSIDERATIONS

8.1 Sample Size Determination

Per original protocol, approximately 810 subjects were to be randomized to the three treatment arms in a 1:1:1 ratio.

The primary objective is to compare Overall Survival (OS) of nivolumab in combination with ipilimumab versus placebo. The analysis of primary endpoint of OS will be conducted when at least 386 deaths have been observed pooled across the two treatment groups. Using accrual and treatment effect assumptions described below, it is expected that 208 events will be observed in placebo and 178 in nivolumab in combination with ipilimumab treatment groups. With 386 events available for comparison of OS in nivolumab in combination with ipilimumab vs placebo groups, power of the log-rank test is approximately 90% to detect a hazard ratio (HR) of 0.72 with a type I error of 0.05 (two-sided). The critical hazard ratio for determining whether nivolumab in combination with ipilimumab is superior to placebo is 0.82.

Power calculations were performed using EAST® Software (version 6.4.1). Results were generated by 10000 simulations. Model assumptions were as follows:

Survival function for placebo arm was modeled using a four hazard pieces: OS rates at 3, 9, 18 and 26 months were assumed to be 90%, 47%, 15% and 9%, respectively, based on published survival curve for placebo maintenance in Extensive-Stage SCLC, adjusted for induction phase ³⁶. Median OS for placebo was 8.8 months.

For nivolumab in combination with ipilimumab, a delayed effect versus placebo with a hazard ratio (HR) of 1 for the first 3 months ³⁷and an HR of 0.68 thereafter was assumed, resulting into overall HR (experim vs placebo) of 0.72 at time of the OS analysis. Median OS for the experimental arm was 11.0 months.

Accrual information used in the simulations had the same pattern as the actual data at time of the protocol amendment (832 subjects were accrued in 28 months and randomized to the three treatment groups). A 5% probability of dropout by month 6 was taken into account. Given the observed accrual and dropout and survival assumptions it is expected that the duration of the study from start of randomization to final analysis will be approximately 35 months (28 months of accrual + 7 months of minimum follow-up, providing an average follow up of 9 months).

This study includes a sub-study to allow enrollment of patients from China (site-specific protocol amendment 12). Data from these additional subjects will be reported separately. Subjects from China randomized on or before end of global study accrual will be included in the population used for the primary analysis clinical study report. The required number of deaths for the primary OS analysis is based on the global study population.

The independent Data Monitoring Committee (DMC) will have access to periodic interim safety and efficacy reports to allow for a risk/benefit assessment.

8.2 **Populations for Analyses - Data set descriptions**

- Global study population: all subjects enrolled during the global accrual window (from first patient first consent date to last patient outside of China's consent date). Any patient from China enrolled during the global accrual window will be included
- All Enrolled Subjects: All subjects who signed an informed consent form and were registered into the IVRS
- All Randomized Subjects: All subjects who were randomized to any treatment group
- All Treated Subjects: All subjects who received at least one dose of any study medication
- PK Subjects: All randomized subjects with available serum time-concentration data
- Immunogenicity Subjects: All randomized subjects with available ADA data
- Biomarker Subjects: All randomized subjects with available biomarker data

8.3 Endpoints

8.3.1 *Primary Endpoint(s)*

OS is defined as the time from randomization to the date of death. A subject who has not died will be censored at last known date alive. OS will be followed continuously while subjects are on the blinded study drug and every 3 months via in-person or phone contact after subjects discontinue the blinded study drug.

8.3.2 Secondary Endpoint(s)

Secondary endpoint of OS comparing nivolumab monotherapy versus placebo is defined similarly to the primary endpoint.

PFS is defined as the time from randomization to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Subjects who die without a reported prior progression will be considered to have progressed on the date of their death. Subjects who did not progress or die will be censored on the date of their last evaluable tumor assessment. Subjects who did not have any on study tumor assessments and did not die will be censored on the date they were randomized. Subjects who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the last evaluable tumor assessment prior to initiation of the subsequent anti-cancer therapy. Progression will be assessed every 6 weeks (from the first on-study radiographic assessment) until disease progression is noted.

An OS descriptive analysis will be performed to evaluate nivolumab monotherapy to nivolumab with ipilimumab treatment regimen.

Tumor mutational burden (TMB) is measured using FoundationOne CDxTM (F1CDx) assay, a comprehensive genomic profile (CGP) assay based on baseline tumor tissue. TMB is defined as

the number of somatic, coding, base substitution, and indel mutations per megabase of genome examined.

8.3.3 Exploratory Endpoint(s)

In this study, ORR, and other related endpoints including duration of objective response (DOR) and time to objective response (TTOR) will be evaluated in each treatment arms as an exploratory endpoint. ORR is defined as the proportion of randomized subjects with at least one lesion (target or non-target) at baseline scan, whose best overall response (BOR) from baseline is either a CR or PR per RECIST 1.1 criteria. BOR is determined by the best response designation recorded between the date of randomization and the date of objectively documented progression or the date of subsequent anti-cancer therapy, (excluding on-treatment palliative radiotherapy of non-target bone lesions, whichever occurs first). For subjects without documented progression and subsequent anticancer therapy, all available response designations will contribute to the BOR determination. For subjects who continue blinded study therapy beyond progression, the BOR should be determined based on response designations recorded at the time of the initial RECIST 1.1 defined progression. DOR is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Subjects who neither progress nor die will be censored on the date of their last assessment. TTOR is defined as the time from randomization to the date of the first confirmed CR or PR. DOR and TTOR will be evaluated for responders (confirmed CR or PR) only.

Safety and tolerability objective will be measured by the incidence of adverse events, serious adverse events, deaths, and laboratory abnormalities. Adverse event assessments and laboratory tests are performed at baseline, and continuously throughout the study at the beginning of each subsequent cycle. The PK objective will be measured from serum concentration. Samples will be collected to characterize pharmacokinetics of nivolumab and to explore exposure-safety and exposure-efficacy relationships.

Patients' overall health status will be assessed using The EuroQol Group's self-reported health status measure (EQ-5D). EQ-5D essentially has 2 health status components - the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, severe problems. The EQ Vas records the subject' s self-rated health state on a 100-point vertical, visual analogue scale (0 = worst imaginable health state; 100 = best imaginable health state). Other exploratory endpoints for phamacogenomics, immunogenicity and outcomes research are discussed in detail in Sections 8.4.5, 8.4.6 and 8.4.7.

8.4 Analyses

8.4.1 Demographics and Baseline Characteristics

Demographics and baseline laboratory results will be summarized by treatment arm as randomized using descriptive statistics for all randomized subjects.

8.4.2 Efficacy Analyses

OS for each of the two experimental arms will be compared to the control group using a two-sided log-rank test stratified by ECOG Performance Status (0 vs 1), Gender (male vs female) and Prophylactic Cranial Irradiation (PCI) following chemotherapy (Yes vs No) (IVRS source) in all randomized subjects. HRs and corresponding two-sided CIs will be estimated using a Cox proportional hazards model, with treatment group as a single covariate, stratified by the above factors. OS curves, OS medians with 95% CIs, and OS rates at 6, 12 and 18 months with 95% CIs will be estimated using Kaplan-Meier methodology.

BICR-assessed PFS for each of the two experimental arms will be compared to the control group using a two-sided log-rank test stratified by the same stratification factors as in the OS primary analysis. HRs and corresponding two-sided CIs will be estimated using a Cox proportional hazards model, with treatment group as a single covariate, stratified by the same stratification factors as above. PFS curves, PFS medians with 95% CIs, and PFS rates at 6, 12 and 18 months with 95% CIs will be estimated for each of the three treatment groups using Kaplan-Meier methodology.

Hierarchical procedure will be used to control the overall Type I error rate at 0.05.

The secondary endpoint, OS comparing nivolumab monotherapy vs placebo, will be tested using 2-sided 5% alpha, if superiority of nivolumab in combination with ipilimumab over placebo is demonstrated at the 5% significance level. If superiority in OS of nivolumab monotherapy over placebo is demonstrated, the 5% alpha is passed to test the secondary endpoints of PFS. PFS will be tested hierarchically, starting with comparison of PFS of nivolumab plus ipilimumab with placebo, followed by comparison of PFS of nivolumab monotherapy with placebo. The exploratory endpoint of ORR will be calculated for each treatment group. Exact two-sided 95% CIs for the rates will be computed using the method of Clopper and Pearson for each of the three treatment groups.

Descriptive analyses of OS, PFS, and ORR will be performed to evaluate differences between the two experimental arms, nivolumab combined with ipilimumab and nivolumab monotherapy. These include HRs and medians with corresponding two-sided 95% CIs for OS and PFS, as well as an ORR odds ratio with corresponding 95% CI.

Descriptive analyses will be performed to evaluate the potential of PD-L1 expression and TMB as a predictive biomarker for PFS and OS.

8.4.3 Safety Analyses

Safety analyses will be performed for all treated subjects. Descriptive statistics of safety will be presented using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. All on-study AEs, drug-related, AEs, SAEs and drug-related SAEs will be tabulated using worst grade per NCI CTCAE v4.0 criteria by system organ class and MedDRA preferred term. The listings by subject will be produced for all deaths, all SAEs, and all AEs leading to discontinuation of blinded study drug. On-study lab parameters including hematology, chemistry, liver function, thyroid function, and renal function will be summarized using worst grade per NCI CTCAE v4.0 criteria.

8.4.4 Pharmacokinetic Analyses

The concentration vs time data obtained in this study may be combined with data from other studies in the clinical development program to develop a population PK model. This model may be used to evaluate the effects of intrinsic and extrinsic covariates on the PK of nivolumab and to determine measures of individual exposure (such as steady-state peak, trough, and time-averaged concentration). Model determined exposures may be used for exposure-response analyses of selected efficacy and safety end points. Results of population PK and exposure-response analyses will be reported separately.

8.4.5 Biomarker Analyses

8.4.5.1 Pharmacodynamic Analyses

To assess pharmacodynamic effects in serum obtained from subjects on each treatment arm, summary statistics for biomarkers and their corresponding changes (or percent changes) from baseline will be tabulated by planned study day and in each arm. The time course of biomarker measures will be investigated graphically, if there is indication of meaningful pattern over time, further analysis (eg, by linear mixed model) may be performed to characterize the relationship.

8.4.5.2 Pharmacogenomic Analyses

Pharmacogenomic and Exploratory Analyses

Potential relationships between biomarker data and efficacy or safety endpoints will be investigated as part of an analysis plan aimed at identifying baseline biomarkers that may be used to prospectively identify subjects likely (or not likely) to respond to nivolumab and to identify subjects who may be predisposed to having adverse reactions to treatment. These exploratory predictive biomarker analyses will be completed with biomarkers measured in blood and in tumor samples and will focus primarily as outlined in the exploratory objectives on NPs in select genes associated with immunity or on the expression of PD-1, PD-L1, and PD-L2 proteins in tumor specimens. Similar analyses will be completed with data regarding serum-soluble factors, serum mRNA content, and putative additional analyses to be completed using FFPE tissue.

Associations between biomarkers and efficacy measures will be analyzed on all randomized subjects with available biomarker data. Efficacy measures will include response, PFS, and OS. Demographic and case-history factors will be examined to determine whether stratification or adjustments should be made within the subsequent statistical analyses, and if necessary, the appropriate stratification or adjustment will be made.

Biomarkers will be summarized graphically as they relate to efficacy and safety endpoints, as applicable. Summary statistics will be tabulated. SNP allele frequencies will be summarized. The relationships between binary measures (eg, response) and candidate biomarkers will be investigated using logistic regression. Associations will be summarized in terms of point and interval estimates of hazard ratios, odds ratios, or other statistics, as appropriate for the analyses completed. Models to predict clinical activity based on combinations of biomarkers may also be investigated.

Additional post hoc statistical analyses not specified in the protocol, such as alternative modeling approaches may be completed. All analyses described in this section are based on the availability of the data.

8.4.6 Outcomes Research Analyses

LCSS questionnaire complete rate, defined as the proportion of questionnaires actually received out of the expected number (ie, the number of subjects still on treatment and in follow-up), will be calculated and summarized at each assessment point.

Baseline and change from baseline of the average symptom burden index score at each assessment point will be summarized using descriptive statistics. Subject's overall health state on a visual analog scale (EQ-VAS) at each assessment time point and the difference from baseline will be summarized using descriptive statistics Proportion of subjects reporting problems for the 5 EQ-5D dimensions at each assessment time point will be summarized by level of problem. Summary statistics will be calculated for the population preference-based health state utility score (EQ-5D Index).

8.4.7 Other Analyses

Methodology for exploratory analyses including immunogenicity, other HRQoL assessments (PRO), and healthcare resource utilization is described in the statistical analysis plan.

8.5 Interim Analyses

Not applicable

9 STUDY MANAGEMENT

9.1 Compliance

9.1.1 Compliance with the Protocol and Protocol Revisions

The investigator should not implement any deviation or change to the protocol without prior review and documented approval/favorable opinion of an amendment from the IRB/IEC (and if applicable, also by local health authority) except where necessary to eliminate an immediate hazard(s) to study subjects.

If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to obtaining relevant approval/favorable opinion(s), the deviation or change will be submitted as soon as possible to:

- IRB/IEC
- Regulatory Authority(ies), if applicable by local regulations per national requirements

Documentation of approval/favorable opinion signed by the chairperson or designee of the IRB(s)/IEC(s) and if applicable, also by local health authority, must be sent to BMS.

If an amendment substantially alters the study design or increases the potential risk to the subject: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review and approval/favorable opinion; (2) the revised form must be used to obtain consent from subjects currently enrolled in the study if they are affected by the amendment; and (3) the new form must be used to obtain consent from new subjects prior to enrollment.

If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).

9.1.2 Monitoring

BMS representatives will review data centrally to identify potential issues to determine a schedule of on-site visits for targeted review of study records.

Representatives of BMS must be allowed to visit all study site locations periodically to assess the data quality and study integrity. On site they will review study records and directly compare them with source documents, discuss the conduct of the study with the investigator, and verify that the facilities remain acceptable.

In addition, the study may be evaluated by BMS internal auditors and government inspectors who must be allowed access to CRFs, source documents, other study files, and study facilities. BMS audit reports will be kept confidential.

The investigator must notify BMS promptly of any inspections scheduled by regulatory authorities, and promptly forward copies of inspection reports to BMS.

9.1.2.1 Source Documentation

The Investigator is responsible for ensuring that the source data are accurate, legible, contemporaneous, original and attributable, whether the data are hand-written on paper or entered electronically. If source data are created (first entered), modified, maintained, archived, retrieved, or transmitted electronically via computerized systems (and/or any other kind of electronic devices) as part of regulated clinical trial activities, such systems must be compliant with all applicable laws and regulations governing use of electronic medical/health records (EMRs/EHRs), adverse event tracking/reporting, protocol required assessments, and/or drug accountability records).

When paper records from such systems are used in place of electronic format to perform regulated activities, such paper records should be certified copies. A certified copy consists of a copy of original information that has been verified, as indicated by a dated signature, as an exact copy having all of the same attributes and information as the original.

9.2 Records

9.2.1 Records Retention

The investigator (or head of the study site in Japan) must retain all study records and source documents for the maximum period required by applicable regulations and guidelines, or

institution procedures, or for the period specified by BMS or designee, whichever is longer. The investigator must contact BMS or designee prior to destroying any records associated with the study.

BMS will notify the investigator (or head of the study site in Japan) when the study records are no longer needed.

If the investigator withdraws from the study (eg, relocation, retirement), the records shall be transferred to a mutually agreed upon designee (eg, another investigator, study site, IRB). Notice of such transfer will be given in writing to BMS.

9.2.2 Study Drug Records

Records for IP (whether supplied by BMS, its vendors, or the site) must substantiate IP integrity and traceability from receipt, preparation, administration, and through destruction or return. Records must be made available for review at the request of BMS/designee or a Health Authority.

If	Then
Supplied by BMS (or its vendors):	Records or logs must comply with applicable regulations and guidelines and should include:
	• amount received and placed in storage area
	• amount currently in storage area
	label identification number or batch number
	• amount dispensed to and returned by each subject, including unique subject identifiers
	• amount transferred to another area/site for dispensing or storage
	• nonstudy disposition (e.g., lost, wasted)
	• amount destroyed at study site, if applicable
	• amount returned to BMS
	 retain samples for bioavailability/bioequivalence, if applicable
	• dates and initials of person responsible for Investigational Product dispensing/accountability, as per the Delegation of Authority Form.
Sourced by site, and not supplied by BMS or its vendors (examples include IP sourced from	The investigator or designee accepts responsibility for documenting traceability and

If	Then
the sites stock or commercial supply, or a specialty pharmacy)	study drug integrity in accordance with requirements applicable under law and the SOPs/standards of the sourcing pharmacy.

BMS or designee will provide forms to facilitate inventory control if the investigational site does not have an established system that meets these requirements.

9.2.3 Case Report Forms

An investigator is required to prepare and maintain adequate and accurate case histories designed to record all observations and other data pertinent to the investigation on each individual treated or entered as a control in the investigation. Data that are derived from source documents and reported on the CRF must be consistent with the source documents or the discrepancies must be explained. Additional clinical information may be collected and analyzed in an effort to enhance understanding of product safety. CRFs may be requested for AEs and/or laboratory abnormalities that are reported or identified during the course of the study.

For sites using the BMS electronic data capture tool, electronic CRFs will be prepared for all data collection fields except for fields specific to SAEs and pregnancy, which will be reported on the paper or electronic SAE form and Pregnancy Surveillance form, respectively. Spaces may be left blank only in those circumstances permitted by study-specific CRF completion guidelines provided by BMS.

The confidentiality of records that could identify subjects must be protected, respecting the privacy and confidentiality rules in accordance with the applicable regulatory requirement(s).

The investigator will maintain a signature sheet to document signatures and initials of all persons authorized to make entries and/or corrections on CRFs.

The completed CRF, including any paper or electronic SAE/pregnancy CRFs, must be promptly reviewed, signed, and dated by the investigator or qualified physician who is a subinvestigator and who is delegated this task on the Delegation of Authority Form. Subinvestigators in Japan may not be delegated the CRF approval task. For electronic CRFs, review and approval/signature is completed electronically through the BMS electronic data capture tool. The investigator must retain a copy of the CRFs including records of the changes and corrections.

Each individual electronically signing electronic CRFs must meet BMS training requirements and must only access the BMS electronic data capture tool using the unique user account provided by BMS. User accounts are not to be shared or reassigned to other individuals.

9.3 Clinical Study Report and Publications

A Signatory Investigator must be selected to sign the clinical study report.

For this protocol, the Signatory Investigator will be selected as appropriate based on the following criteria:

- External Principal Investigator designated at protocol development
- National Coordinating Investigator
- Study Steering Committee chair or their designee
- Subject recruitment (eg, among the top quartile of enrollers)
- Involvement in trial design
- Regional representation (eg, among top quartile of enrollers from a specified region or country)
- Other criteria (as determined by the study team)

The data collected during this study are confidential and proprietary to BMS. Any publications or abstracts arising from this study must adhere to the publication requirements set forth in the clinical trial agreement (CTA) governing [Study site or Investigator] participation in the study. These requirements include, but are not limited to, submitting proposed publications to BMS at the earliest practicable time prior to submission or presentation and otherwise within the time period set forth in the CTA.

10 GLOSSARY OF TERMS

Term	Definition
Complete Abstinence	Complete Abstinence is defined as complete avoidance of heterosexual intercourse and is an acceptable form of contraception for all study drugs. This also means that abstinence is the preferred and usual lifestyle of the patient. This does not mean periodic abstinence (eg, calendar, ovulation, symptothermal, profession of abstinence for entry into a clinical trial, post-ovulation methods) and withdrawal, which are not acceptable methods of contraception. Women must continue to have pregnancy tests. Acceptable alternate methods of highly or less effective contraception's must be discussed in the event that the subject chooses to forego complete abstinence.

11 LIST OF ABBREVIATIONS

Term	Definition
AE	adverse event
ALT	alanine aminotransferase
ANC	absolute neutrophil count
AIDS	Acquired immunodeficiency syndrome
aPTT	activated partial thromboplastin time
AST	aspartate aminotransferase
AT	aminotransaminases
β-HCG	beta-human chorionic gonadotrophin
BID, bid	bis in die, twice daily
BICR	Blinded independent central review
BMI	body mass index
BMS	Bristol-Myers Squibb
BP	blood pressure
BUN	blood urea nitrogen
С	Celsius
Ca++	Calcium
Cavg	average concentration
CBC	complete blood count
CFR	Code of Federal Regulations
CI	confidence interval
C1-	Chloride
CLcr	creatinine clearance
cm	Centimeter
CNS	Central nervous system
CRC	Clinical Research Center
CRF	Case Report Form, paper or electronic
CTLA-4	Cytotoxic t lymphocyte-associated antigen 4
СҮР	cytochrome p-450
D/C	Discontinue

Term	Definition
dL	Deciliter
ECG	Electrocardiogram
ECOG	Eastern Cooperative Oncology Group
eCRF	Electronic Case Report Form
EDC	Electronic Data Capture
Eg	exempli gratia (for example)
ESR	Expedited Safety Report
FDA	Food and Drug Administration
FISH	Fluorescent in situ hybridization
FSH	follicle stimulating hormone
g	Gram
GCP	Good Clinical Practice
GGT	gamma-glutamyl transferase
GFR	glomerular filtration rate
h	hour
HBsAg	hepatitis B surface antigen
HBV	hepatitis B virus
HCV	hepatitis C virus
НСО3-	bicarbonate
HIV	Human Immunodeficiency Virus
HR	heart rate
HRQoL	Health Related Quality of Life
HRT	hormone replacement therapy
ICD	International Classification of Diseases
ICH	International Conference on Harmonization
ie	id est (that is)
IEC	Independent Ethics Committee
IMP	investigational medicinal products
IMAE	Immune-mediated adverse events
IND	Investigational New Drug Exemption

Term	Definition
IRB	Institutional Review Board
IU	International Unit
IU/L	International unit per liter
IU/mL	International unit per milliliter
IVRS	Interactive voice response system
IV	intravenous
K+	potassium
kg	Kilogram
КМ	Kaplan-meier
L	Liter
LAM	Lactation amenorrhea method
LCSS	Lung cancer symptom scale
LDH	lactate dehydrogenase
mAB	Monoclonal antibody
mg	Milligram
Mg++	magnesium
Min	Minute
mL	Milliliter
mmHg	millimeters of mercury
MTD	maximum tolerated dose
μg	Microgram
N	number of subjects or observations
Na+	Sodium
N/A	not applicable
NE	Not evaluable
Ng	Nanogram
NCCN	National Comprehensive Cancer Network
NIMP	non-investigational medicinal products
ORR	Overall response rate
OS	Overall survival

Term	Definition
PD	Progressive disease
PD	Pharmacodynamics
PD-1	Programmed Death-1
PD-L1	Programmed death-ligand 1
PD-L2	Programmed death-ligand 2
PFS	progression-free survival
PR	Partial response
РК	Pharmacokinetics
РТ	prothrombin time
RCC	Renal cell carcinoma
RECIST 1.1	Resonse evaluation criteria in solid tumors version 1.1
RBC	red blood cell
SAE	serious adverse event
SD	standard deviation
SD	Stable disease
SOP	Standard Operating Procedures
t	Temperature
Т	Time
ТАО	Trial Access Online, the BMS implementation of an EDC capability
T-HALF	Half life
TID, tid	ter in die, three times a day
TILs	Tumor infiltrating lymphocytes
TSH	Thyroid stimulating hormone
Tmax, TMAX	time of maximum observed concentration
ULN	Upper limit of normal
VAS	Visual analog scale
WBC	white blood cell
WOCBP	women of childbearing potential

12 **REFERENCES**

REFERENCES FOR THE USE OF CONDOMS WITH SPERMICIDE.

Kestelman P. et. al., Efficacy of the Simultaneous Use of Condoms and Spermicides Family Planning Perspectives.Vol 23 (5); October 1991.

Gabbay MB, Thomas J, Gibbs A, Hold P. A Randomized Crossover Trial of The Impact of Additional Spermicide on Condom Failure Rates. Sex Transm Dis 2008; 35: 862-8.

- ¹ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
- ² Lung. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 253-70.
- ³ National Comprehensive Cancer Network. Small Cell Lung Cancer, v 1.2016. NCCN. Available at http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf. Accessed 8 June 2015.
- ⁴ Sorensen M, Pijls-Johannesma M, Felip E. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010; 21 (Supplement 5):v120-v125.
- ⁵ Jänne PA, Freidlin B, Saxman S, et al. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 2002; 95:1528-38.
- ⁶ Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. JCO 1999; 17:1794-1801.
- ⁷ Schiller JH, Adak S, Cella D et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Apr 15;19(8):2114-22.
- ⁸ Ready NE, Pang HH, Gu L, et al. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). J Clin Oncol. 2015 May 20;33(15):1660-5. doi: 10.1200/JCO.2014.57.3105. Epub 2015 Mar 2.
- ⁹ Koyama K, Kagamu H, Miura S, et al. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008; 14:6770-6779.
- ¹⁰ Ishii et al. Significance of Programmed cell death-ligand 1 expression and its association with survival in patients with small-cell lung cancer. J Thorac Oncol. 2015 Mar;10(3):426-30.
- ¹¹ Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 May 31. [Epub ahead of print]
- ¹² Paz-Ares L, Horn L, Borghaei H, et al. Phase III, Randomized Trial (Checkmate 057) of Nivolumab (NIVO) versus Docetaxel (DOC) in Advanced Non-Squmaous (non-SQ) Non-Small Cell Lung Cancer. J Clin Oncol 33, 2015 (suppl; abstrLBA109).

- ¹³ Hellman MD, Callahan MK, Awad M et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018: 33, 853–861
- ¹⁴ Hellmann MD, Ott PA, Zugazagoitia J et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. Journal of Clinical Oncology 2017. 35;15. 8503-8503.
- ¹⁵ Rivzi N et al. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. WCLC 2017.
- ¹⁶ Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. NEJM 2015; DOI: 10.1056/NEJMoa1504030.
- ¹⁷ Kearney ER, Walunas TL, Karr RW, et al. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol 1995;155(3):1032-6.
- ¹⁸ Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. PNAS 2010; 107: 4275-80.
- ¹⁹ Ji RR, Chasalow SD, Wang L, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61: 1019-31.
- ²⁰ Taube JM, Anders RA, Young GD, et al. Co-localization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Trans Med 2012; 4: 127-37.
- ²¹ Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose ranging study. Lancet Oncol. 2010; Feb;11(2):155-64
- ²² Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. New Engl J Med 2012;366:2443-2454.
- ²³ Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus Ipilimumab in Advanced Melanoma. NEJM 2013. doi:10.1056/NEJMoal1302369.
- ²⁴ Julie Brahmer, Reckkamp KL, Baas P et al, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N Engl J Med 2015;373:123-35.
- ²⁵ Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med 2015; 373:1627-1639
- ²⁶ Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. 2017; 18. 31-41.The Lancet Oncology
- ²⁷ Larkin J, Chiarion-Sileni V, Gonzalez R. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34

- ²⁸ Motzer, RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 2015;373.1803-1813.
- ²⁹ Schadendorf D, Larkin J, Postow M, et al. Efficacy and safety outcomes in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity; Presented at: 12th Congress of the European Association of Dermato Oncology; August 31-September 3, 2016; Vienna, Austria.
- ³⁰ Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015:33,17:1889-1894.
- ³¹ Brahmer J, Horn L, Jackman D, et al. Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer: clinical characteristics of long-term survivors. Oral presentation presented at: American Association for Cancer Research (AACR) Annual Meeting; April 1-5, 2017; Washington, DC, USA.
- ³² Herbst RS et al. KEYNOTE-010: Durable clinical benefit in patients with previously treated, PD-L1-expressing NSCLC who completed pembrolizumab. Poster presentation at the World Conference on Lung Cancer 2016 Dec 4-7; Vienna, Austria)
- ³³ Robert C et al. Long-term outcomes in patients with ipilimumab-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab treatment; Journal of Clinical Oncology 2017 35:15_suppl, 9504-9504
- ³⁴ Antonia S, Bendell J, Taylor M, et al. Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209032. Submitted for ASCO 2015, accepted for presentation.
- ³⁵ Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus Ipilimumab in Advanced Melanoma. NEJM 2013. doi:10.1056/NEJMoal1302369.
- ³⁶ Reck M, Luft A, Szczesna A, et al. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol 2016;34:3740-8
- ³⁷ Ready NE, Pang HH, Gu L, et al. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive- Stage Small-Cell Lung Cancer: A Randomized, Double- Blind, Placebo Controlled Phase II Study-CALGB 30504 (Alliance). J Clin Oncol 2015;33:1660-5.

APPENDIX 1 ECOG PERFORMANCE STATUS

ECOG PERFORMANCE STATUS ^a	
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, eg, light house work, office work
2	Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
3	Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4	Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5	Dead

^a Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, and Carbone PP. Toxicity and Response Criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.

APPENDIX 2 MANAGEMENT ALGORITHMS FOR IMMUNO-ONCOLOGY AGENTS

These general guidelines constitute guidance to the Investigator and may be supplemented by discussions with the Medical Monitor representing the Sponsor. The guidance applies to all immuno-oncology agents and regimens.

A general principle is that differential diagnoses should be diligently evaluated according to standard medical practice. Non inflammatory etiologies should be considered and appropriately treated.


Corticosteroids are a primary therapy for immuno-oncology drug-related adverse events. The oral equivalent of the recommended IV doses may be considered for ambulatory patients with low-grade toxicity. The lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.

Consultation with a medical or surgical specialist, especially prior to an invasive diagnostic or therapeutic procedure, is recommended.

The frequency and severity of the related adverse events covered by these algorithms will depend on the immuno-oncology agent or regimen being used.

GI Adverse Event Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause is identified, treat accordingly and continue I-O therapy. Opiates/narcotics may mask symptoms of perforation. Infliximab should not be used in cases of perforation or sepsis.




Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids. Updated 05-Jul-2016

Revised Protocol No: 06 Date: 20-Sep-2018

Renal Adverse Event Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy




Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.

Updated 05-Jul-2016

Revised Protocol No: 06 Date: 20-Sep-2018

Pulmonary Adverse Event Management Algorithm


Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy. Evaluate with imaging and pulmonary consultation.



Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.

Hepatic Adverse Event Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy. Consider imaging for obstruction.



Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.


*The recommended starting dose for grade 4 hepatitis is 2 mg/kg/day methylprednisolone IV.

Updated 27-Jun-2018

Revised Protocol No: 06 Date: 20-Sep-2018

Endocrinopathy Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy. Consider visual field testing, endocrinology consultation, and imaging.




Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.

Updated 05-Jul-2016

Revised Protocol No: 06 Date: 20-Sep-2018

Skin Adverse Event Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy.




Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids. *Refer to NCI CTCAE v4 for term-specific grading criteria.

Alf SJS/TEN is suspected, withhold I-O therapy and refer patient for specialized care for assessment and treatment. If SJS or TEN is diagnosed, permanently discontinue I-O therapy.

Updated 05-Jul-2016

Neurological Adverse Event Management Algorithm

Rule out non-inflammatory causes. If non-inflammatory cause, treat accordingly and continue I-O therapy.



Patients on IV steroids may be switched to an equivalent dose of oral corticosteroids (e.g. prednisone) at start of tapering or earlier, once sustained clinical improvement is observed. Lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids.

Updated 05-Jul-2016

APPENDIX 3 RESPONSE EVALUATION CRITERIA IN SOLID TUMORS GUIDELINES (VERSION 1.1) WITH BMS MODIFICATIONS

1 EVALUATION OF LESIONS

Solid tumors will be evaluated using <u>Response Evaluation Criteria In Solid T</u>umors version 1.1 (RECIST 1.1) guideline with BMS modifications. (Eisenhauer EA et al. Eur J Cancer 2009; 45: 228-47)

At baseline, tumor lesions/lymph nodes will be categorized as measurable or non-measurable as follows:

1.1 Measurable

Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of:

10 mm by CT/MRI scan (scan slice thickness no greater than 5 mm), or $\ge 2x$ slice thickness if greater than 5mm.

Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph node must be ≥ 15 mm in short axis when assessed by CT/MRI scan (scan slice thickness recommended to be no greater than 5 mm).

Lymph nodes merit special mention since they are normal anatomical structures which may be visible by imaging even if not involved by tumor. Pathological nodes which are defined as measurable and may be identified as target lesions must meet the criterion of a short axis of ≥ 15 mm by CT/MRI scan. Only the short axis of these nodes will contribute to the baseline sum. The short axis of the node is the diameter normally used by radiologists to judge if a node is involved by solid tumor. Nodal size is normally reported as two dimensions in the plane in which the image is obtained (for CT scan this is almost always the axial plane; for MRI the plane of acquisition may be axial, sagittal or coronal). The smaller of these measures is the short axis. For example, an abdominal node which is reported as being 20 mm x 30 mm has a short axis of 20 mm and qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the node measurement. All other pathological nodes (those with short axis ≤ 10 mm are considered non-pathological and should not be recorded or followed.

Note: Lesions on X-Ray are not to be selected as Target or Non-Target Lesions.

1.2 Non-Measurable

All other lesions are considered non-measurable, including small lesions (longest diameter < 10mm or pathological lymph nodes with ≥ 10 to < 15 mm short axis) as well as truly non-measurable lesions. Lesions considered truly non-measurable include: leptomeningeal disease, inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly identified by physical exam that is not measurable by reproducible imaging techniques.

Note: Lesions on X-Ray are not to be selected as Target or Non-Target Lesions.

1.3 Special considerations regarding lesion measurability

1.3.1 Bone lesions

- Bone scan, PET scan and plain films are *not* considered adequate imaging techniques to measure bone lesions. However, these techniques can be used to confirm the presence or disappearance of bone lesions.
- Lytic bone lesions or mixed lytic-blastic lesions, with *identifiable soft tissue components*, that can be evaluated by cross sectional imaging techniques such as CT or MRI can be considered as measurable lesions if the *soft tissue component* meets the definition of measurability described above.
- Blastic bone lesions are non-measurable.

1.4 Baseline Documentation Of 'Target' And 'Non-Target' Lesions

When more than one measurable lesion is present at baseline all lesions up to a maximum of five lesions total (and a maximum of two lesions per organ) representative of all involved organs should be identified as target lesions and will be recorded and measured at baseline (this means in instances where patients have only one or two organ sites involved a maximum of two and four lesions respectively will be recorded).

Note: A maximum of two lesions can be selected per organ system. For example, a maximum of two lung lesions can be selected (selected from one lung or one lesion from each). A maximum of two lymph nodes can be selected at baseline, as the lymphatic system is considered one organ.

Target lesions should be selected on the basis of their size (lesions with the longest diameter), be representative of all involved organs, but in addition should be those that lend themselves to reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does not lend itself to reproducible measurement in which circumstance the next largest lesion which can be measured reproducibly should be selected.

A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum diameters. If lymph nodes are to be included in the sum, then as noted above, only the short axis is added into the sum. The baseline sum diameters will be used as reference to further characterize any objective tumor regression in the measurable dimension of the disease.

All other lesions (or sites of disease) including pathological lymph nodes should be identified as non-target lesions and should also be recorded at baseline. Measurements are not required and these lesions should be followed as 'present', 'absent', or in rare cases 'unequivocal progression' (more details to follow). In addition, it is possible to record multiple non-target lesions involving the same organ as a single item on the case record form (eg, 'multiple enlarged pelvic lymph nodes' or 'multiple liver metastases').

2. RESPONSE CRITERIA

2.1 Evaluation of Target Lesions

- **Complete Response (CR):** Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
- **Partial Response (PR):** At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
- **Progressive Disease (PD):** At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).
- **Stable Disease (SD):** Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
- Not Evaluable (NE): If one or more target lesions cannot be measured or adequately assessed as either fully resolved or too small to measure (due to missing or poor quality images), and the sum of diameters of the remaining measured target lesions (if any) has not increased sufficiently to meet Progressive Disease as defined above.

2.1.1 Special Notes on the Assessment of Target Lesions

2.1.1.1 Lymph nodes

Lymph nodes identified as target lesions should always have the actual short axis measurement recorded (measured in the same anatomical plane as the baseline examination), even if the nodes regress to below 10 mm on study. This means that when lymph nodes are included as target lesions, the 'sum' of lesions may not be zero even if complete response criteria are met, since a normal lymph node is defined as having a short axis of < 10 mm. Case report forms or other data collection methods may therefore be designed to have target nodal lesions recorded in a separate section where, in order to qualify for CR, each node must achieve a short axis < 10 mm. For PR, SD and PD, the actual short axis measurement of the nodes is to be included in the sum of target lesions.

2.1.1.2 Target lesions that become 'too small to measure'

While on study, all lesions (nodal and non-nodal) recorded at baseline should have their actual measurements recorded at each subsequent evaluation, even when very small (eg, 2 mm). However, sometimes lesions or lymph nodes which are recorded as target lesions at baseline become so faint on CT scan that the radiologist may not feel comfortable assigning an exact measure and may report them as being 'too small to measure'. When this occurs it is important that a value be recorded on the case report form. If it is the opinion of the radiologist that the lesion has likely disappeared, the measurement should be recorded as 0 mm. If the lesion is believed to be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned as the reference diameter. (Note: It is less likely that this rule will be used for lymph nodes since they usually have a definable size when normal and are frequently surrounded

by fat such as in the retroperitoneum; however, if a lymph node is believed to be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned in this circumstance as well). This default value is derived from the 5 mm CT slice thickness (but should not be changed with varying CT slice thickness). The measurement of these lesions is potentially non-reproducible, therefore providing this default value will prevent false responses or progressions based upon measurement error. To reiterate, however, if the radiologist is able to provide an actual measure, that should be recorded, even if it is below 5 mm.

2.1.1.3 Lesions that split or coalesce on treatment

When non-nodal lesions 'fragment', the longest diameters of the fragmented portions should be added together to calculate the target lesion sum. Similarly, as lesions coalesce, a plane between them may be maintained that would aid in obtaining maximal diameter measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the maximal longest diameter for the 'coalesced lesion'.

2.2 Evaluation of Non-Target Lesions

This section provides the definitions of the criteria used to determine the tumor response for the group of non-target lesions. While some non-target lesions may actually be measurable, they need not be measured and instead should be assessed only qualitatively at the time points specified in the protocol.

- **Complete Response (CR):** Disappearance of all non-target lesions. All lymph nodes must be non-pathological in size (< 10mm short axis).
- Non-CR/Non-PD: Persistence of one or more non-target lesion(s)
- **Progressive Disease (PD):** Unequivocal progression of existing non-target lesions.

2.2.1 Special Notes on Assessment of Progression of Non-Target Disease

The concept of progression of non-target disease requires additional explanation as follows:

2.2.1.1 When the patient also has measurable disease

In this setting, to achieve 'unequivocal progression' on the basis of the non-target disease, there must be an overall level of substantial worsening in non-target disease such that, even in presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to merit discontinuation of therapy A modest 'increase' in the size of one or more non-target lesions is usually not sufficient to qualify for unequivocal progression status. Pleural effusions, pericardial effusions and ascites will not be followed as target or non-target lesions and will not contribute to response or progression. The designation of overall progression solely on the basis of change in non-target disease in the face of SD or PR of target disease will therefore be extremely rare.

2.2.1.2 When the patient has only non-measurable disease

This circumstance arises in some trials when it is not a criterion of study entry to have measurable disease. The same general concepts apply here as noted above, however, in this instance there is no measurable disease assessment to factor into the interpretation of an increase in non-measurable disease burden. Because worsening in non-target disease cannot be easily quantified (by definition: if all lesions are truly non-measurable) a useful test that can be applied when assessing patients for unequivocal progression is to consider if the increase in overall disease burden based on the change in non-measurable disease: ie, an increase in tumor burden representing an additional 73% increase in 'volume' (which is equivalent to a 20% increase diameter in a measurable lesion). Examples include, an increase in lymphangitic disease from localized to widespread, or may be described as 'sufficient to require a change in therapy'. If 'unequivocal progression' is seen, the patient should be considered to have had overall PD at that point. While it would be ideal to have objective criteria to apply to non-measurable disease, the very nature of that disease makes it impossible to do so; therefore the increase must be substantial.

2.2.2 New Lesions

The appearance of new malignant lesions denotes disease progression; therefore, some comments on detection of new lesions are important. There are no specific criteria for the identification of new radiographic lesions; however, the finding of a new lesion should be unequivocal: ie, not attributable to differences in scanning technique, change in imaging modality or findings thought to represent something other than tumor (for example, some 'new' bone lesions may be simply healing or flare of pre-existing lesions). This is particularly important when the patient's baseline lesions show partial or complete response. For example, necrosis of a liver lesion may be reported on a CT scan report as a 'new' cystic lesion, which it is not.

NOTE: Fluid collections (pleural effusions, pericardial effusions, and ascites) will not be considered new lesions and will not contribute to response or progression. In the event a new fluid collection is seen on a post-baseline imaging exam, a comment may be made, but the appearance of a new fluid collection alone should not result in an assessment of Progressive Disease (PD). A lesion identified on a follow-up study in an anatomical location that was not scanned at baseline is considered a new lesion and will indicate disease progression. An example of this is the patient who has visceral disease at baseline and while on study has a CT or MRI brain ordered which reveals metastases. The patient's brain metastases are considered to be evidence of PD even if he/she did not have brain imaging at baseline. A lesion identified on Chest X-Ray that was not present in prior CT can be considered a new lesion and will result in Progressive Disease (PD).

If a new lesion is equivocal, for example because of its small size, continued follow-up evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new lesion, then progression should be declared using the date of the initial scan. While FDG-

PET response assessments need additional study, it is sometimes reasonable to incorporate the use of FDG-PET scanning to complement CT scanning in assessment of progression (particularly possible 'new' disease). New lesions on the basis of FDG-PET imaging can be identified according to the following algorithm:

- 1. Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD based on a new lesion.
- 2. No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-PET at follow-up corresponds to a new site of disease confirmed by CT, this is PD. If the positive FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up CT scans are needed to determine if there is truly progression occurring at that site (if so, the date of PD will be the date of the initial abnormal FDG-PET scan). If the positive FDG-PET at follow-up corresponds to a pre-existing site of disease on CT that is not progressing on the basis of the anatomic images, this is not PD.

2.3 Response Assessment

2.3.1 Evaluation of Best Overall Response

The best overall response is the best response recorded from the start of the study treatment until disease progression or the last response recorded, taking into account any requirement for confirmation and censoring rules regarding subsequent therapy. The patient's best overall response assignment will depend on the findings of both target and non-target disease and will also take into consideration the appearance of new lesions. Furthermore, depending on the nature of the study and the protocol requirements, it may also require confirmatory measurement.

2.3.2 Time Point Response

At each protocol specified time point, a response assessment occurs. Table 2.3.2-1 provides a summary of the overall response status calculation at each time point for patients who have measurable disease at baseline. When patients have non-measurable (therefore non-target) disease only, Table 2.3.2-2 is to be used.

Table 2.3.2-1:Time Point Response: Patients With Target (± Non-Target) Disease			
Target Lesions	Non-Target Lesions	New Lesions	Overall Response
CR	CR	No	CR
CR	Non-CR/non-PD	No	PR
CR	Not evaluated	No	PR
PR	Non-PD or not all evaluated	No	PR
SD	Non-PD or not all evaluated	No	SD
Not all evaluated	Non-PD	No	NE
PD	Any	Yes or No	PD

Table 2.3.2-1:Time Point Response: Patients With Target (± Non-Target) Disease			
Target Lesions	Non-Target Lesions	New Lesions	Overall Response
Any	PD	Yes or No	PD
Any	Any	Yes	PD

CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease and NE = inevaluable

Table 2.3.2-2:Time Point Response: Patients with Non-target Disease Only			
Non-Target Lesions	New Lesions	Overall Response	
CR	No	CR	
Non-CR/non-PD	No	Non-CR/non-PD ^a	
Not all evaluated	No	NE	
Unequivocal PD	Yes or No	PD	
Any	Yes	PD	
CR = complete response, PD = progressive disease and NE = inevaluable			

^a Non-CR/non-PD is preferred over SD for non-target disease since SD is increasingly used as endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised.

2.3.3 Best Overall Response

Best response determination of complete or partial response requires confirmation: Complete or partial responses may be claimed only if the criteria for each are met at a subsequent time point of \geq 4 weeks (28 days) later. In this circumstance, the best overall response can be interpreted as in Table 2.3.3-1. When SD is believed to be best response, it must meet the protocol specified minimum time from the date of first treatment or randomization date.

For example, if the first scheduled follow-up imaging visit is Week 6 (\pm 7 days) for a particular protocol, a Best Response of SD can only be made after the subject is on-study for a minimum of 6 weeks (42 days) minus 7 days, for an absolute minimum time on-study of 35 days from the reference start date (reference date is considered Day 1 on study). If the subject is not on-study for at least this amount of time, any tumor assessment indicating stable disease before this time period will have a Best Response of NE unless PD is identified.

Special note on response assessment: When nodal disease is included in the sum of target lesions and the nodes decrease to 'normal' size (< 10 mm), they may still have a measurement reported on scans. This measurement should be recorded even though the nodes are normal in order not to overstate progression should it be based on increase in size of the nodes. As noted earlier, this means that patients with CR may not have a total sum of 'zero' on the case report form (CRF).

Table 2.3.3-1:Best Overall Response (Confirmation of CR and PR Required)		
Overall Response First Time Point	Overall Response Subsequent Time Point	Best Overall Response
CR	CR	CR
CR	PR	SD, PD OR PR ^a
CR	SD	SD provided minimum criteria for SD duration met, otherwise, PD
CR	PD	SD provided minimum criteria for SD duration met, otherwise, PD
CR	NE	SD provided minimum criteria for SD duration met, otherwise, NE
PR	CR	PR
PR	PR	PR
PR	SD	SD
PR	PD	SD provided minimum criteria for SD duration met, otherwise, PD
PR	NE	SD provided minimum criteria for SD duration met, otherwise, NE
NE	NE	NE
CR = complete respo NE = inevaluable	onse, PR = partial response, S	SD = stable disease, PD = progressive disease, and

^a If a CR is truly met at first time point, then any disease seen at a subsequent time point, even disease meeting PR criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). Best response would depend on whether minimum duration for SD was met. However, sometimes 'CR' may be claimed when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR at the first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR.

2.3.4 Confirmation Scans

<u>Verification of Response</u>: To be assigned a status of CR or PR, changes in tumor measurements must be confirmed by consecutive or subsequent repeat assessments that should be performed no less than 28 days after the criteria for response are first met. Subsequent documentation of a CR may provide confirmation of a previously identified CR even with an intervening NE or PR (eg, CR NE CR or CR PR CR). Subsequent documentation of a PR may provide confirmation of a previously identified PR even with an intervening NE or SD (eg, PR NE PR or PR SD PR). However, only one (1) intervening time point will be allowed between PR/CRs for confirmation.

<u>Verification of Progression</u>: Progression of disease should be verified in cases where progression is equivocal. If repeat scans confirm PD, then progression should be declared using the date of the initial scan. If repeat scans do not confirm PD, then the subject is considered to not have progressive disease.

APPENDIX 4 LUNG CANCER SYMPTOM SCALE (LCSS)

Standard Procedures:

- 1. It is recommended that the patient scale be administered **before** the patient sees or talks with the physician, undergoes any tests or treatments, and/or receives results of any tests (x-rays, blood tests, etc).
- 2. The patient should be **assessed alone**. Family members or significant others should be asked to leave, but if they decline, proceed with administering the instrument. Reinforce that the response desired is the **patient's response**. Make an effort to have no other hospital personnel in the room.
- 3. Test administrators should **remain with the patient** to given instructions, answer questions, and facilitate completion on time.
- 4. The **order of the questions is important**. Questions should be presented in an order progressing from the least threatening items to the most threatening ones as they were tested. Thus, the questions should be in the following fixed order:

First: * **Example question about the weather**

Then: 1) Appetite loss

- 2) Fatigue
- 3) Cough
- 4) Shortness of breath
- 5) Blood in sputum
- 6) Pain
- 7) Symptoms from lung cancer
- 8) Normal activities
- 9) Quality of life
- 5. Convey the following introduction to the patient (not necessarily verbatim):
- 6. "In addition to measuring changes in your tumor, we also want to find out exactly how you feel, and we need your help. This scale asks about your lung cancer symptoms. It takes approximately 5 8 minutes to complete the first time and, generally, 3 5 minutes once you are familiar with the scale. You may be asked to complete the scale multiple times throughout the course of your treatment and follow-up period."
- 7. Give simple, clear instructions for completing the scale: "Please put a mark along each line where it would best describe the symptoms of your lung cancer DURING THE PAST DAY (within the last 24 hours). Focus on your lung cancer symptoms, not symptoms related to some other health problem you may have."
- 8. If the patient has difficulty with the time frame, remind the patient that "today" means the past day (or within the last 24 hours). Tell the patient this short time frame is needed because symptoms fluctuate rapidly and it is difficult to remember accurately beyond that time frame.
- 9. Emphasize that it is the **patient's personal feelings** that count, and there are **no right or wrong answers** to any of the questions. Reflect the questions back to the patient to obtain the patient's subjective response. If the patient asks what does "as much as it could be" mean,

reply that it means "as bad as you believe it can be" (not necessarily verbatim). If a patient asks what you mean by "normal activities," again reply "whatever normal activities mean to you."

Any further explanation by the administrator of the instrument may influence the patient's answer.

- 10. Reinforce that the patient should read the questions and pay particular **attention to the words at the extremes of the line** because they change on different questions.
- 11. Present the example question first (How good is the weather today?). Demonstrate making a vertical mark on the example question line. Do not proceed until the patient understands. The patient will be less likely to make an "X" or " $\sqrt{}$ " on the line if properly "trained."
- 12. Be sure that the patient understands that marks can be made on the end markers (either 0 or 100) by **extending the end mark**. Many patients have a tendency to mark beside the line to mean a **true zero or true 100**, which then is actually measured as 1 2 mm. instead of zero. Again, it is best to **demonstrate extending the end marker** for a true "none" or true "as much as it can be."
- 13. Allow the patient to read and complete **one question at a time** before continuing to the next question. Most patients should **not need the questions read** to them.
- 14. As each question is presented, **check to see if the patient understands key words** such as "fatigue" and "sputum."
- 15. If the patient asks for more explanation for **item #7** related to **total symptomatic distress**, respond that it means: "All together, how bad are your symptoms from lung cancer?"
- 16. If the patient speaks another language, provide an interpreter fluent in that language to administer the scale. The LCSS patient form is now available in many languages.
- 17. Check to be sure the patient has **not skipped a question**. If one was skipped, ask the patient about that question. If the patient refuses to complete a question, ask, "Why?" as it may be simple to reassure the patient.

Administration by Telephone

The LCSS has been easily administered by telephone to patients who have previously completed the measure in an **initial face-to-face interview** (in which the use of a visual analogue scale has been demonstrated and the patient shows understanding). A time is set with the patient that the observer will call and the patient is either given the LCSS at the last contact or mailed the questions prior to the **"telephone appointment"**.

- 1. When the patient answers the telephone, **ask the patient to get the LCSS patient form while you remain on the telephone**. Remind the patient that the LCSS should be completed without help from others (such as family members or helpers).
- 2. Review the instructions for the LCSS as if administering the scale in person and wait on the telephone while the patient completes the 9 items (usually 3 5 minutes).
- 3. Remind the patient that a "true zero" ("none") or "true 100" ("as much as it can be") is represented by extending the short lines at the end of the long line, not by making a mark beside one of them.

4. After completion of the telephone interview, ask the patient to seal the self-addressed envelope and write the date on the back of the envelope. The patient should then be asked to either mail the envelope the next day or bring it to the next appointment.

Copying the Instrument

Photocopying will lengthen the lines of the LCSS patient scale. To recreate the patient scale, printing is recommended.

Lung Cancer

Lung Cancer Symptom Scale (LCSS): Patient scale

English Version

Directions: Please place a mark along each line where it would best describe the symptoms of your lung cancer DURING THE PAST DAY (within the last 24 hours).

low good is the weather?	
As good as it could be	As bad as it could be

1. How good is your appetite?

As good as	As bad as
it could be	it could be

2. How much fatigue do you have?

	As much as
None	it could be

3. How much coughing do you have?

	As much as
None	it could be

4. How much shortness of breath do you have?

	As much as
None	it could be

LCSS - United States/English LCSS - Cancer_AU1.0_eng-USori.doc

Lung Cancer 5. How much blood do you see in your sputum? As much as None ______ it could be 6. How much pain do you have? As much as _____ None it could be 7. How bad are your symptoms from lung cancer? As bad as I have none ______ As bad as 8. How much has your illness affected your ability to carry out normal activities? So much that I can do nothing for Not at all myself 9. How would you rate the quality of your life today? Very high Very low

LCSS - United States/English LCSS - Cancer_AU1.0_eng-USorl.doc

APPENDIX 5 EQ-5D QUESTIONNAIRE



Health Questionnaire

English version for the USA

USA (English) © 1998 EuroQol Group EQ-5D™ is a trade mark of the EuroQol Group

By placing a checkmark in one box in each group below, please indicate which statements best describe your own health state today.

1. Mobility


I have no problems in walking about	1
I have some problems in walking about	
I am confined to bed	D 3
2. Self-Care	
I have no problems with self-care	
I have some problems washing or dressing myself	
I am unable to wash or dress myself	D 3
3. Usual Activities (e.g. work, study, housework, family or leisure activities)	
I have no problems with performing my usual activities	
I have some problems with performing my usual activities	
I am unable to perform my usual activities	D 3
4. Pain / Discomfort	
I have no pain or discomfort	Π,
I have moderate pain or discomfort	
I have extreme pain or discomfort	D 3
5. Anxiety / Depression	
I am not anxious or depressed	
I am moderately anxious or depressed	D 2
I am extremely anxious or depressed	D 3

Best imaginable health state

6. To help people say how good or bad a health state is, we have drawn a scale (rather like a thermometer) on which the best state you can imagine is marked 100 and the worst state you can imagine is marked 0.

We would like you to indicate on this scale how good or bad your own health is today, in your opinion. Please do this by drawing a line from the box below to whichever point on the scale indicates how good or bad your health state is today.

> Your own health state today



3

APPENDIX 6 EQ-5D QUESTIONNAIRE (PHONE VERSION)



Health Questionnaire

English version for the USA

SCRIPT FOR TELEPHONE ADMINISTRATION

GENERAL INTRODUCTION

It is suggested that the telephone administrator follows the script of the EQ-5D. Although allowance should be made for the interviewer's particular style of speaking, the wording of the questionnaire instructions should be followed as closely as possible. In the case of the EQ-5D descriptive system on page 2, the exact wording must be followed.

It is recommended that the administrator has a copy of the EQ-5D in front of him or her as it is administered over the telephone. This enables the respondent's answers to be entered directly on the EQ-5D by the administrator on behalf of the respondent (i.e. the appropriate boxes on page 2 are marked and the scale on page 3 is marked at the point indicating the respondent's 'own health state today'). If the respondent asks for clarification, the administrator can help by re-reading the question verbatim. The administrator should not try to offer his or her own explanation but suggest that the respondent uses his or her own interpretation.

If the respondent has difficulty with regard to which box to mark, the administrator should repeat the question verbatim and ask the respondent to answer in a way that most closely resembles his or her thoughts about his or her health state today.

INTRODUCTION TO EQ-5D

We are trying to find out what you think about your health. I will first ask you a few brief and simple questions about your own health state today. I will then ask you to do a different task that involves rating your health on a measuring scale. I will explain the tasks fully as I go along but please interrupt me if you do not understand something or if things are not clear to you. Please also remember that there are no right or wrong answers. We are interested here only in your personal view.

EQ-5D DESCRIPTIVE SYSTEM - PAGE 2: INTRODUCTION

First I am going to read out some questions. Each question has a choice of three answers. Please tell me which answer best describes your own health state today.

Do not choose more than one answer in each group of questions.

(Note for administrator: it may be necessary to remind the respondent regularly that the timeframe is today)

EQ-5D DESCRIPTIVE SYSTEM - PAGE 2: TASK

MOBILITY

First I'd like to ask you about mobility.

Question 1: Would you say you have ...

- 1. No problems in walking about?
- 2. Some problems in walking about?
- 3. You are confined to bed?

So, would you say you have no problems in walking about, some problems in walking about or you are confined to bed?

(Note for administrator: mark the appropriate box on EQ-5D)

SELF-CARE

Next I'd like to ask you about self-care.

Question 2: Would you say you have ...

- 1. No problems with self-care?
- 2. Some problems washing or dressing yourself?
- 3. You are unable to wash or dress yourself?

So, would you say you have no problems with self-care, some problems washing or dressing yourself or *you are* unable to wash or dress yourself?

(Note for administrator: mark the appropriate box on EQ-5D)

USUAL ACTIVITIES

Next I'd like to ask you about your usual activities, for example work, study, housework, family or leisure activities.

Question 3: Would you say you have ...

- 1. No problems with performing your usual activities?
- 2. Some problems with performing your usual activities?
- 3. You are unable to perform your usual activities?

So, would you say you have no problems performing your usual activities, some problems performing your usual activities or you are unable to perform your usual activities?

(Note for administrator: mark the appropriate box on EQ-5D)

PAIN / DISCOMFORT

Next I'd like to ask you about pain or discomfort.

Question 4: Would you say you have ...

- 1. No pain or discomfort?
- 2. Moderate pain or discomfort?
- 3. Extreme pain or discomfort?

So, would you say you have no pain or discomfort, moderate pain or discomfort or extreme pain or discomfort?

(Note for administrator: mark the appropriate box on the EQ-5D questionnaire)

ANXIETY / DEPRESSION

Finally I'd like to ask you about anxiety or depression.

Question 5: Would you say you are ...

- 1. Not anxious or depressed?
- 2. Moderately anxious or depressed?
- 3. Extremely anxious or depressed?

So, would you say you are not anxious or depressed, moderately anxious or depressed or extremely anxious or depressed?

(Note for administrator: mark the appropriate box on the EQ-5D questionnaire)

EQ VAS - PAGE 3: INTRODUCTION

(Note for administrator: If possible, it might be useful to send a visual aid (i.e. the EQ VAS) before the telephone call so that they can have this in front of them when completing the task)

I would now like to ask you to do a different task.

To help you say how good or bad your health state is, I'd like you to try to picture in your mind a scale that looks a bit like a thermometer. Can you do that? The best health state you can imagine is marked 100 (one hundred) at the top of the scale and the worst state you can imagine is marked 0 (zero) at the bottom.

EQ VAS - PAGE 3: TASK

I would now like you to tell me the point on this scale where you would put your own health state today.

Thank you for taking the time to answer these questions.

APPENDIX 7 REVISED PROTOCOL SUMMARY OF CHANGE HISTORY

Overall Rationale for the Revised Protocol 05, 14-Jul-2018

BICR-assessed PFS was changed as a primary objective to secondary objective and PFS interim analysis was removed. Subsequently, statistical analyses were updated. OS analyses will be performed and if significant, the secondary endpoint will be tested.

BICR-assessed PFS was initially included as a co-primary endpoint in order to mitigate the potential effect of subjects receiving subsequent immuno- therapy (IO) at progression. An analysis of the current, pooled dataset shows that the rate of crossover to subsequent IO therapy is low (~5%), suggesting that the impact on OS will be minimal. Further, recent results from a single arm Ph 2 trial of pembrolizumab monotherapy as maintenance treatment following 1L chemotherapy (in the same setting as the 451 study) demonstrated a PFS of 1.4 months that is not improving the expected PFS in the placebo arm of 451 (Gadgeel M et al. JCO. 2017. 35;15. 8504), suggesting that PFS might not be appropriate to capture clinical benefit with immunotherapy based approach. Therefore, the decision has been made to allocate the full 5% alpha to a primary endpoint of OS to increase probability of success of the study (previously PFS had 1% of alpha spending).

Additionally, the study duration was extended and tumor mutational burden was added as a potential predictive biomarker as a secondary endpoint.

Summary of key changes for Revised Protocol 05		
Section Number & Title	Description of Change	Brief Rationale
Synopsis, Section 1.3.1 Primary Objectives	BICR-assessed PFS was changed as a primary objective to secondary objective	Endpoint analyses were updated with emerging data and revised statistical
Section 1.3.2 Secondary Objectives	Subsequently, statistical	assumptions, as described in
Section 3.5 Discontinuation of Subjects following any Treatment with Study Drug(s)	analyses were updated.	the statistical section of the protocol.
Section 5.4.2 Primary and Secondary Efficacy Assessments		
Section 8.1 Sample Size Determinations		
Section 8.2 Population for Analyses - Data set descriptions		
Section 8.3.1 Primary Endpoints		
Section 8.3.2 Secondary Endpoints		
Section 8.4.2 Efficacy Analyses		
Section 8.5 Interim Analyses	Interim analysis for superiority using PFS endpoint (planned approximately 6 months after last subject is randomized) was removed.	OS analysis will be performed and if significant, the secondary endpoint will be tested.

Summary of key changes for Revised Protocol 05		
Section Number & Title	Description of Change	Brief Rationale
Synopsis Section 1.3.3 Section 5.6.1 Tumor Tissue Specimens	Tumor mutational burden (TMB) added as a potential predicative biomarker secondary objective	TMB will be evaluated as a potential predictive biomarker
Synopsis Section 3.1 Study Design and Duration	Study duration changed from 30 months to 37 months	The number of events required for primary analysis of OS was changed from 576 events to 593 events.

Overall Rationale for the Revised Protocol 04, 19-Oct-2017

In Protocol Amendment CA209451, information in the study regarding details of tissue requirements, maximum treatment duration, contraception, exclusion criteria, prohibited/restricted treatments, dose modifications, immune-mediated adverse events, and RECIST 1.1 assessment procedures were updated per program or BMS standards. Other changes listed in the summary of key changes table below are described. The revised protocol applies to all currently enrolled and future patients.

Summary of key changes of Revised Protocol 04			
Section Number & Title	Description of Change	Brief Rationale	
Synopsis Inclusion Criterion 6	Updated the number of slides and tissue requirements for FFPE tumor tissue block.	Number of slides and tissue requirements were updated for biomarker assessment.	
Section 1.1.9.2: Rationale for Duration of Treatment with Nivolumab Alone or in Combination with Ipilimumab	Two-year maximum treatment duration information added with supporting data.	Treatment duration information added per program specific requirement and with drug efficacy rationale outlined in protocol.	
Section 3.2 Post Study Access to Therapy	Two-year maximum treatment duration added.	Updated to comply with maximum treatment duration program standard	
Section 3.3.1: Inclusion Criteria	Change to sperm donation prohibition after study completion.	Updated to comply with program specific requirements regarding sperm donation for drug safety.	
Section 3.3.1: Inclusion Criteria	Updated user-dependent and unacceptable contraceptive methods.	Updated to comply with program specific requirements regarding user dependent and unacceptable contraceptive methods for drug safety.	
Section 3.3.2:	Updated previous malignancy exclusion criterion requirements.	Updated to comply with program specific requirements for drug safety	

Summary of key changes of Revised Protocol 04			
Section Number & Title	Description of Change	Brief Rationale	
Exclusion Criteria			
Section 3.3.2: Exclusion Criteria	Changed limits for inadequate hematologic function and inadequate hepatic function.	Updated to comply with program requirements for hematologic and hepatic function for drug safety.	
Section 3.3.2: Exclusion Criteria	Added botanical preparations as an exclusion criterion within 2 weeks prior to randomization.	Updated exclusion criterion for concomitant treatments that may affect drug safety and/or efficacy.	
Section 3.3.2: Prohibited and/or Restricted Treatment	Added thymosin, thymalfasin, thymopentin, and botanical preparations to the prohibited treatments list.	Updated to limit concomitant medications that may affect drug safety and/or efficacy.	
Section 4.5.2.1: Nivolumab Monotherapy (Arm A)	Added information on nivolumab monotherapy (Arm A) treatment procedures for progression, unacceptable toxicity, withdrawal of consent, maximum treatment duration, or study conclusion. In addition, information was added to denote the start of therapy.	Updated for additional clarity for study conduct and to comply with program specific standard.	
Section 4.5.2.2: Nivolumab and ipilimumab combination therapy (Arm B)	Added information on nivolumab monotherapy (Arm A) treatment procedures for progression, unacceptable toxicity, withdrawal of consent, maximum treatment duration, or study conclusion. In addition, information was added to denote the start of therapy.	Updated for additional clarity for study conduct and to comply with program specific standard.	
Section 4.5.3: Dose Modification and Delays	Information added on delayed or discontinued dosing based on patient's tolerance.	Added to allow for dosing delays and discontinuation based on patient tolerance and drug safety.	
Section 4.5.3.2: Dose Delays	Modified information on dose delays for Grade 3 and \geq 3 drug-related laboratory abnormalities.	Updated to comply with program specific standards for drug safety.	
Section 4.5.3.3: Criteria to Resume Treatment	Added information regarding resuming treatment in subjects with Grade 2 skin toxicity. In addition, clarification added regarding adrenal insufficiency discontinuations.	Resumption of treatment requirements were needed to discern between Grade 2 and 3 skin adverse events (AEs). Clarification was needed for adrenal insufficiency discontinuation.	
Section 4.5.3.4: Discontinuation Criteria	Clarification added regarding adrenal insufficiency discontinuations. Removed isolated Grade 4 amylase or lipase abnormalities discontinuation criteria.	Clarification was needed for adrenal insufficiency discontinuations. Isolated Grade 4 amylase or lipase abnormalities were removed to comply with program specific standards for drug safety.	
Section 5.4: Efficacy Assessments	Removed requirements for patients to undergo radiation treatment for asymptomatic brain metastases in order to be eligible.	Updated to comply with program specific standards.	
Section 5.5: Pharmacokinetic	Changed the maximum duration of treatment to 2 years	Treatment duration information added per program specific	

Section Number & Title	Description of Change	Brief Rationale
Assessments		requirement and with drug efficacy rationale outlined in protocol.
Section 5.6.1: Tumor Tissue Specimens	Clarification on when tumor tissue specimens should be taken in the event of initiation of subsequent treatment.	Updated to allow for consistent tissue sampling procedures for biomarker analyses.
Section 5.7:Outcomes Research Assessment	Clarification on the capture of health resource utilization data.	Updated to allow for proper capture and description of health resource utilization data.
Section 6.1.1: Serious Adverse Event Collection and Reporting	Added information for the collection of SAEs from patients who are randomized but not treated.	Updated to comply with compliant SAE reporting procedures.
Section 6.2.2: Immune- Mediated Adverse Events	Added descriptions of immune-mediated AEs	Updated to comply with program specific standards and inform sites of potential AEs.
Section 9.2.2: Study Drug Records	Removed information regarding the records to be sourced by the site.	Removed language for clarity in study conduct.
Section 9.2.3: Case Report Forms	Removed information regarding blank Case Report Form (CRF) spaces.	Information updated to remove the ability of the site to leave blank spaces in the CRF in certain circumstances for clarity in study conduct
Section 12: References	Added new references for the new information added to the protocol	New references were needed to cite the new protocol information.
Appendix 3: Response Evaluation Criteria in Solid Tumors Guidelines	Updated solid tumor evaluation information to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.	Updated to comply with language from the RECIST version 1.1 criteria and clarity in study conduct.